---
document_datetime: 2023-09-21 20:20:04
document_pages: 101
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/nplate-h-c-942-ii-0077-epar-assessment-report-variation_en.pdf
document_name: nplate-h-c-942-ii-0077-epar-assessment-report-variation_en.pdf
version: success
processing_time: 133.0850968
conversion_datetime: 2025-12-17 07:59:54.024103
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

10 December 2020 EMA/CHMP/45192/2021 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Nplate

International non-proprietary name

: romiplostim

Procedure No. EMEA/H/C/000942/II/0077

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                  | 6                                                                                                      |
|---------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation................................................................................................    | 6                                                                                                      |
| 1.2. Steps taken for the assessment of the product.......................................................                 | 7                                                                                                      |
| 2. Scientific discussion................................................................................                  | 7                                                                                                      |
| 2.1. Introduction......................................................................................................   | 7                                                                                                      |
| 2.1.1. Problem statement.........................................................................................10       |                                                                                                        |
| 2.1.2. About the product                                                                                                  | ..........................................................................................10           |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific                                                 | advice......11                                                                                         |
| 2.2. Non-clinical aspects...........................................................................................11    |                                                                                                        |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                          | ........................................................11                                             |
| 2.3. Clinical aspects.................................................................................................11  |                                                                                                        |
| 2.3.1. Introduction                                                                                                       | ..................................................................................................11   |
| 2.3.2. Pharmacokinetics                                                                                                   | ...........................................................................................11          |
| 2.3.3. Pharmacodynamics.........................................................................................12        |                                                                                                        |
| 2.3.4. PK/PD modelling                                                                                                    | ............................................................................................12         |
| 2.3.5. Discussion on clinical pharmacology..................................................................23            |                                                                                                        |
| 2.3.6. Conclusions on clinical pharmacology................................................................25             |                                                                                                        |
| 2.4. Clinical efficacy.................................................................................................25 |                                                                                                        |
| 2.4.1. Main studies..................................................................................................26   |                                                                                                        |
| 2.4.2. Discussion on clinical efficacy...........................................................................45       |                                                                                                        |
| 2.4.3. Conclusions on the clinical efficacy....................................................................49         |                                                                                                        |
| 2.5. Clinical safety...................................................................................................50 |                                                                                                        |
| 2.5.1. Discussion on clinical safety.............................................................................81       |                                                                                                        |
| 2.5.2. Conclusions on clinical safety                                                                                     | ...........................................................................83                          |
| 2.5.3. PSUR cycle....................................................................................................83   |                                                                                                        |
| 2.6. Risk management plan                                                                                                 | ......................................................................................83               |
| 2.7. Update of the Product information.......................................................................89           |                                                                                                        |
| 2.7.1. User consultation                                                                                                  | ...........................................................................................89          |
| 3. Benefit-Risk Balance .............................................................................                     | 89                                                                                                     |
| 3.1. Therapeutic Context..........................................................................................89      |                                                                                                        |
| 3.1.1. Disease or condition                                                                                               | .......................................................................................89              |
| 3.1.2. Available therapies and unmet medical need......................................................90                 |                                                                                                        |
| 3.1.3. Main clinical studies........................................................................................91    |                                                                                                        |
| 3.2. Favourable effects.............................................................................................91    |                                                                                                        |
| 3.3. Uncertainties and limitations about favourable effects                                                               | ............................................92                                                         |
| 3.4. Unfavourable effects..........................................................................................93     |                                                                                                        |
| 3.5. Uncertainties and limitations about unfavourable effects.........................................94                  |                                                                                                        |
| 3.6. Effects Table                                                                                                        | ....................................................................................................94 |
| 3.7. Benefit-risk assessment and discussion................................................................98             |                                                                                                        |
| 3.7.1. Importance of favourable and unfavourable effects                                                                  | .............................................98                                                        |
| 3.7.2. Balance of benefits and risks............................................................................99        |                                                                                                        |
| 3.7.3. Additional considerations on the benefit-risk balance.........................................100                  |                                                                                                        |

<div style=\"page-break-after: always\"></div>

3.8. Conclusions  ....................................................................................................  100

4. Recommendations  ............................................................................... 100

5. EPAR changes ..................................................................................... 101

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADR adverse drug reaction AGSD      Amgen Global Safety Database AGSD AML acute myeloid leukemia AMQ Amgen MedDRA query Δ OFV      difference in the objective function value of two hierarchical models ASH American Society of Hematology AUC        area under the concentration-time curve AUDC      total drug dose that reached precursor compartment CI           confidence interval CV          coefficient of variation CWRES    conditional weighted residual EOI events of interest η , ETA     eta - Interindividual random effect eTPO endogenous thrombopoietin EU European Union EMA European Medicines Agency IIV          interindividual variability IPRED     individual predictions ITP immune (idiopathic) thrombocytopenic purpura, also known as immune thrombocytopenia ITPDIAG   duration of ITP at study entry IVIG intravenous immunoglobulin IWG International Working Group ktr          first-order rate constants K-PD      pharmacodynamic dose-response model K-PD        elimination rate constant for romiplostim dose PC prediction corrected MAA       marketing authorization application MAH       marketing authorization holder MDS myelodysplastic syndrome MedDra   Medical Dictionary for Regulatory Activities MTT        mean transit time NONMEM nonlinear mixed effects modeling

<div style=\"page-break-after: always\"></div>

| NUMITP   | number of ITP treatments prior to the study enrollment   |
|----------|----------------------------------------------------------|
| OFV      | objective function value                                 |
| PC       | prediction corrected                                     |
| PD       | pharmacodynamic                                          |
| PK       | pharmacokinetic                                          |
| PSUR     | Periodic Safety Update Report                            |
| PT       | preferred term                                           |
| pcVPC    | prediction corrected visual predictive check             |
| RMP      | Risk Management Plan                                     |
| RSE      | relative standard error                                  |
| RWE      | real world evidence                                      |
| SC       | subcutaneous(ly)                                         |
| SD       | standard deviation                                       |
| SE       | standard error                                           |
| SGOT     | aspartate aminotransferase                               |
| SGPT     | alanine aminotransferase                                 |
| SmPC     | summary of product characteristics                       |
| SMQ      | standardized MedDRA query                                |
| SOC      | standard of care                                         |
| THETA    | typical value of a structural model parameter            |
| TPO      | thrombopoietin                                           |
| TPO-RA   | thrombopoietin receptor agonist                          |
| US       | United States                                            |
| USPI     | United States prescribing information                    |
| VPC      | visual predictive checks                                 |
| WT       | body weight (kg)                                         |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Amgen Europe B.V. submitted to the European Medicines Agency on 28 May 2020 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to add the use of romiplostim in adult patients who have had ITP for ≤ 12 months and who have had an insufficient response to corticosteroids or immunoglobulins. Sections 4.1, 4.4., 4.8, 5.1 and 5.2 of the SmPC have been updated. In addition, the MAH has taken the opportunity to implement minor editorial changes in sections 4.2, 4.4, 4.8 and 5.1 of the SmPC. The Package Leaflet is updated in accordance. Version 20.0 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template (version 10.1).

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included (an) EMA Decision(s) P/0233/2017 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0233/2017 was completed.

The PDCO issued an opinion on compliance for the PIP P/0233/2017.

Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan PIP P/0233/2017 and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

<div style=\"page-break-after: always\"></div>

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Maria Concepcion Prieto Yerro

Co-Rapporteur:

N/A

4 September 2020

11 September 2020

17 September 2020

9 November 2020

9 November 2020

26 November 2020

3 December 2020

| Timetable                                            | Actual dates      |
|------------------------------------------------------|-------------------|
| Submission date                                      | 28 May 2020       |
| Start of procedure:                                  | 20 June 2020      |
| CHMP Rapporteur Assessment Report                    | 13 August 2020    |
| PRAC Rapporteur Assessment Report                    | 24 August 2020    |
| PRAC Outcome                                         | 4 September 2020  |
| CHMP members comments                                | 7 September 2020  |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 11 September 2020 |
| Request for supplementary information (RSI)          | 17 September 2020 |
| CHMP Rapporteur Assessment Report                    | 9 November 2020   |
| PRAC Rapporteur Assessment Report                    | 9 November 2020   |
| PRAC members comments                                | 8 November 2020   |
| PRAC Outcome                                         | 26 November 2020  |
| CHMP members comments                                | 30 November 2020  |
| Updated CHMP Rapporteur Assessment Report            | 3 December 2020   |
| CHMP Opinion                                         | 10 December 2020  |

## 2. Scientific discussion

## 2.1. Introduction

## Disease or condition

Immune (idiopathic) thrombocytopenia (ITP) is an autoimmune disorder characterised by a low circulating platelet  count  (thrombocytopenia),  decreased  platelet  production  and  increased  platelet  destruction. Thrombocytopenia  places  patients  at  risks  for  bruising,  mucocutaneous  bleeding  and  more  seriously intracranial haemorrhage. Although its basic pathophysiology has been elucidated, no clinically apparent cause has been established for ITP.

In 2007, a need was recognised to standardize terminology related to ITP, and an International Working Group (IWG) was convened to develop definitions and recommendation criteria for ITP. The IWG decided to

<div style=\"page-break-after: always\"></div>

avoid the term 'idiopathic,' preferring 'immune,' to emphasise the immune-mediated mechanism of the disease and to choose 'primary' (as opposed to idiopathic) to indicate the absence of any obvious initiating and/or underlying cause. The term 'purpura' was felt inappropriate, because bleeding symptoms are absent or minimal in a large proportion of cases. Nevertheless, the acronym ITP (proposed to stand for immune thrombocytopenia) was preserved because of its widespread and time-honoured use and taking into account its utility for literature search.' The IWG further classified ITP by duration into newly diagnosed (within 3 months of diagnosis), persistent (3 to 12 months from diagnosis) and chronic (ITP lasting more than 12 months) [Rodeghiero et al, 2009].

Newly diagnosed ITP' was defined as all cases at first diagnosis. A new category, 'persistent ITP,' was introduced which included patients who did not achieve a spontaneous remission or who did not maintain their response after stopping treatment between 3 to 12 months from diagnosis. The IWG noted that the possibility of spontaneous remission is significant during this period and deferral of aggressive therapeutic approaches (such as splenectomy) should therefore be considered.  The term 'chronic ITP' was reserved for patients  with  ITP  lasting  for  more  than  12  months.  In  2011,  ASH  updated  the  practice  guidelines  and adapted  the  IWG  terminology  throughout  it  [Neunert  et  al,  2011].  Recently,  an  updated  international primary ITP consensus report have been published, including up-to-date evidence, expert opinion from around the world, and patients' perspective [Provan et al, 2019]. In this publication and in the corresponding updated 2019 ASH guidelines, the classification of ITP by disease duration remained as newly diagnosed (within 3 months of diagnosis), persistent (3 to 12 months from diagnosis) and chronic (ITP lasting more than 12 months) [Neunert et al, 2019].

## State the claimed therapeutic indication

The proposed indication is:

## 'Adults:

Nplate is indicated for the treatment of immune (idiopathic) thrombocytopenia purpura (ITP)  in  adult  patients  who  are  refractory  to  other  treatments  (e.g.  corticosteroids, immunoglobulins) (see section 4.2 and 5.1)

## Paediatrics:

Nplate is indicated for the treatment of chronic immune (idiopathic) thrombocytopenia purpura (ITP) in paediatric patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see section 4.2 and 5.1).'

## Epidemiology

The reported incidence data for ITP in the European Union (EU) ranges from 1.6 to 4.4 per 100,000 (Moulis et al, Blood 2014; Schoonen et al, Br J Haematol 2009; Neylon et al, Br J Haematol 2003; Frederiksen &amp; Schmidt, Blood 1999). The prevalence is 9.5 per 100,000 adults (Lambert &amp; Gernsheimer, Blood 2017). There is an increasing incidence with older age and equal for the sexes except in the mid-adult years (30-60 years), when the disease is more prevalent in women. Childhood ITP has an incidence of between 1.9 and 6.4 per 100,000 per year with equal distribution between the sexes. There are an estimated 50,000 adult patients with chronic ITP in the EU (Gernsheimer, Eur J Haematol 2008).

## Biologic features, Aetiology and pathogenesis

Primary ITP in adults has no known trigger or obvious cause. ITP is characterised by immune-mediated thrombocytopenia resulting from increased clearance of normal platelets and decreased platelet production:

<div style=\"page-break-after: always\"></div>

- antibodies bind to circulating platelets and mediate clearance of platelets by tissue macrophages (primarily in spleen, but also liver) via surface fragment crystallizable (Fc) receptors
- antibodies may impair platelet function, resulting in bleeding that is disproportionate to the platelet count
- antibodies may bind to megakaryocytes, resulting in decreased platelet production.

## Clinical presentation, diagnosis and stage/prognosis

Signs and symptoms vary widely. Many patients have either no symptoms or minimal bruising, whereas others experience serious bleeding, which may include gastrointestinal haemorrhage, extensive skin and mucosal haemorrhage, or intracranial haemorrhage. The severity of thrombocytopenia correlates to some extent but not completely with the bleeding risk. Additional factors may increase the risk (e.g., advanced age, lifestyle factors, concomitant medications, congenital or acquired bleeding disorders) and should be evaluated before the appropriate management is determined. Although haemorrhagic death is a major concern it has been reported that the estimated rate of fatal haemorrhage is around 0.02 to 0.04 cases per adult patient-year risk.

Diagnosis of ITP is one of exclusion, when the history, physical examination, complete blood count and examination of peripheral blood smear do not suggest other aetiology for the thrombocytopenia. Physical examination should be normal apart from bleeding signs. The peripheral blood count reveals isolated thrombocytopenia and normal red cell and white cell indices. If significant bleeding occurs there may be anaemia proportional to the degree of bleeding with possible iron deficiency. The peripheral blood smear reveals normal to large platelets in size and no abnormalities should be seen in red and white cell morphology. Bone marrow examination is currently not routinely conducted in patients with typical ITP presentations but reserved to selected cases such as those with an atypical presentation (Guideline on the clinical development of medicinal products intended for the treatment of chronic primary immune thrombocytopenia, EMA/CHMP/153191/2013, Oncology Working Party).

## Management

There are no specific approved treatments for patients with newly diagnosed ITP or persistent ITP within 3 to 6 months from diagnosis. Although there are no approved treatments, standard of care (SOC) first line therapies, or initial treatment for newly diagnosed ITP, consist of corticosteroids for most patients and anti-D immunoglobulin and intravenous immunoglobulin (IVIG) for selected patients. According to the 2019 ASH Guidelines [Neunert et al, 2019], in patients treated with steroids, a short course (&lt; 6 weeks including treatment  and  taper)  is  recommended.  In  adults  with  ITP  for  3  to  12 months  who  are  corticosteroid dependent  or  unresponsive  to  corticosteroids  the  primary  treatment  options  include  thrombopoietin receptor agonists (TPO-RAs) and rituximab. Eltrombopag is currently approved for treatment of patients 1 year of age and above with primary ITP lasting 6 months or longer from diagnosis. Splenectomy is an additional option for adults with ITP &gt; 12 months [Neunert et al, 2019; Provan et al, 2019]. However, there is  no  consensus  regarding  the  best  sequence  of  treatments  and  therapy  should  be  individualised.  The therapeutic  goal  is  to  avoid  or  defer  the  risks  of  more  toxic  treatments  (e.g.  splenectomy  or immunosuppression), reduce corticosteroid  exposure  to  minimum  levels  and  for  the  shortest  time  and achieve long-lasting responses [EMA/CHMP/153191/2013, 2014].

<div style=\"page-break-after: always\"></div>

## 2.1.1. Problem statement

In the current variation application, the MAH proposes to modify the indication statement in ITP to address the change established in the disease terminology and in definition of chronic ITP. Because the definition of chronic ITP was revised (patients with ITP lasting for more than 12 months), some patients who would have been previously considered to have chronic ITP per 1996 ASH guidelines, would now be considered to have persistent ITP (3 to 12 months from diagnosis) per the 2011 and 2019 ASH guidelines.

To address this aspect and recognise the unmet medical need for patients with newly diagnosed and persistent ITP, the MAH seeks to modify the indication statement for romiplostim to include adult patients with ITP ≤ 12 months who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

The proposed indication statement is:

## Adults:

Nplate is indicated for the treatment of immune (idiopathic) thrombocytopenia purpura (ITP)  in  adult  patients  who  are  refractory  to  other  treatments  (e.g.  corticosteroids, immunoglobulins) (see section 4.2 and 5.1)

## Paedriatics:

Nplate is indicated for the treatment of chronic immune (idiopathic) thrombocytopenia purpura (ITP) in paediatric patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see section 4.2 and 5.1).

The MAH supports this application with data from 311 adult subjects with ITP ≤ 12 months (n = 277 romiplostim; 34 placebo/SOC) who were enrolled in previously submitted clinical studies and with a pharmacodynamics modelling and simulation study.

## 2.1.2. About the product

Nplate (romiplostin) is an Fc-peptide fusion protein, thrombopoietin (TPO)-receptor agonist.

Nplate (INN romiplostim) is a recombinant protein that signals and activates intracellular transcriptional pathways via the TPO receptor to increase platelet production. Romiplostim stimulates platelet production by  a  mechanism  similar  to  that  of  endogenous  thrombopoietin  (eTPO),  but  no  amino  acid  sequence homology exists between romiplostim and eTPO.

Nplate is currently indicated for chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

Romiplostim  was  approved  in  the  European  Union  (EU)  on  04  February  2009.  The  original  marketing authorisation application (MAA), submitted in 2008, was based upon 2 pivotal, phase 3 studies of adult subjects with ITP (Studies 20030212 and 20030105) and included supportive data from 7 other clinical studies in subjects with ITP (Studies 20010218, 20000137A, 20000137B, 20050162, 20040209, 20030213 and  20050123).  Cumulative  evidence  is  now  available  from  13  completed  clinical  studies  (including  5 additional studies in adult subjects with ITP (Studies 20060113, 20060131, 20060216, 20080009, and 20080435) in support of the  proposed  use  of  romiplostim  as  an  effective  treatment  in  increasing  and maintaining platelet counts within a therapeutically relevant range in the ITP patient population.

<div style=\"page-break-after: always\"></div>

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

## The development programme/compliance with CHMP guidance and scientific advice.

- Scientific Advice from AEMPS was sought on 23 May 2017, for the romiplostim clinical program in adult patients who have ITP for ≤ 12 months. The proposal for Study 20130273, an RCT designed to evaluate the efficacy and safety of romiplostim compared to placebo for the treatment of adult subjects with ITP ≤ 12 months was discussed. AEMPS agreed in general that the phase 3 study along with the existing data may prove sufficient to support the extension of the indication, provided that the results are internally robust  and  clinically  and  statistically  meaningful.  Recommendations  regarding  the  proposed  study design were provided.
- In June 2018, an EMA protocol assistance discussion meeting was held to discuss the proposal for Study 20180029, a non-interventional cohort study designed to evaluate the comparative effectiveness of romiplostim versus SOC in adult patients with ITP ≤ 12 months by using data from patients in clinical practice settings to provide real world evidence. The MAH proposed to conduct this study in place of the RCT Study 20130273 that had been previously discussed with AEMPS. EMA advised that a decision would not be made on the extension of indication to patients without restriction in terms of disease duration in a refractory setting based only on observational data but a combination of available clinical trial data, justification of extrapolation of findings to adult patients earlier in their disease course, the PK/PD modelling and the observational study were thought likely to be sufficient  for  the  proposed extension of indication.

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

The active substance, Romiplostim is a protein and therefore no environmental risk assessment studies have been submitted, in line with guidelines.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

Not Applicable as no new clinical trials have been submitted.

## 2.3.2. Pharmacokinetics

The  pharmacokinetics  of  romiplostim  was  described  for  ITP  in  the  original  marketing  authorisation application and is essentially unchanged. No additional information is provided in this application.

<div style=\"page-break-after: always\"></div>

## 2.3.3. Pharmacodynamics

The  pharmacodynamics  of  romiplostim  was  described  for  ITP  in  the  original  marketing  authorisation application and is essentially unchanged. In previous clinical trials, treatment with romiplostim resulted in dose-dependent increases in platelet counts.

According to current Nplate SmPC, romiplostim should be administered as a weekly SC injection with dose adjustments based upon the platelet count response. The initial dose for romiplostim is 1 µg/kg based on actual  body  weight.  Dose  adjustment  may  be  required  to  achieve  desired  platelet  count  level.  When adjusting the dose, the actual body weight at initiation of therapy should be used, the weekly dose of romiplostim can then be adjusted by increments of 1 µg/kg until the patient achieves a platelet count ≥ 50 x 10 9 /L, as necessary, to reduce the risk for bleeding. A maximum weekly dose of 10 µg/kg should not be exceeded.

Adjustment of romiplostim dose should be made as follows:

- If the platelet count is &lt; 50 x 10 9 /L, increase the once weekly dose by 1 µg/kg.
- If platelet count is &gt; 150 x 10 9 /L for 2 consecutive weeks, reduce the once weekly dose by 1 µg/kg.
- If platelet count is &gt; 250 x 10 9 /L, do not dose. Continue to assess the platelet count weekly. After the platelet count has fallen to &lt; 150 x 50 x 10 9 /L, resume romiplostim dosing with once weekly dose reduced by 1 µg/kg.

It should be used the lowest dose of romiplostim to achieve and maintain a platelet count ≥ 50 x 10 9 /L as necessary to reduce the risk for bleeding.

## 2.3.4. PK/PD modelling

The MAH has conducted a PD modelling and simulation study (study 150780) to support the appropriateness of the romiplostim labelled dosing algorithm to treat patients with ITP ≤ 12 months.

## Study 150780

## Study objectives:

The aim of the modelling and simulation study were to characterise the romiplostim dose-platelet count relationship in patients with ITP ≤12 months and to confirm the appropriateness of the romiplostim labelled dosing regimen for treatment of these patients.

The objectives of the romiplostim population PD analysis were as follows:

- Quantitatively characterise the romiplostim dose - platelet-response relationship and to quantify its inter-individual variability after weekly SC administration of romiplostim.
- Evaluate effects of patients' demographic characteristics and other covariates on the PD parameters of romiplostim.
- Confirm the appropriateness of the romiplostim labelled dosing regimen for treatment of adults with ITP ≤ 12 months.

## Data included

The population PD analysis (Study 150780) used data from 7 main clinical studies in patients with primary ITP diagnosed within 12 months prior to study enrolment. Those 7 studies comprised: 20080435, 20030105,

<div style=\"page-break-after: always\"></div>

20030212, 20060216, 20040209, 20060131, and 20080009 (Figure 1). Although the current submission package includes 7 parent studies plus 2 extension studies, the extension studies were not included in the modelling and simulation study.

Figure 1. Studies used for the population modeling and simulation study (150780)

<!-- image -->

Weekly platelet counts following administration of romiplostim were available from patients with ITP. The modelling dataset consisted of a total of 7854 platelet counts from 268 patients with ITP receiving weekly SC romiplostim at doses ranging from 1 to 15 µg/kg. In total, 9 subjects were excluded from the analysis. Subjects with missing time from ITP diagnosis, missing platelet count at baseline, and subjects with platelet data but no dosing data, were excluded from the analysis.

The median age of subjects was 52 years (range: 18- 93 years). The median body weight was 78 kg (range: 45- 184 kg). In total, 125 men and 143 women were included in the analysis; 90.7% were white, 2.6% black, 2.6% Asian, and 4.1% Hispanic. The median baseline platelet count was 18 x 10 9 /L (range: 1-130 x 10 9 /L). All Patients were ≤ 12 months from ITP diagnosis with a median of 3 months from diagnosis (range: 1-12 months).

The pharmacodynamic (PD) modelling exercise was informed by the previously published model which described the dose-response of romiplostim in patients with ITP [Perez-Ruixo et al, 2012]. The previously published analysis included data from 52 patients with ITP (98% were &gt; 12 months from ITP diagnosis) receiving SC romiplostim in 3 phase 1/2 studies. Because the previous model was based on fewer patients (52 patients from 3 studies with up to 6 months of platelet counts) compared to the current analysis dataset (268 patients from 7 studies with up to 3 years of platelet counts), an update to the previous model was required (refer to Method´s section below).

## Methods- analysis of data submitted

## Analysis plan

The population K-PD analysis was performed using a nonlinear mixed effects modelling approach. Studies with different designs were combined and evaluated simultaneously in this meta-analysis. The analysis was performed according to the following plan:

<div style=\"page-break-after: always\"></div>

1. Exploratory Analysis. Majority of the studies included changing the dose according to response-controlled  dose-adjustment  algorithm.  The  exploratory  analysis  aimed  to  investigate whether  basic  goodness-of-fit  plots  (observed  platelets  versus  population  [PRED]  or  individual [IPRED] predictions, and conditional weighted residuals [CWRES]) or prediction-corrected visual predicted check (pcVPC) could be used for evaluation of response-controlled trials.
2. Model  Development:  A  previously  developed  base  population  K-PD  model  was  first  evaluated [Perez-Ruixo  et  al,  2012].  The  model  was  then  updated  to  better  reflect  the  data.  Following establishment of the base model, a covariate model was developed.
3. Model Evaluation: Two types of model evaluation were employed: comparison of platelet count statistics  between  observed  and  predicted  values  and  simulation-based  comparisons  of  platelet counts and doses. Standard simulation-based visual predictive check (VPC) and prediction corrected VPC (pcVPC) cannot be used for response driven dosing trials, therefore simulations were performed for one of the trials (20080435) and implemented a dose-adjustment algorithm according to the study protocol.
4. Simulations: Model-based simulations that implemented dose-adjustment algorithm according to the  approved  label  were  performed  and  various  statistics  of  platelet  counts  and  doses  were computed to confirm adequacy of this dosing algorithm in the investigated patient population.

## Description of Population Pharmacodynamic Modelling

The  PD  modelling  exercise  was  informed  by  the  previously  published  model  which  described  the dose-response of romiplostim in patients with ITP [Perez-Ruixo et al, 2012]. The published analysis included data from 52 patients with ITP (98% [51 of 52] of which were &gt; 12 months from ITP diagnosis) receiving SC romiplostim in 3 phase 1/2 studies (dose range, 0.2 to 10 µg/kg). The published model adequately described the  platelet  time  course  and  durable  response  rate  in  patients  with  ITP,  and  model-based  simulations confirmed the effectiveness of the romiplostim dose titration scheme to prevent platelet excursions.

The published model consisted of 6 compartments: 1 representing proliferative cells such as stem cells and other  progenitor  cells,  4  transit  compartments  with  maturing  cells,  and  1  compartment  for  circulating platelets  (Figure  6).  A  maturation  chain  with  transit  compartments  and  first-order  rate  constants  (ktr) allowed  for  the  lag  between  drug  administration  and  observed  platelet  effects.  The  generation  of proliferative cells was dependent on the number of cells in that compartment, which is consistent with the mechanism of self-renewal or mitosis. In the absence of romiplostim pharmacokinetic data, 'kinetics of drug action' (K-PD) model (Jacqmin, 2007) was used to quantify the romiplostim effect on the progenitor cells according  to  a  linear  function.  Two  different  subject  populations  were  identified  with  respect  to  the romiplostim effect, one population with a reduced response and a second population with a more robust response  (approximately  29x  higher  than  in  the  first  population)  to  romiplostim  treatment.  Model parameters  were  assumed  to  be  log-normally  distributed  and  residual  variability  was  modelled  in  the log-domain.

To assess similarities (or differences) in romiplostim PD between patients ≤ 12 months from ITP diagnosis and those included in the previously published analysis, an external validation of the analysis dataset was conducted, using the published model and parameter estimates in adults with ITP ≤ 12 months. External validation consisted of prediction corrected (PC) visual predictive check (VPC) and goodness of fit plots of the analysis dataset using the previous model. PC VPC is a simulation-based method which uses the previously developed model to predict platelet counts in patients with ITP and then visually compares the distribution and time course of predicted and observed platelet counts.

Following external validation, the published model was updated to obtain estimates of model parameters based on patients with ITP ≤ 12 months from diagnosis included in the analysis dataset. The impact of potential covariates (time from diagnosis, platelet count at baseline, sex, age, weight, number of prior

<div style=\"page-break-after: always\"></div>

therapies, region, and use of rescue mediations) on model parameters was evaluated. The updated model was internally evaluated using VPCs. Clinical trial simulations were then performed using the updated model to demonstrate the appropriateness of the romiplostim labelled dosing algorithm to treat patients with ITP ≤ 12 months.

## Results

## Exploratory analysis

The diagnostic plots of platelet counts simulated from the model with dose-adjustment and fitted afterwards to  the  same  model  (Figure  2)  showed  that  the  population  predictions  could  not  be  used  for  model diagnostics, as they do not reflect the data. The results for responders and non-responders separately were even worse (not shown). Individual predictions and conditional weighted residuals did show the good fit (overall and for both groups of response), so these variables can be used. Prediction-corrected VPC plots were also poor (Figure 3). They improved (Figure 4) when pcVPC simulations were performed separately for each of the 2 responder subpopulations of the model (i.e. all simulations and estimations used only 1 subpopulation), but even in this scenario platelet counts (medians and upper 90% prediction intervals) were apparently over-estimated by the model. Thus, to be able to use VPC for model evaluation, simulations needed to implement the dose-adjustment algorithm that was used for dosing in the study.

Figure 2. Goodness-of-fit Plots for the exploratory analysis

<!-- image -->

Note: The data (DV) were simulated from the model, and dosing according to dose-adjustment algorithm

Was implemented. The same model was then fitted to the simulated data.

DV:obsenvedvalues;PRED:populationpredictions of the model; IPRED:individualpredictions of the lines are included forreference. The red lines are thelowess (local regression smoother) trend lines.

<div style=\"page-break-after: always\"></div>

Figure 3. Prediction-corrected VPC for the exploratory analysis

<!-- image -->

Note: Prediction-corrected platelet count values are plotted versus time from the first dose. The circles show the observed values.The lines show median (red),and the 10th and 90th percentiles(blue)of the simulated (bold solid lines) and observed (dash lines) concentrations. The simulated values were computed from plots.

<div style=\"page-break-after: always\"></div>

Figure 4- Prediction-corrected VPC for the exploratory analysis, separately for responders and non-responders

<!-- image -->

Sourcec 010slmlest2PRED\\_VPC\\_80\\_byEST.png

Note: Prediction-corrected platelet count values are plotted versus time from the first dose. The circles show the observed values. The lines show median (red),. and the 10th and 90th percentiles (blue) of the simulated (bold solid lines) and observed (dash lines) concentrations. The simulated values were computed from 1000 trials. All simulations and estimations were performed separately for non-responders (EST=1) and responders (EST=2). Right plots are the zoomed versions of the left plots.

## Base model development

The summary of base model development was presented in Table 12-13 of study report 150780. The previously developed model was first re-run with the new data. Since the model was developed on only 52 patients'  data  and  their  baseline  platelet  count  could  have  been  different,  baseline  platelet  count  and variability parameters (inter-individual and residual) were re-estimated (Model 010). Comparison of the observed platelet counts with individual predicted values from the model showed that for some subjects the model could not describe the data at later times and/or when dosing was stopped or reduced. Contrary to model predictions, platelets continued to rise for a long time at a stable dose or did not decrease when the dose was stopped. Evaluation of the model by VPC with dose-adjustment also suggested that the model needed improvement: population VPC simulations under-estimated platelet count and severely over-estimated romiplostim doses. Conditional simulations, although better, over-estimated platelet count variability and median romiplostim doses at later times. Therefore, the model was developed further. First, all model parameters were re-estimated (Model 011) except K10 that was left fixed as its value closely corresponded to the elimination rate constant of romiplostim in healthy volunteers (Wang 2010). To account for  platelet  improvement  at  later  points  with  low  (or  no  dosing),  in  Model  021  KSYN  was  modelled  as increasing with time through an Emax function (in addition to the already present effect of the drug) in both subpopulations. Time of half increase was estimated to be zero, and in Model 031 the increase was made to

<div style=\"page-break-after: always\"></div>

be instantaneous (with no change in OFV). For models where the response variable depends on baseline value and this value has high variability in the population of the analysis, it is preferable to include the observed baseline (BASL) as a covariate on the estimated baseline (E0) early in the analysis. This was done in Model 100, where E0 was modelled as E0=BASL*THETA\\_BASL*EXP(ETA\\_BASL).

As expected, θ BASL was estimated to be close to 1, and it was fixed to 1 in Model 105 (with no change in OFV). The IIV on E0 was estimated to be small and with high shrinkage; therefore η E0 was fixed to zero in Model 108. Dosing in the trials depended on observed platelet counts and it, therefore, was important that the residual error model could accurately capture the residual variability. Thus, a more flexible Emax-type residual error model was introduced in Model 108, IIV on the magnitude of the residual variability was also added. This led to a large drop of OFV.

Instantaneous increase of KSYN when the drug is given is not physiologically sound, therefore, the model where  increase  in  KSYN  was  driven  by  the  total  amount  of  drug  (AUDC)  that  reached  the  precursor compartment (in addition to the already present effect of the current drug 'concentration') was introduced instead (Model 111). In this model, a Hill function of AUDC acted additively on KSYN; the parameters Emax and EC50 were different for the 2 subpopulations, while the Hill coefficient and IIV were the same. In one of the two subpopulations, EC50 was estimated to be very low and it was fixed to be near zero in Model 110 (without significant increase of OFV). The parameter K10 that was kept fixed was allowed to be estimated in Model 115; this did not appreciably change neither the value of K10 nor the OFV. Finally, the Hill coefficient was added to the Emax residual error model in Model 120, which significantly decreased the OFV. Two more models were tested: Model 125 tried to estimate KDEG (KDEG was assumed to be equal the transit rate KT in all previous models) and Model 130 tried to fit the data without using the mixture model. KDEG was not identifiable (the KDEG/KT ratio was estimated with RSE &gt; 350%) and the model with only one population was significantly worse (OFV increased by &gt; 100 points and IIV on EC50 became huge). Therefore, Model 120 was accepted as the base model (Table 12-14 study report 150780).

All model parameters of the base model were estimated with good precision. The NONMEM control stream and output files for the base model are provided in Appendix 3 (study report 150780). The goodness-of-fit plots (Figure 5), the distributions of CWRES and of the estimated random effects together with the shrinkage values and correlations between the random effects demonstrated adequate fit of the data, centered and close to normal distributions of weighted residuals and individual random effects, no correlations between the random effects, and moderate shrinkage (except for EC50).

Figure 5. Goodness of Fit Plots, base model 120.

<!-- image -->

Note: The red line is the lowess (local regression smoother) trend line.

<div style=\"page-break-after: always\"></div>

## Covariate analysis

The summary of covariate model development was presented in Table 12-15 of study report 150780. The plots  of  the  individual  random  effects  versus  covariates  for  the  base  model  suggested  that  two  most prominent relationships were increase of EC50 with increasing ITPDIAG (Figure 13-34 study report 150780) and of MTT with increasing age (Figure 13-34 study report 150780).

These two covariates were explored first by adding both simultaneously, using the linear (Model 173) or power (Model 175) relationship of EC50 with ITPDIAG, and by testing the model without the effect of age (Model 176). Of these models, Model 173 was the best. The other possible relationships suggested by the plots of the random effects versus covariates were: AGE on EMAX and EC50; ITPDIAG&lt;0.2 years or baseline platelet count &lt; 20x10 9 /L on EMAX WT on EMAX, EC50, and SLP; Asian race on SLP; Australia geographical region on SLP, EMAX, and EC50. They all were tested univariately by adding the effect to Model 173 (except of the effect of body weight that was added to 3 parameters at once). None of the models significantly decreased the objective function (&lt; 4 points change for all models with 1 additional parameter, and 5.13 points change for the model with 3 additional parameters) and were all rejected. Therefore, the further forward addition procedure was not performed, and Model 173 was accepted as the final model.

## Final model

The parameter estimates for the final model, Model 173, are shown in Table 1. The NONMEM control stream and output files are provided in Appendix 4 of study report 150780.

The final model, Model 173, had the same structure as the previously developed model (Figure 6), but besides the hypothetical drug concentration influencing production of platelet precursors (KPD*A1), it was also influenced by the cumulative AUC of this concentration (proportional to total administered dose, AUDC):

KPROD = (KSYN + EMAX*AUDCγ/(EC50 γ + AUDCγ))*(1+ALPHA* KPD*A1).

Figure 6. Schematic Representation of the Previous Romiplostim K-PD Model

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 1. Population pharmacodynamic parameters for romiplostim

| Parameter (Units)                                  | Central Tendency (RSE, %)   | Inter-Individual variability, % (RSE, %)   |
|----------------------------------------------------|-----------------------------|--------------------------------------------|
| Krpp (/day)                                        | 0.597 (28.3)                |                                            |
| MTT (day)                                          | 7.47 (5.9)                  | 28.6 (24.1)                                |
| Effect of Age on MTT                               | 0.249 (30.4)                |                                            |
| ProportioninSubpopulation 1                        | 51.5 (8.83)                 |                                            |
| Linear effect onprogenitor cells                   |                             |                                            |
| Subpopulation 1 α (h/μg)                           | 0.19 (21.6)                 | 148 (13.0)                                 |
| Subpopulation 2 α (h/μg)                           | 1.26 (17.6)                 |                                            |
| Cumulative effect of treatment on progenitor cells |                             |                                            |
| Subpopulation 1 Emax                               | 1.02 (19.5)                 | 141 (15.6)                                 |
| Subpopulation 2 Emax                               | 1.97 (18.2)                 |                                            |
| Subpopulation 1 ECso (μg)                          | 0.0001 (FIXED)              | 112 (18.7)                                 |
| Subpopulation 2 ECso (μg)                          | 4047 (14.1)                 |                                            |
| Hill coefficient                                   | 4.23 (2.95)                 |                                            |
| Residual Error (%)                                 |                             |                                            |
| Lowplatelet concentrations                         |                             | 62.7 (3.5)                                 |
| High platelet concentrations                       |                             | 20.5 (4.64)                                |

ECso=romiplostimdosewhichachieves50%ofmaximumcumulativeeffect;Emax=maximumcumulative effect;Kpp = elimination rate constant forromiplostim dose; MTT = mean transit time; RSE = Relative

standarderror

Source:PopulationPDReport 150780.

Table 2. Parameter estimates of the previous romiplostim pharmacodynamic model

| Parameter (Units)    | Central Tendency (RSE, %)   | Inter-lndividual variability, % (RSE, %)   | Inter-Occasion variability, % (RSE, %)   |
|----------------------|-----------------------------|--------------------------------------------|------------------------------------------|
| Krpo (/day)          | 0.61 (93.3)                 |                                            |                                          |
| Circo (x10%/L)       | 11.1 (13.3)                 | 61.9 (28.2)                                |                                          |
| MTT (hr)             | 170 (23.1)                  | 24.3 (57.6)                                |                                          |
| SLP                  |                             | 78.2 (61.1)                                | 84.9 (37.7)                              |
| Proportion Subpop. 1 | 0.321 (36.4)                |                                            |                                          |
| Subpop. 1 (h/μg)     | 0.152 (81.6)                |                                            |                                          |
| Subpop. 2 (h/μg)     | 5.93 (33.1)                 |                                            |                                          |
| Residual Error (%)   |                             | 60.1 (2.0)                                 |                                          |

In general, the model parameters following model update based on data from patients with ITP ≤ 12 months from diagnosis (Table 1) were similar to those previously reported (Table 2). The romiplostim elimination rate was 0.6 day-1, the same as previously estimated. The mean transit time (MTT) for platelets was 7.47 days compared to 7.1 days reported previously. With the updated model, the proportion of subjects in each subpopulation was divided more equally with 51.5% of subjects in subpopulation 1, compared to 32% previously.  Population  2  (better  responders)  had  higher α or  linear  slope  (SLP)  (1.26  versus  0.19  for population  1),  higher  Emax  (1.97  versus  1.02)  and  EC50  value  that  would  for  70  kg  person  (with ITPDIAG=0.2 years) correspond to 1 μg/kg romiplostim dose given for 96 days (or 2 μg/kg dose for 48 days, etc.). The effect of romiplostim treatment on progenitor cells for subpopulation 1 was the same as previously reported (0.19 vs 0.2) and the effect in subpopulation 2 was reduced (1.97 vs 5.9). The difference in

<div style=\"page-break-after: always\"></div>

treatment effect for subpopulation 2 could be attributed to the cumulative effect of treatment on progenitor cells in addition to the linear effect. For population 1, there was no accumulation of the effect, EC50 was zero, so the EMAX effect was immediate while the cumulative effect of romiplostim treatment was evident in subpopulation 2 with the synthesis rate of progenitor cells rapidly increasing as cumulative dose approached and exceeded 4047 µg. The EC50 value in population 2 was proportional to the duration of ITP at study entry (i.e.  EC50  was  5  times  higher  for  a  subject  with  ITPDIAG  of  1  year  compared  to  0.2  year).  The  2 subpopulations did not differ with respect to covariates.

In addition, mean transit time was shorter in younger patients: 24% and 10% shorter in 20 and 40-year-old patients respectively compared to 60 years old, and 7% longer in 80 years old. This means that it takes longer for older patients from time of increase in production of platelet precursors to increase in platelet count in blood.

No other covariates, including sex, body weight, number of prior therapies, baseline platelet count, and region were found to influence any model parameters.

Unexplained IIV was high for treatment related parameters (CV was 148% for SLP, 141% for Emax, and 112% for EC50) and was low for the MTT parameter (28.6%). Residual variability was 20.5% and 62.7% at high and low platelet count values, respectively, and at the platelet count value of 120x109/L the residual variability was halfway between the two values (41.6%). The model parameters were estimated with good precision (RSE &lt; 20% for all parameters except for 4, for them RSE of 21 - 30%).

Figure 7. VPC with dose-adjustment, final model 173 .

<!-- image -->

Note: Population (top) and conditional (bottom) VPC simulations for platelet count (left) and romiplostim doses (right) versus time from the first dose for Study 20080435. The lines show median (red). and the 10th and 90th percentiles (blue) ofthe observed values. The shaded regions show the 80% confidence intervals on these quantities obtained by simulations. The simulated values were computed from 500 trials with platelet measurement times and the covariate values of the analysis dataset (See Model Evaluation Section).

## Model prediction of summary metrics

After  incorporating  these  changes  to  the  previously  published  model,  the  updated  model  was  able  to adequately describe patients with ITP ≤ 12 months from diagnosis. Summary metrics of the incidence of durable platelet response, sustained platelet response, and duration of platelet response were summarised for the model predictions and patients included in the modelling dataset (Table 3).

<div style=\"page-break-after: always\"></div>

Table 3.  Predicted  and  Observed Incidence of Durable Platelet Response, Sustained Platelet Response, and Duration of Platelet Response for Patients Included in the Modelling Dataset

| FromITP Diagnosis   |      | DurablePlatelet (%ofSubjects) Response?   | DurablePlatelet (%ofSubjects) Response?   | SustainedPlatelet (%ofSubjects) Responseb   | SustainedPlatelet (%ofSubjects) Responseb   | DurationofPlatelet Response\" %ofMonths Mean (SD)   | DurationofPlatelet Response\" %ofMonths Mean (SD)   |
|---------------------|------|-------------------------------------------|-------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| FromITP Diagnosis   | N    | Predicted                                 | Observed                                  | Predicted                                   | Observed                                    | Predicted                                          | Observed                                           |
| <3                  | 127  | 26                                        | 22                                        | 54.3                                        | 50.4                                        | 81.7 (34.6)                                        | 81.2 (32.9)                                        |
| 3≤to<6              | 70   | 24.3                                      | 21.4                                      | 64.3                                        | 54.3                                        | 83.6 (30.2)                                        | 80.8 (25.7)                                        |
| 6≤to≤12             | 63   | 25.4                                      | 20.6                                      | 57.1                                        | 49.2                                        | 79.8 (32.7)                                        | 80.3 (25.5)                                        |
| Total               | 260d | 25.4                                      | 21.5                                      | 57.7                                        | 51.2                                        | 81.8 (32.9)                                        | 80.9 (29.3)                                        |

aPatientswhoachievedaplatelet tresponse(medianweekyplateletcount&gt;50x1o9/L)foratleast6of 8weeksduringweeks17to24.

P =immune thrombocytopenia

bSubjectswhoachievedaplateletresponse(medianweeklyplateletcount&gt;50x1o9/L)for9weeksinany

cAmonthlyplateletresponseisdefinedasthemedianoftheplateletcountsmeasuredduringthatmonthis ≥50x109/L

dof the268subjectsincludedinthemodelingdataset,8subjeclsdidnothaveenoughplateletobservations tocalculatedurableorsustainedplateletresponse,ordurationofplateletresponse.

Summary metrics of response were predicted well by the model and were within 5 to 10% of the values observed for the patients in the modelling dataset demonstrating adequacy of the updated model to describe the romiplostim doseplatelet response in patients with ITP ≤ 12 months from diagnosis.

## Model-based simulations

Following the model update, clinical trial simulations in patients with ITP ≤ 12 months from diagnosis were performed with romiplostim dosing based on the dosing algorithm specified in the Eu SmPC and in the UPSI. Simulations, based on 500 replicates of the analysis dataset which included sampling of baseline platelet counts and model covariates, were conducted to predict and summarize platelet counts and romiplostim doses over 52 weeks of treatment (Tables 4 and 5, respectively).

Table 4.  Simulated  metrics  of  platelet  response  by  time  from  ITP  diagnosis  and  by subpopulation based on the dosing algorithm in the EU SmPC

|                         |                           | Observations Above or Below Threshold (%)   | Observations Above or Below Threshold (%)   | Observations Above or Below Threshold (%)   | Durable Platelet (% )a   |
|-------------------------|---------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|--------------------------|
| Time From ITP Diagnosis | Evaluation Period (weeks) | <20x10%/L                                   | Between50 and150x10%/L>250x10%/L            |                                             | Response                 |
| ≤12 months              | 18-25                     | 6                                           | 46.2                                        | 14.2                                        | 76                       |
| ≤12 months              | 26 -52                    | 5.8                                         | 47.5                                        | 14                                          | 76                       |
| ≤6 months               | 18 -25                    | 5.8                                         | 45.9                                        | 14.8                                        | 77                       |
| ≤6 months               | 26 -52                    | 5.6                                         | 47.2                                        | 14.5                                        | 77                       |
| >6 months to≤12 months  | 18 -25                    | 6.9                                         | 47.4                                        | 12.5                                        | 74                       |
| >6 months to≤12 months  | 26 -52                    | 6.5                                         | 48.4                                        | 12.6                                        | 74                       |
| Subpopulation           | Subpopulation             | Subpopulation                               | Subpopulation                               | Subpopulation                               | Subpopulation            |
| 1                       | 18-25                     | 6.9                                         | 46.5                                        | 13.7                                        | 69                       |
| 1                       | 26 -52                    | 6.9                                         | 46.9                                        | 13.8                                        | 69                       |
| 2                       | 18 -25                    | 5                                           | 46.0                                        | 14.8                                        | 84                       |
| 2                       | 26 -52                    | 4.5                                         | 48.2                                        | 14.2                                        | 84                       |

aPercentage of patients whoachieved a platelet response (median weekly platelet count≥ 50 x 10%/L) for at least6of8weeksbetweenweeks 17to24.

IP=immunethrombocytopenia;EU SmPC=EuropeanUnionSummaryof Product Characteristics.

<div style=\"page-break-after: always\"></div>

Table 5.  Simulated  metrics  of  platelet  response  by  time  from  ITP  diagnosis  and  by subpopulation based on the dosing algorithm in the USPI

|                         |                           | Observations Above or Below Threshold (%)   | Observations Above or Below Threshold (%)   | Observations Above or Below Threshold (%)   | Durable Platelet   |
|-------------------------|---------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|--------------------|
| Time From ITP Diagnosis | Evaluation Period (weeks) | <20 x 10%/L                                 | Between50 and 250 × 10%/L > 400 x 10%/L     |                                             | Response (%)a      |
| ≤12months               | 18-25                     | 5.6                                         | 64.5                                        | 6.5                                         | 77                 |
|                         | 26 -52                    | 5.4                                         | 66.9                                        | 6.2                                         |                    |
| ≤6 months               | 18 -25                    | 5.3                                         | 64.4                                        | 6.9                                         | 78                 |
|                         | 26 -52                    | 5.2                                         | 66.7                                        | 6.5                                         |                    |
| >6 months               | 18-25                     | 6.5                                         | 64.9                                        | 5.5                                         | 76                 |
| to≤12 months            | 26 -52                    | 6.1                                         | 67.5                                        | 5.3                                         |                    |
| Subpopulation           |                           |                                             |                                             |                                             |                    |
|                         | 18 -25                    | 7.7                                         | 69.1                                        | 1.7                                         | 70                 |
|                         | 26 -52                    | 7.7                                         | 70.6                                        | 1.7                                         |                    |
| 2                       | 18 -25                    | 2.1                                         | 71.4                                        | 6.3                                         | 87                 |
|                         | 26 -52                    | 1.5                                         | 75.4                                        | 5.5                                         |                    |

Percent of palients who achieved a platelet response (median weekly platelet count ≥ 50 x 10?/L)forat least6of8weeksbetweenweeks17to24.

IP =immune thrombocytopenia; USPl = United States Package hsert.

Model-based simulations show that, treatment with romiplostim according to the dosing titration algorithm in EU SmPC and UPSI, maintains platelet counts in patients with ITP ≤ 12 months from diagnosis with similar proportion of observations and durable platelet response for patients with ITP ≤ 6 months and &gt; 6 to ≤ 12 months from diagnosis. The dosing algorithm specified in the EU SmPC is effective in increasing platelet counts to the desired range of 50 to 150 x 10 9 /L (or to 250 x 10 9 /L in the UPSI) and minimising the proportion below 20 x 10 9 /L across ITP patients regardless of time since ITP diagnosis or model-based subpopulation. The percentage of observations above 400 x 10 9 /L is predicted to be &lt; 7% across subgroups, being this fact consistent with the predicted percentage of &lt; 35% of subjects above 400 x 10 9 /L across subgroups  observed  in  the  adult  ITP  safety  datasets  (please  refer  to  the  safety  section).  In  general, approximately 46% and 65% of subjects are predicted to maintain platelet counts between 50 to 150 x 10 9 /L after titration according to the SmPC.

## 2.3.5. Discussion on clinical pharmacology

Romiplostim is currently approved to be administered as a weekly SC injection with dose adjustments based upon the platelet count response. The initial dose for romiplostim is 1 μ g/kg based on actual body weight and could be adjusted up to a maximum weekly dose of 10 μ g/kg. In order to support the adequacy of this labelled dosing algorithm in patient with ITP ≤ 12 months, the MAH has provided an updated PD population analysis with data form 7 parent studies previously assessed. The modeling dataset consisted of a total of 7854 platelet counts from 268 patients (with ITP ≤ 12 months from diagnosis and a median of 3 months from diagnosis) receiving weekly SC romiplostim at doses ranging from 1 to 15 μ g/kg and platelet counts collected over 3 years.

This  PD  modeling  exercise  was  informed  by  the  previously  published  model  [Perez-Ruixo  et  al,  2012]. Nevertheless, an external validation demonstrated that the previous model was not adequate to describe the time course of platelets in patients with ITP ≤ 12 months from diagnosis. The model was, therefore, updated, based on the new analysis dataset and included re-estimation of model parameters. Instead of estimating baseline  platelet  count,  it  was  set  to  observe  individual  baseline  to  account  for  substantial  variability between  subjects.  To  account  for  the  patients  whose  platelets  recovered  to  normal  levels  following treatment over time, a cumulative effect of romiplostim dosing on platelet synthesis was also incorporated.

<div style=\"page-break-after: always\"></div>

The main difference of the updated PD model suggested that romiplostim increased production of platelet precursors by 2 mechanisms. The first, present in the earlier model, was increase of production proportional to  hypothetical  drug  concentrations.  The  second,  not  present  in  the  earlier  model,  was  increase  of production as the Hill function of cumulative AUC on progenitor cells (or dose, since PK was not measured). The previously developed model was based on the data following much shorter treatment (1 to 6 doses) and without  intra-subject  dose  changes.  Therefore,  the  second  mechanism  was  included  to  describe  the increased platelet production in approximately 50% of the population could not have been identified or differentiated from the first in that model. Unfortunately, the bimodal distribution could not be explained by none of the covariates selected, diminishing the impact of the population PK model developed.

A mixture model was implemented since, as in the previous model, patients with ITP ≤ 12 months from diagnosis continued to demonstrate a bimodality in response, 50% of patients with a substantial response to romiplostim treatment with cumulative improvement in platelet counts over time (subpopulation 2) and others with reduced response to romiplostim with minimal cumulative effect over time (subpopulation 1). However, there is an increase in the proportion of patients who are less sensitive to romiplostim treatment (51.5% vs 32%).

The model parameters, based on data from patients with ITP ≤ 12 months, were similar to those previously reported (Tables 1 and 2). As previously estimated, the romiplostim elimination rate was 0.6 day-1, while the mean transit time (MTT) for platelets was 7.47 days (vs 7.1 days in previous). Proportion of subjects in each subpopulation was divided more equally, 51.5% of subjects in subpopulation 1 (vs 32% previously). The effect of romiplostim treatment on progenitor cells for subpopulation 1 was the same as previously reported (0.19 vs 0.2) while the effect in subpopulation 2 was reduced (1.97 vs 5.9). The MAH argues that this  difference  in  treatment  effect  for  subpopulation  2  could  be  attributed  to  the  cumulative  effect  of treatment on progenitor cells in addition to the linear effect. The cumulative effect of romiplostim treatment was evident in subpopulation 2 as the synthesis rate of progenitor cells rapidly increasing as cumulative dose approached and exceeded 4047 μ g while in subpopulation 1 was minimal with the effect fully achieved after the initial romiplostim dose. Differences in the sensitivity of the effect of cumulative dose were hypothesised to be related to ITP severity or disease status, but it could not be scientifically justified due to the lack of experimental evidence available.

It is remarkable that, 2 covariate effects were also added to the model: the age effect on MTT suggested increasing MTT with increasing age. The effect of time since ITP diagnosis led to a linear decrease (if &lt; 2.4 months since diagnosis) or increase (≥ 2.4 months since diagnosis) in cumulative dose needed to achieve 50% of the maximal effect. No other covariates were found to influence any model parameters.

The model was evaluated by a VPC procedure with response-guided dose adjustment simulations and by comparison of various statistics of platelet counts and was shown to be acceptable to perform simulations. Durable platelet response, sustained platelet response, and duration of platelet response were predicted well by the model, within 5 to 10% of the values observed for the patients in the modeling dataset (Table 3).

Simulations were then performed to evaluate whether the current approved dosing algorithm (USPI or EU SmPC), is suitable for dosing patients with duration of ITP &lt;  12 months. No notable differences were observed in proportions of observations and durable platelet response for patient with ITP ≤ 6 months and &gt; 6 to ≤ 12 months from diagnosis, demonstrating that dosing algorit hm is effective in increasing platelet counts to the desire range of 50 to 150 x 10 9 /L and minimising the proportion below 20 x 10 9 /L across ITP patients regardless of time since ITP diagnosis or model-based subpopulation. In general, approximately 46% and 65% of subjects are predicted to maintain platelet counts between 50 to 150 x 10 9 /L after titration according to the EU SmPC or between 50 and 250 x 10 9 /L after titration according to the USPI (Tables 4 and 5). The percentage of observations above 400 x 10 9 /L is predicted to be &lt; 7% across subgroups, consistent with the percentage of &lt; 35% of subjects above 400 x 10 9 /L observed in the adult ITP safety datasets (please refer to the safety section).

<div style=\"page-break-after: always\"></div>

## 2.3.6. Conclusions on clinical pharmacology

The updated population model provided by the MAH to support the appropriateness of the current labelled dosing algorithm of romiplostim in patient with ITP ≤ 12 months, is considered appropriate. The updated model adequately describes platelet counts in the overall population of patients with ITP ≤ 12 months and, in the same way as the previous model, identified 2 subpopulations, with reduced response and increased response  to  romiplostim  treatment.  In  addition,  the  updated  model  identified  2  drivers  of  increase  of production  of  platelet  precursors:  increase  proportional  to  concentration  (or  dose)  of  romiplostim (immediate response) and saturable increase due to total romiplostim dose from treatment start (delayed response).

Two new covariates were added in the updated model that may have influence in model parameters. The age effect on MTT and the effect of time since ITP diagnosis in EC50. Time from increase of production of platelet precursors to appearance of platelets in blood increased with aged, while age did not influence response to romiplostim. Time since ITP diagnosis led to a linear decrease (if &lt; 2.4 months since diagnosis) or increase (≥ 2.4 months since diagnosis), in cumulative dose needed to achieve 50% of the maximal effect. No other covariates were found to influence any model parameters.

Finally, model-based simulations demonstrated that, romiplostim administered according to the currently approved label dosing titration, achieved and maintained platelet counts in an adequate range (of 50 to 150 x 10 9 /L and minimizing the proportion below 20 x 10 9 /L) with no notable differences between patient with ITP ≤ 6 months and &gt; 6 to ≤ 12 months from diagnosis.

## 2.4. Clinical efficacy

Efficacy data of romiplostim in adult ITP were described in the original marketing authorisation application and are essentially unchanged.

Efficacy of romiplostim has been sufficiently demonstrated in the original MAA and following variations. Romiplostin increases platelet counts, which is considered a reliable surrogate outcome measure in ITP correlated to a decreased bleeding risk and as the basis for clinical practice guidelines recommendations [Provan, et al 2019, Neunert, et al 2019]. Many studies on romiplostim have been published.

As the basis of this application, the company provides an integrated analysis with data from 311 subjects with ITP ≤ 12  months included in 7 parent clinical studies previously assessed in previous applications regarding the MAA of Nplate (studies 20030105, 20030212, 20040209, 20060131, 20060216, 20080009, 20080435) and 2 extension studies (20030213, 20060113) (Figure 8).

<div style=\"page-break-after: always\"></div>

Figure 8. Romiplostim ITP clinical studies including subjects with ITP ≤ 12 months

<!-- image -->

ITP = immune thrombocytopenia; SOC = standard of care; OL = open label; OLE = open-label extension N = number of subjects in the integrated ITP analysis set, which consisted of adult subjects (≥ 18 years of age at screening) who had received ≥ 1 dose of romiplostim in any of the parent ITP studies 20030105, 20030212, 20040209, 20060131, 20060216, 20080009, 20080435 and the subjects' data from the open-label extension studies (20030213 and 20060113). Data after treatment switch were excluded. N*= Number of subjects with ITP duration ≤ 12 months at study entry of the parent study. Across all studies, a total of 311 subjects (277 romiplostim, 34 pla cebo/SOC) were included in the integrated ITP analysis set.

Prior to integrating studies, the MAH has sent a very brief summary of each individual study to determine appropriateness of the integration. The information provided is summarised below.

## 2.4.1. Main studies

## 2.4.1.1. Individual studies

The following table summarise the efficacy results from the main studies through which the integrated analysis has been carried out supporting the present application.

<div style=\"page-break-after: always\"></div>

| Study Numbera/ (Original CSR Submission Date)   | Study Design                               | Dosing / Treatment Duration               | Study Endpoints (Primary and Other Efficacy Endpoints)                                                                                                                                                                                                               | Study Population Total Enrolled (ITP ≤ 12 months) / Median (Range) Time From ITPDiagnosis      | Overall Key StudyResults (Primary Endpoint)                                                                                                                                                              |
|-------------------------------------------------|--------------------------------------------|-------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 20030105 (02November2007; SN 0000)              | Phase 3, double-blind, placebo- controlled | Romiplostim 1-15 μg/kg Q1W; SC/ 24 weeks  | Primary endpoint:incidence of durableplateletresponseb Key secondary endpoints: incidence ofoverallplatelet response°,numberof weeks with platelet response, proportion of subjects requiringrescue medication, incidenceofdurableplatelet response with stabledosed | Adults with ITPe refractory to splenectomy 63(5romiplostim,0placebo)/ 8.00 (0.6 to 44.8) years | Romiplostim was significantly superior to placebofor the primary efficacyendpointof incidence of durable plateletresponse.                                                                               |
| 20060216a (12 March 2015; SN 0135)              | Phase 3, double-blind, placebo- controlled | Romiplostim 3-10 μg/kg Q1W; SC / 12 weeks | Primaryendpoint:numberof weekswithweeklyplatelet responses!, Key secondary endpoints: incidence of increase in platelet count',incidence of administration of rescue medication                                                                                      | Japanese adults with ITPi 34 (1 romiplostim,1 placebo) / 5.8 (1 to 40) yearst                  | Demonstrated short-term safety of romiplostim compared withplacebo in Japanese subjects withITPandshowed evidenceforefficacyof romiplostim in raising and sustaining platelet counts in this population. |

| StudyNumbera/ (Original CSR Submission Date)   | Study Design                                | Dosing / Treatment Duration                    | Study Endpoints (Primary and Other Efficacy Endpoints)                                                                                                                                                                                                     | Study Population Total Enrolled (ITP≤12months)/ Median (Range)Time From ITP Diagnosis     | Overall Key Study Results (Primary Endpoint)                                                                                                                           |
|------------------------------------------------|---------------------------------------------|------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 20030212a (02November2007; SN 0000)            | Phase 3, double- blind, placebo- controlled | Romiplostim 1-15 μg/kg Q1W; SC/ 24 weeks       | Primaryendpoint:incidenceof durableplateletresponseb Keysecondaryendpoints: incidenceofoverallplatelet response°,numberofweeks withplateletresponse, proportion of subjects requiring rescuemedication,incidence ofdurableplateletresponse withstabledosed | AdultswithITPepriorto splenectomy 62 (15 romiplostim,6 placebo) 2.10 (0.1 to 31.6) yearst | Romiplostim demonstratedsignificant superiorityoverplacebo for all key efficacy endpointsanda tolerablesafetyprofilein subjectswithITPwho hadnotreceiveda splenectomy. |
| 200402098 (02November2007; SN 0000)            | Phase 3b, open-label                        | Romiplostim 1-10 μg/kg Q1W;SC/ Up to 201 weeks | Primaryendpoint:incidenceof adverseevents,including clinically significant changes in laboratoryvalues,incidence of antibodyformation Secondaryendpoint: incidenceofplateletresponsei                                                                      | Adults with ITPe 407(92romiplostim)/ 4.25 (0.03 to 57.14) years                           | Romiplostimwaswell toleratedandwasableto induceplatelet responseswithinweeks ofstartingtreatmentin themajorityofsubjects enrolled.                                     |

| Study Numbera / (Original CSR Submission Date)   | Study Design                                 | Dosing / Treatment Duration              | Study Endpoints (Primary and Other Efficacy Endpoints)                                                                                                                                                                                                                                                                            | Study Population Total Enrolled (ITP≤12months)/ Median(Range) Time From ITPDiagnosis       | Overall Key Study Results (Primary Endpoint)                                                                                                                                                        |
|--------------------------------------------------|----------------------------------------------|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 20060131a (09 March 2012; SN 0078)               | Phase 3, open-label, versus standard of care | Romiplostim 3-10 μg/kg Q1W; SC/ 52 weeks | Primary endpoints: number of subjects undergoing a splenectomy during the treatmentperiodby randomized treatment group; number of subjects with a treatmentfailureduringthe treatmentperiodby randomized treatment groupk Secondaryendpoints:timeto splenectomy,number of plateletresponses,changein ITPpatient-reported outcomes | Nonsplenectomized adults with ITPe 234 (56 romiplostim,27 S0C)/ 2.09 (0.01 to 44.22) years | Romiplostim administered weekly was welltoleratedand significantlyreduced the incidences of splenectomy and treatment failurein nonsplenectomized subjects with ITP comparedwiththe standardofcare. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Study Numbera / (Original CSR Submission Date)   | Study Design        | Dosing/ Treatment Duration               | Study Endpoints (Primary and Other Efficacy Endpoints)                                                                                                                                                                                         | Study Population Total Enrolled (ITP≤12months / Median (Range) Time From ITP Diagnosis   | Overall Key Study Results (Primary Endpoint)                                                                                                                                                                                                                                                                             |
|--------------------------------------------------|---------------------|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 20080009 (10 December 2014; SN 0131)             | Phase 4, open-label | Romiplostim 1-10 μg/kg Q1W; SC / 3 years | Primaryendpoint:incidenceof collagen fibrosis. Secondary endpoints: incidenceofcollagenfibrosis afterromiplostim discontinuation,incidenceof increased reticulin fibrosis, electrocardiogram changes, incidence of cytopenias, overall safety. | Adults with ITPe 169(33romiplostim)/ 4.11 (0.0 to 47.7) years                            | Among subjects with evaluablebonemarrow results,0of35subjects in cohort 1, 0 of 39 subjects in cohort 2, and 2of58subjects (3.4%) in cohort 3 developed collagen. One of the2subjects who developed collagen hadnoevidenceof collagen at the follow-up bone marrow biopsy 12 weeks after discontinuation of romiplostim. |

| Study Numbera/ (Original CSR Submission Date)   | Study Design        | Dosing / Treatment Duration              | Study Endpoints (Primary and Other Efficacy Endpoints)                                                                                                                                        | Study Population Total Enrolled (ITP≤12months/ Median(Range) Time From ITPDiagnosis                     | Overall Key Study Results (Primary Endpoint)                                                                                                                           |
|-------------------------------------------------|---------------------|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 20080435 (12 March 2015; SN 0135)               | Phase 2, single-arm | Romiplostim 1-10 μg/kg Q1W; SC/ 12months | Primary endpoint: number of months a subject achieved a plateletresponseduringthe 12-month treatment period Secondary endpoints: subject incidence ofITPremissionm, splenectomy,adverseevents | AdultswithITPwho previouslyreceivedonly first-line therapies 75 (75 romiplostim)/ 2.2(0.1to 6.6) months | Treatmentwith12monthsof romiplostimwasassociated withameanof9.2months of platelet response during the12-monthtreatment period; 93.3% of subjects hadaplateletresponse. |

CSR=clinical studyreport;ITP=immune thrombocytopenla;Q1W=once a week;SC=subcutaneous;SN=sequencenumber;SOC=standardof care

Subjeclswhocompleted aromiplostimITPstudy wereeligible toenrollintheopen-labelextensionstudies:Study20030213described inSection7.1.3.1,(parent studies included20000137A,20000137B,20010218,20030105,20030212,20040209,20060131,and 20060195)orStudy 20060113 described inSection7.1.3.2, (parent studies included 20050162 and 20060216).

° Overallplatelet response (mutually exclusive categories of durable platelet response [defined above] plus transient platelet response [at least 4 weekly platelet responses, without durable platelet responsel).

b Durable platelet response = at least 6 weekly platelet responses during the last 8 weeks of treatment in the absence of rescue medication.

d Durable platelet response with stable dose = dose maintained within ± 1 μg/kg during the last 8 weeks of treatment.

fYears are calculated as (randomization date - ITP diagnosis date) / 365.25. When applicable, partial dates of ITP diagnosis with missing day only are imputed as 15, partialdateswithmissingmonthanddayareimputed asO1July.

e ITP diagnosed according to American Society of Hematology (ASH) guidelines (George et al, 1996).

9Weekly platelet response=platelet count of ≥50x 109/L ona weekly scheduled dose day from week 2to week13 excluding platelet counts within 4 weeksfollowing the use of rescue medication.

iITP diagnosed according to the diagnostic criteria proposed by the Research Commilee for Idiopathic Hematopoietic Disorders of the Ministry of Health, Labour and Welfare

h Incldence of increase in platelet count = increase ≥ 20 x 109L from baseline

jincidence of platelet response = either a doubling of baseline platelet count and a platelet count ≥ 50 x 109/L, or a platelet count increase of ≥ 20 x 109/L from baseline.

IPlatelet response during any 1 month = median of platelet counts measured in the month ≥ 50 x 10%/L.

k Treatment fallure was defined as a lack of efficacy, defined as a platelet count ≤ 20 x 10°/L for 4 consecutive weeks at the highest recommended dose and schedule change in therapy due to an intolerable side effect or bleeding symptoms (including a minor bleeding event).

m Remission = maintaining every platelet count ≥ 50 x 109/L for at least 6 months in the absence of romiplostim and any medication for ITP (concomitant or rescue).

A brief description of the efficacy of romiplostim in individual studies used in the integrated analysis is provided below:

- Controlled Studies: Four controlled studies (Study 20030105, Study 20030212, Study 20060131 and Study 20060216) provide efficacy data supporting the current application (Figure 8), with key efficacy data provided from Study 20030105 and Study 20030212, which were conducted to support initial approval of romiplostim for the treatment of patients with chronic ITP.

Because the definition of chronic ITP was revised, some subjects enrolled in pivotal studies, 20030105 and 20030212, who were considered to have chronic ITP per the 1996 ASH guidelines [George et al, 1996], would  now  be  considered  to  have  newly  diagnosed  or  persistent  ITP  per  the  2011  ASH  guidelines [Rodeghiero et al, 2009].  Specifically, 5 of 63 (7.9%) subjects in Study 20030105 and 21 of 62 (33.9%) subjects in Study 20030212 had a duration of ITP ≤ 12 months at study entry. The MAH has performed, prior to the integrated analysis, a post-hoc analysis of durable platelet response by ITP duration at study entry

<div style=\"page-break-after: always\"></div>

regarding these two pivotal studies. Study 20060131 and Study 20060216 were supporting phase 3b and phase 3 studies, respectively.

-  Study  20030105 : This study was a phase 3, randomized, double blind, placebo controlled, 24-week study designed to assess the efficacy and safety of romiplostim in adult thrombocytopenic subjects with ITP refractory  to  splenectomy.  The  primary  objective  was  to  evaluate  the  efficacy  of  romiplostim  in  the treatment of thrombocytopenia in adult subjects with ITP, as measured by durable platelet response during the last 8 weeks of treatment, and other platelet response parameters. The secondary objectives were to evaluate the overall safety of romiplostim; to evaluate possible reductions in concurrent ITP therapies while receiving romiplostim; and to evaluate changes in patient-reported outcomes and health resource utilization due to treatment with romiplostim.

A total  of  63  subjects  (21  placebo,  42  romiplostim)  were  enrolled.  The  median  (range)  time  from  ITP diagnosis  to  the  first  dose  of  investigational  product  was  8.0  (0.6  to  44.8)  years;  median  time  since splenectomy was 6.56 (0.2 to 43.0) years. The mean (SD) platelet count at screening was 14.1 (8.1) x10 9 /L in the placebo group and 15.0 (7.8) x 10 9  /L in the romiplostim group.

Overall efficacy results Romiplostim was statistically significantly superior to placebo for the primary efficacy endpoint  and  for  the  key  secondary  endpoints.  A  significantly  greater  proportion  of  subjects  in  the romiplostim group (16 subjects, 38.1%) than in the placebo group (no subjects) achieved a durable platelet response  (p  =  0.0013).  Descriptive  secondary  endpoints  and  additional  planned  efficacy  analyses  also demonstrated  the  efficacy  of  romiplostim.  No  subjects  in  the  placebo  group  and  33  subjects  in  the romiplostim group (78.6%) achieved an overall platelet response (p &lt; 0.0001). The number of weeks with platelet response was also significantly greater for the romiplostim group: mean (SD) 0.2 (0.5) weeks for placebo and 12.3 (7.9) weeks for romiplostim (p &lt; 0.0001). A total of 12 subjects (57.1%) in the placebo group and 11 subjects (26.2%) in the romiplostim group received rescue medication during the treatment period (p = 0.0175). A total of 13 subjects (31.0%) were able to achieve a durable platelet response at a stable dose of romiplostim (no subject in the placebo group) (p = 0.0046) ('stable dose' was defined as a dose maintained within ± 1 μ g/kg during the last 8 weeks of treatment).

By the end of study (week 25), all 12 subjects in the romiplostim treatment group who had been receiving ITP therapies at baseline had either reduced (&gt; 25%) or discontinued those therapies (compared with 1 subject in the placebo group).

Platelet counts increased above their baseline values by ≥ 20 x 10 9 /L for 5 subjects (23.8%) in the placebo group and 37 subjects (88.1%) in the romiplostim group (p &lt; 0.0001). The mean change from baseline in platelet  counts  showed  no  change  for  the  placebo  group  and  a  rapid  increase  followed  by  steady maintenance above 50 x 10 9 /L for the romiplostim group when rescue medications were excluded from the analysis.

## Post-hoc Analysis of Durable Platelet Response by ITP Duration at Study Entry

Of the 63 subjects enrolled in Study 20030105, a total of 5 subjects (0 placebo, 5 romiplostim) had a duration of ITP ≤ 12 months at study entry, and 58 subjects (21 placebo, 37 romiplostim) had a duration of ITP &gt; 12 months (Table 24, section 5.4.1.2 ). Among subjects in the subgroup with ITP ≤ 12 months, 2 of 5 subjects (40.0%) treated with romiplostim attained a durable platelet response. Among subjects in the subgroup with ITP &gt; 12 months, 14 of 37 subjects (37.8%) treated with romiplostim attained a durable platelet response as compared with 0 of 21 subjects (0%) treated with placebo (Table 6).

The MAH concludes that romiplostim demonstrated significant superiority over placebo for all key efficacy endpoints in this phase 3, randomized, placebo-controlled study of adult thrombocytopenic subjects with ITP who were refractory to splenectomy. Durable platel et response in both the subset of subjects with ITP ≤ 12 months duration and the subset of subjects with ITP &gt; 12 months duration was similar to that reported in the overall study population evaluated in this study.

<div style=\"page-break-after: always\"></div>

-Study 20030212: this was a phase 3, randomized, double blind, placebo controlled, 24-week study designed to assess the efficacy and safety of romiplostim in adult thrombocytopenic subjects with ITP who had not undergone splenectomy.

Subjects with a diagnosis of ITP according to 1996 ASH practice guidelines [George et al, 1996] who had not undergone splenectomy, had completed at least 1 prior treatment, and had a platelet count of ≤ 30 x 10 9  /L prior to study entry were randomized (2:1) to 24 weeks of romiplostim or placebo. The primary objective was also to evaluate the efficacy of romiplostim in the treatment of thrombocytopenia in adult subjects with ITP, as measured by durable platelet response during the last 8 weeks of treatment, and other platelet response parameters. The secondary objectives were to evaluate the overall safety of  romiplostim;  to evaluate  possible  reductions  in  concurrent  ITP  therapies  while  receiving  romiplostim;  and  to  evaluate changes in patient-reported outcomes and health resource utilization due to treatment with romiplostim.

A total of 62 subjects (21 placebo, 41 romiplostim) were enrolled. The median time from ITP diagnosis to the first dose of investigational product was 2.10 years (range: 0.1 to 31.6). All subjects received prior first-line treatment. The mean (SD) platelet count at screening was 19.1 (8.3) x10 9  /L in the placebo group and 17.9 (7.6) x 10 9  /L in the romiplostim group.

## Overall efficacy Results

Romiplostim was statistically significantly superior to placebo for the primary efficacy endpoint and for the key  secondary  endpoints.  A  significantly  greater  proportion  of  subjects  in  the  romiplostim  group  (25 subjects, 61.0%) than in the placebo group (1 subject, 4.8%) achieved a durable platelet response (p &lt; 0.0001). The analyses for additional secondary efficacy endpoints and descriptive secondary endpoints also demonstrated the efficacy of romiplostim. A total of 3 subjects (14.3%) in the placebo group and 36 subjects (87.8%) in the romiplostim group achieved an overall platelet response (p &lt; 0.0001). The mean (range) number of weeks with platelet response was 1.3 (0 to 15) weeks for the placebo group and 15.2 (0 to 24) weeks for the romiplostim group (p &lt; 0.0001). A total of 13 subjects (61.9%) in the placebo group and 7 subjects (17.7%) in the romiplostim group received rescue medication during the treatment period (p = 0.0004). A total of 21 subjects (51.2%) were able to achieve a durable platelet response at a stable dose of romiplostim (no subject in the placebo group) (p = 0.0001) ('stable dose' was defined as a dose maintained within ± 1 μ g/kg during the last 8 weeks of treatment).

A  total  of  11  subjects  in  the  romiplostim  group  and  10  subjects  in  the  placebo  group  were  receiving concurrent ITP therapies at baseline. At week 13, in the romiplostim group, 5 subjects (45.5%) had a &gt; 25% reduction in concurrent ITP treatment and 2 subjects (18.2%) had discontinued all concurrent ITP therapies; 1 subject (10.0%) in the placebo group had a &gt; 25% reduction and 3 subjects (30%) discontinued all concurrent ITP treatment. At week 25, in the romiplostim group,4 subjects (36.4%) had a &gt; 25% reduction and 4 subjects (36.4%) had discontinued all concurrent ITP therapies; in the placebo group, 2 subjects (20.0%) had a &gt; 25% reduction and 3 subjects (30.0%) discontinued all concurrent ITP treatment.

Platelet counts increased above their baseline values by ≥ 20 x 10 9 /L for 7 subjects (33.3%) in the placebo group and 38 subjects (92.7%) in the romiplostim group (p &lt; 0.0001). Platelet counts in the placebo group remained relatively steady throughout the study, while median platelet count in the romiplostim group increased to a maximum of 100 x 10 9 /L at week 11, and then remained at an increased level of between 62.5 x 10 9 /L and 96 x 10 9 /L above baseline for the remainder of the 25-week treatment period.

## Post-hoc Analysis of Durable Platelet Response by ITP Duration at Study Entry

Of the 62 subjects enrolled in Study 20030212, a total of 21 subjects (6 placebo, 15 romiplostim) had a duration of ITP ≤ 12 months at study entry, and 41 subjects (14 placebo, 27 romiplostim) had a duration of ITP &gt; 12 months (Table 9 section 5.4.1.2). Among subjects in the subgroup with ITP ≤ 12 months, 10 of 15 subjects (66.7%) treated with romiplostim attained a durable platelet response, as compared with 1 of 6 subjects (16.7%) treated with placebo (Table 6). Among subjects in the subgroup with ITP &gt; 12 months, 15

<div style=\"page-break-after: always\"></div>

of 26 subjects (57.7%) treated with romiplostim attained a durable platelet response as compared with 0 of 15 subjects (0%) treated with placebo (Table 7).

The MAH concludes that romiplostim demonstrated significant superiority over placebo for all key efficacy endpoints and a tolerable safety profile in  this  phase  3,  randomized,  placebo-controlled  study  of  adult thrombocytopenic subjects with ITP who had not received a splenectomy. Durable platelet response in both the subset of subjects wit h ITP ≤ 12 months duration and the subset of subjects with ITP &gt; 12 months duration was similar to that reported in the overall study population evaluated in this study.

Table  6.  Subject  Incidence  of  Durable  Platelet  Response  -  Studies  20030105  and  20030212 (Subjects with ≤ 12 Months of ITP Duration)

|                                                             | Study20030105   | Study20030105      | Study20030212   | Study20030212        | Overall        | Overall              |
|-------------------------------------------------------------|-----------------|--------------------|-----------------|----------------------|----------------|----------------------|
|                                                             | Placebo (N = 0) | Romiplostim (N= 5) | Placebo (N=6)   | Romiplostim (N = 15) | Placebo (N =6) | Romiplostim (N = 20) |
| Subjectswhoachieveda plateletresponseforat least6ofthelast8 | 0 (0.0%)        | 2 (40.0%)          | 1 (16.7%)       | 10 (66.7%)           | 1 (16.7%)      | 12 (60.0%)           |
| 95%exactbinomial confidenceinterval                         | (..)            | (5.3%, 85.3%)      | (0.4%,64.1%)    | (38.4%, 88.2%)       | (0.4%, 64.1%)  | (36.1%, 80.9%)       |

Subjectsaresummarizedbyrandomizedtreatment.

ITPdurationiscalculatedfromtheITPdiagnosistotheenrollmentofstudy.

Durableplateletresponsewasdefinedasweeklyplateletcount≥50x109/Lfor6ormoretimesforWeeks18-25measurementsintheabsenceofrescuemedication anytimeduringthetreatmentperiod.

Table  7.  Subject  Incidence  of  Durable  Platelet  Response  -  Studies  20030105  and  20030212 (Subjects with &gt; 12 Months of ITP Duration)

|                                                             | Study20030105    | Study20030105        | Study20030212    | Study20030212        | Overall        | Overall              |
|-------------------------------------------------------------|------------------|----------------------|------------------|----------------------|----------------|----------------------|
|                                                             | Placebo (N = 21) | Romiplostim (N = 37) | Placebo (N = 15) | Romiplostim (N = 26) | Placebo (N=36) | Romiplostim (N = 63) |
| Subjectswhoachieveda plateletresponseforat least6ofthelast8 | 0 (0.0%)         | 14 (37.8%)           | 0 (0.0%)         | 15 (57.7%)           | 0 (0.0%)       | 29 (46.0%)           |
| 95%exactbinomial confidenceinterval                         | (0.0%,16.1%)     | (22.5%,55.2%)        | (0.0%,21.8%)     | (36.9%,76.6%)        | (0.0%, 9.7%)   | (33.4%,59.1%)        |

Subjectsaresummarizedbyrandomizedtreatment.

ITPdurationiscalculatedfromtheITPdiagnosistotheenrollmentofstudy.

Durableplateletresponsewasdefinedasweeklyplateletcount≥50x109/Lfor6ormoretimesforWeeks18-25measurementsintheabsenceofrescuemedication anytimeduringthetreatmentperiod.

Study  20060131 was  a  supporting  phase  3b,  multi-center,  randomized,  SOC-controlled,  open-label, 52-week treatment study to compare romiplostim with the  medical  SOC  for  ITP  in  nonsplenectomised subjects who were ≥ 18 years of age and who had received at least 1 prior therapy for ITP. Overall, the median time since ITP diagnosis was 2.090 years (2.260 years for SOC group, 2.080 years for romiplostim group). The study showed that romiplostim administered weekly by SC injection significantly reduced the incidences of splenectomy and treatment failure in nonsplenectomized subjects with ITP compared with the standard of care. The overall safety profile reported for romiplostim was comparable with that for SOC and consistent with the safety findings from previous studies.

Study 20060216 was a supporting phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of romiplostim in thrombocytopenic Japanese subjects with ITP. Eligible subjects were Japanese adults ≥ 20 years of age with a diagnosis of ITP at least 6 months before their first screening visit and who had received at least 1 prior treatment for ITP. Overall, the mean number of years since ITP diagnosis was 9 years (7.6 for the placebo group and 9.7 years for the romiplostim group); range of 1 to 40 years. This study demonstrated the short-term safety (up to 12 weeks of treatment and 12

Page1of1

Page 1of 1

<div style=\"page-break-after: always\"></div>

weeks of  follow-up)  of  romiplostim  compared  with  placebo  in  Japanese  subjects  with  ITP  and  showed evidence for  efficacy  of  romiplostim  over  this  duration  in  raising  and  sustaining  platelet  counts  in  this population.

## · Single-arm Studies

Three single-arm studies provide efficacy data supporting the current application, with key efficacy data provided from Study 20080435.

Study 20080435: this study was a phase 2, interventional, single-arm, describing platelet responses and ITP  remission  rates  in  adult  subjects  with  immune  thrombocytopenia  purpura  receiving  romiplostim. Subjects enrolled were adults with primary ITP diagnosed within 6 months of study entry who had an insufficient response to first-line therapy for treatment of ITP.

The  primary  endpoint  was the  number  of  months  a  subject  achieved  a  platelet  response  during  the 12-month treatment period. A platelet response during any 1 month was defined as the median of platelet counts measured in the month ≥ 50 x 10 9 /L.

The secondary endpoints include subject incidence of ITP remission (defined as maintaining every platelet count ≥ 50 x 10 9 /L  for  at  least  6  months  in  the  absence  of  romiplostim  and  any  medication  for  ITP (concomitant or rescue)) during the 12-month treatment or tapering period of the study,  incidence of splenectomy  during  the  12-month  treatment  period,  incidence  of  adverse  events,  including  clinically significant changes in laboratory values and the incidence of antibody formation at any time during the study.

Seventy-five subjects were enrolled and received at least 1 dose of romiplostim; 59 subjects (78.7%) completed the 12-month treatment period, and 57 (76.0%) completed the study. Reasons for romiplostim treatment discontinuation more than 1 subject included full consent withdrawn, requirement for alternative therapy, adverse event, and lost to follow-up.

The median time (range) from ITP diagnosis to the first dose of romiplostim was 2.2 months (0.1 to 6.6 months). All subjects received prior first-line treatment. The mean (SD) platelet count at screening was 19.78 (15.80) x 10 9  /L.

## Efficacy Results

The primary endpoints of platelet response and remission were both evaluated after initiation of treatment (consistent with the definition of the safety analysis set). Of the 75 subjects in the safety analysis set, 70 (93.3%) had a platelet response ≥ 50 x 10 9 /L during the 12-month treatment period. The mean (standard error) number of months with platelet response during the 12-month treatment period was 9.2 (0.4) months (95% CI: 8.3, 10.1); the median (Q1, Q3) was 11 (8, 12) months. The Kaplan-Meier estimate of the median time to first platelet response was 2.1 weeks (95% CI: 1.1, 3.0). Of the 75 subjects in the safety analysis set, 24 achieved ITP remission during the study, for a subject incidence of 32.0% (95% CI: 21.7, 43.8). The median (range) time to onset of ITP remission for these subjects was 27 (6 to 57) weeks. One subject (1.3%) had a splenectomy during the 12-month treatment period.

## Post-hoc Analysis of Durable Platelet Response

Durable platelet response was defined as subjects who achieved a platelet response (weekly platelet count ≥ 50 x 10 9 /L) for at least 6 of the last 8 weeks of treatment for the week 18 to 25 measurements. Platelet counts within 4 weeks following a rescue medication use or following splenectomy were considered as non-response. Weekly platelet counts may not be available due to either self-administration of romiplostim or other reasons. If a weekly platelet count was not measured, it was imputed as a responding week only if the closest neighboring weeks before and after had a platelet response. A total of 55 of 75 subjects (73.3%,

<div style=\"page-break-after: always\"></div>

95% CI: 61.9, 82.9) attained a durable platelet response (Table 8). A sensitivity analysis was conducted, in which  imputation  of  weekly  platelet  response  was  done  only  for  subjects  who  had  self-administered romiplostim; a total 48 of 75 subjects (64.0%, 95% CI: 52.1, 74.8) attained a durable platelet response (Table 9).

Table 8. Subject Incidence of Durable Platelet Response (Study 20080435) (Full Analysis Set)

|                                        | Romiplostim (N =75)   |
|----------------------------------------|-----------------------|
| Subjectswhohad≤12monthsofITPduration   | N1 = 75               |
| Incidencerateofdurableplateletresponse | 55 (73.3%)            |
| 95%exactbinomialconfidenceinterval     | (61.9%, 82.9%)        |

Full analysisset includes all randomized subjects

ITP duration is calculated from the ITP diagnosis to the enrollment of study.

N1 = Total number of subjects in early ITP subgroup. Percentage was calculated based on N1.

Durableplateletresponsewasdefined asweeklyplateletcount≥50x109/Lfor6ormoretimesforWeeks18-25measurements.

Plateletcountswithin4weeksfollowingarescuemedicationuseorfollowingsplenectomywereconsideredasnon-response.

If a week does not have a collected platelet count measurement, then neighboring platelet count logic was used. If any/most immediate prior platelet week has plateletcount≥50x10%/L andany/most immediatefollowingplateletweekhasplateletcount≥50x10%/L,thenimputedweekhasplateletresponse,elseimputed weekhasnoplateletresponse.

Table 9 Subject Incidence of Durable Platelet Response (Study 20080435) (Weekly Platelet was only Imputed for Self Administration Subjects) (Full Analysis Set)

|                                          | Romiplostim (N = 75)   |
|------------------------------------------|------------------------|
| Subjectswhohad≤12 months of ITP duration | N1 = 75                |
| Incidencerateofdurableplateletresponse   | 48 (64.0%)             |
| 95%exactbinomialconfidenceinterval       | (52.1%, 74.8%)         |

Fullanalysissetincludesallrandomizedsubjects.

ITPdurationiscalculatedfromtheITPdiagnosistotheenrollmentofstudy.

N1=Total numberofsubjectsinearlyITPsubgroup.PercentagewascalculatedbasedonN1.

Durableplateletresponsewasdefinedasweeklyplateletcount≥50x109/Lfor6ormoretimesforWeeks18-25measurements.

Plateletcountswithin4weeksfollowingarescuemedicationuseorfollowingsplenectomywereconsideredasnon-response.

weekhasnoplateletresponse.

Platelet imputationwasdoneonlyforselfadministeringsubjects.

The  MAH  concludes  that  this  study  in  subjects  diagnosed  with  ITP  within  6  months  of  study  entry demonstrated similar safety and efficacy of romiplostim to that seen in the subjects with ITP &gt; 12 months in other clinical studies.

Study  20040209 was an open-label phase 3b study to allow for expanded access to romiplostim and ongoing assessment of the safety of romiplostim in adult thrombocytopenic subjects with ITP.  Eligible adult subjects were diagnosed with and had received at least 1 prior therapy for ITP and had a platelet count of ≤ 30 x 10 9 /L and/or bleeding that was uncontrolled with conventional therapies.

Study 20080009 was a prospective, phase 4, multi-center, open-label study evaluating changes in bone marrow  reticulin  and  collagen  in  adult  subjects  receiving  romiplostim  once-weekly  for  3  years  for  the treatment of thrombocytopenia associated with ITP.  Eligible subjects with ITP were required to have had a platelet count &lt; 50 x 10 9 /L, had received at least 1 prior ITP therapy, and had a baseline bone marrow biopsy without collagen fibrosis at screening.

Page 1 of 1

<div style=\"page-break-after: always\"></div>

· Extension Studies: Two extension studies provide long-term efficacy data, which are available for up to 277 weeks in Study 20030213 and up to 243 weeks in Study 20060113 .

In both extension studies, Study 20030213 and Study 20060113, the primary objective was to evaluate the safety  of  romiplostim.    The  secondary  (efficacy)  endpoints  were  the  incidence  of  platelet  response, proportion of subjects who were able to reduce or discontinue concurrent ITP therapies, and changes in patient-reported outcomes due to the use of romiplostim.

Study  20030213 was a multicenter, open-label, extension study evaluating the safety and efficacy of long-term  dosing  of  romiplostim  in  thrombocytopenic  subjects  with  ITP.    Subjects  who  completed  a romiplostim ITP clinical study were eligible to screen for inclusion in this study (parent Studies 20000137A, 20000137B, 20010218, 20030105, 20030212, 20040209, 20060131, and 20060195).  Of these parent studies, Studies 20030105, 20030212, 20040209, and 20060131 were included in the integrated analysis. The parent studies that were excluded from the integrated analysis (20000137A, 20000137B, 20010218, and  20060195)  were  either  dose-finding  studies  and  therefore  had  fixed  dosing  rules  that  differed significantly from those used in the remainder of the clinical development program for romiplostim, or, in the case of Study 20060195 evaluated pediatric subjects and did not enroll any adult subjects with ITP ≤ 12 months duration.

Most subjects  in  Study  20030213  had  previously  participated  in  one  of  the  controlled  phase  3  studies (20030105 [16.6%], 20030212 [16.0%], and 20060131 [43.5%]).  Of the 313 enrolled subjects in Study 20030213, 292 were adult subjects and 21 were pediatric subjects. Median (Q1, Q3) years since primary diagnosis was 4.91 (2.11, 10.49) years (range: 0.6 to 46.4 years).

The study demonstrated that romiplostim was well tolerated, and the long-term safety profile in the study was consistent with the safety profiles in the pivotal phase 3 studies. administration of romiplostim can maintain platelet counts over time in subjects with ITP, regardless of splenectomy status, and can allow the reduction of other ITP medications.

Study  20060113 was  an  open-label  extension  study  designed  to  assess  the  safety  and  efficacy  of long-term  dosing  of  romiplostim  in  thrombocytopenic  Japanese  subjects  with  ITP.    Subjects  who  had completed a previous romiplostim ITP study in Japan (parent Studies 20050162 or 20060216) were eligible to screen for this study.  Only data from Study 20060216 was included in the integrated analysis, as Study 20050162 was a dose-finding study and had fixed dosing rules that differed significantly from those used in the remainder of the clinical development program for romiplostim.  A total of 25% of enrolled subjects had previously completed Study 20050162 and 75% had completed Study 20060216.  Median (Q1, Q3) years since primary diagnosis was 7.1 (4.2, 13.0 years (range: 1 to 40 years).

Administration of romiplostim for up to 243 weeks at a median weekly dose of 3.81 µg/kg (range: 0.3 to 9.9 µg/kg) was well tolerated in Japanese subjects with ITP and resulted in a platelet response for 95.5% of subjects. Except for the final week of the study, median platelet counts stayed at or above 50 x 10 9  /L each 4-week study period from week 2 onwards.

## Analysis performed across trials (pooled analyses and meta-analysis)

## Integrated analysis

## Methods

The integrated analysis includes data from 311 subjects with ITP ≤ 12 months across the 7 parent clinical studies (20030105, 20030212, 20040209, 20060131, 20060216, 20080009, 20080435) and 2 extension studies (20030213, 20060113) (Table 10).

<div style=\"page-break-after: always\"></div>

Prior to integrating studies, data from the individual studies was examined (refer to previous section) to determine appropriateness of the integration. For results that were derived from an individual study, the integrated analysis referred to the results presented in the original clinical study report for that study; in general analyses and results for specific individual studies were not reproduced in the integrated analysis.

The  integrated  analysis  analyzed  the  platelet  response,  the  rescue  medication  use  and  the  incidence on-study splenectomy.

## Study participants

The integrated ITP data set consists of adult subjects who received at least 1 dose of investigational product in  any  of  the  following  ITP  studies:  20030105,  20030212,  20030213  (extension  study),  20040209, 20060113 (extension study), 20060131, 20060216, 20080009, and 20080435. Data after treatment switch were excluded. Duration of ITP at study entry was calculated from the time of ITP diagnosis to enrollment in the first ITP study.

The integrated data set was analysed by ITP duration subgroup. Of the subjects enrolled in these studies, 311 subjects had a duration of ITP ≤ 12 months at study entry and 726 had a duration of ITP &gt; 12 months at study entry (Table 10).

Of the 311 subjects with ITP ≤ 12 months, 277 received romiplostim and 34 received placebo/SOC and were included in the integrated data set for analysis of efficacy endpoints in subjects with ITP ≤ 12 months (Table 10). Of these, a total of 111 subjects (77 romiplostim, 34 placebo/SOC) had been enrolled in the controlled studies (Studies 20030105, 20030212, 20060216, and 20060131) and a total of 200 subjects had been enrolled in single-arm studies (Studies 20040209, 20080009, and 20080435). Of the 277 subjects with ITP ≤ 12 months who received romiplostim, approximately 50% of these subjects (140 subjects) had a duration of ITP &lt; 3 months at study entry (Table 11).

The  percentages  of  subjects  in  the  romiplostim  group  who  completed  the  parent  study  were  equally distributed between subjects with ITP ≤ 12 months duration at study entry (74.7% [N = 277]) and those with &gt; 12 months duration (74.6% [N = 634]) (ISE Table 14-1.4). Similar results were seen for completion of the open-label extension studies (71.9% [N = 57] and 71.7% [N = 166], respectively).

Table 10. Subjects With ≤ 12 Months and &gt; 12 Months of ITP Duration by Study

|          | Subjects with≤ 12 Months of ITP Duration   | Subjects with≤ 12 Months of ITP Duration   | Subjects with≤ 12 Months of ITP Duration   | Subjectswith>12 Monthsof ITPDuration   | Subjectswith>12 Monthsof ITPDuration   | Subjectswith>12 Monthsof ITPDuration   |
|----------|--------------------------------------------|--------------------------------------------|--------------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| Study ID | Romiplostim N                              | Placebo/SOc N (N1)                         | Total N                                    | Romiplostim N                          | Placebo/SOC N (N1)                     | Total N                                |
| 20030105 | 5                                          | 0(0)                                       | 5                                          | 37                                     | 21 (18)                                | 58                                     |
| 20030212 | 15                                         | 6 (4)                                      | 21                                         | 27                                     | 14 (11)                                | 41                                     |
| 20040209 | 92                                         | 0(0)                                       | 92                                         | 313                                    | 0(0)                                   | 313                                    |
| 20060131 | 56                                         | 27 (2)                                     | 83                                         | 100                                    | 46 (16)                                | 146                                    |
| 20060216 | 1                                          | 1(1)                                       | 2                                          | 21                                     | 11 (11)                                | 32                                     |
| 20080009 | 33                                         | 0(0)                                       | 33                                         | 136                                    | 0(0)                                   | 136                                    |
| 20080435 | 75                                         | 0(0)                                       | 75                                         |                                        |                                        |                                        |
| Total    | 277                                        | 34 (7)                                     | 311                                        | 634                                    | 92 (56)                                | 726                                    |

ITP=immune thrombocytopenia;SoC=standard of care;N1=numberof subjectsswitched toromiplostimgroupin an extensionstudy.

Adult subjects(age ≥18 years at screening) who received at least 1 dose of investigational product in any ofITP studies(20030105, 20030212, 20030213 (extension duration is calculated from the ITP diagnosis to the enrollment of first ITP study.

Source:ISETable14-1.1andISETable14-1.1.1

<div style=\"page-break-after: always\"></div>

Table 11. Subject Disposition by ITP

| ITPDurationin Months   |   Romiplostim N | Placebo/SOC N (N1)   |   Total N |
|------------------------|-----------------|----------------------|-----------|
| 23                     |             140 | 15 (2)               |       155 |
| ≥3 to ≤12              |             137 | 19 (5)               |       156 |
| ≤ 12                   |             277 | 34 (7)               |       311 |
| >12                    |             634 | 92 (56)              |       726 |

Adult subjects (3ge&gt;=18 years at screening)who received atleast one dose of investigationalproduct in any ofITPstudies（20030105,20030212,20030213（extensionstudy）.20040209.20060113（extension study).20060131,20060216,20080009,and20080435)areincluded.Data afertreatmentswitchare excluded.

ITP duration is calculated from the ITP diagnosis to the enrollment of first ITP study.

SOC=StandardofCare.

N1 =Number of subjects switched to romiplostim group in an extension study.

Most subjects (subjects with ITP ≤ 12 months, subjects with ITP &gt; 12 months) were from Europe (191 subjects, 375 subjects) and North America (93, 259) but subjects from Australia (25, 60) and Japan (2, 32) were also included.

In  the  integrated  data  set,  among  subjects  with  ITP  ≤  12  months  who  received  at  least  1  dose  of romiplostim, 46.6% were men and 53.4% were women; most subjects were white (90.3%) (Table 12). Mean (standard deviation [SD], range) age was 51.0 (19.6, 18 to 93) years and the median (Q1, Q3) time since ITP diagnosis was 0.25 (0.10, 0.47) years. The mean (SD) baseline platelet count was 21.0 (16.6) x 10 9 /L.

Table 12. Duration and Treatment Group Demographics and Baseline Disease Characteristics by ITP Duration (Subjects with ≤ 12 Months of ITP Duration).

|                              |                                          |                                          |                                          |                                              |                                              |                                              | Subjects with > 12 Months ofITP   | Subjects with > 12 Months ofITP   |
|------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|-----------------------------------|-----------------------------------|
|                              | Placebo/SOC (N = 34) ITPDurationinMonths | Placebo/SOC (N = 34) ITPDurationinMonths | Placebo/SOC (N = 34) ITPDurationinMonths | Romiplostim (N = 277) ITP Duration in Months | Romiplostim (N = 277) ITP Duration in Months | Romiplostim (N = 277) ITP Duration in Months | Placebo/ SOC (N = 92)             | Romiplostim (N= 634)              |
|                              | g> (N = 15)                              | ≥3to≤12 (N = 19)                         | Total (N = 34)                           | > (N = 140)                                  | ≥3 to≤12 (N = 137)                           | Total (N = 277)                              |                                   |                                   |
| Sex -n (%)                   |                                          |                                          |                                          |                                              |                                              |                                              |                                   |                                   |
| Male                         | 8 (53.3)                                 | 9 (47.4)                                 | 17 (50.0)                                | 70 (50.0)                                    | 59 (43.1)                                    | 129 (46.6)                                   | 29 (31.5)                         | 227 (35.8)                        |
| Female                       | 7 (46.7)                                 | 10 (52.6)                                | 17 (50.0)                                | 70 (50.0)                                    | 78 (56.9)                                    | 148 (53.4)                                   | 63 (68.5)                         | 407 (64.2)                        |
| Race -n (%)                  |                                          |                                          |                                          |                                              |                                              |                                              |                                   |                                   |
| AmericanIndianorAlaskaNative | 0 (0.0)                                  | 0 (0.0)                                  | 0 (0.0)                                  | 0 (0.0)                                      | 0 (0.0)                                      | 0 (0.0)                                      | 1 (1.1)                           | 0 (0.0)                           |
| Asian                        | 0 (0.0)                                  | 1 (5.3)                                  | 1 (2.9)                                  | 1 (0.7)                                      | 6 (4.4)                                      | 7 (2.5)                                      | 11 (12.0)                         | 35 (5.5)                          |
| BlackorAfricanAmerican       | 0 (0.0)                                  | 0 (0.0)                                  | 0 (0.0)                                  | 5 (3.6)                                      | 2 (1.5)                                      | 7 (2.5)                                      | 3 (3.3)                           | 13 (2.1)                          |
| HispanicorLatino             | 1 (6.7)                                  | 0 (0.0)                                  | 1 (2.9)                                  | 6 (4.3)                                      | 6 (4.4)                                      | 12 (4.3)                                     | 5 (5.4)                           | 24 (3.8)                          |
| NativeHawaiianorOtherPacific | 0 (0.0)                                  | 0 (0.0)                                  | 0 (0.0)                                  | 0 (0.0)                                      | 0 (0.0)                                      | 0 (0.0)                                      | 0 (0.0)                           | 2 (0.3)                           |
| White                        | 14 (93.3)                                | 18 (94.7)                                | 32 (94.1)                                | 127 (90.7)                                   | 123 (89.8)                                   | 250 (90.3)                                   | 71 (77.2)                         | 557 (87.9)                        |
| Other                        | 0 (0.0)                                  | 0 (0.0)                                  | 0 (0.0)                                  | 0 (0.0)                                      | 0 (0.0)                                      | 0 (0.0)                                      | 1 (1.1)                           | 3 (0.5)                           |
| Unknown                      | 0 (0.0)                                  | 0 (0.0)                                  | 0 (0.0)                                  | 1 (0.7)                                      | 0 (0.0)                                      | 1 (0.4)                                      | 0 (0.0)                           | 0 (0.0)                           |
| Age-years                    |                                          |                                          |                                          |                                              |                                              |                                              |                                   |                                   |
| n                            | 15                                       | 19                                       | 34                                       | 140                                          | 137                                          | 277                                          | 92                                | 634                               |
| Mean                         | 53.9                                     | 47.7                                     | 50.4                                     | 50.7                                         | 51.3                                         | 51.0                                         | 55.1                              | 53.2                              |
| SD                           | 20.9                                     | 18.1                                     | 19.3                                     | 21.0                                         | 18.1                                         | 19.6                                         | 18.1                              | 16.8                              |
| Median                       | 64.0                                     | 45.0                                     | 47.5                                     | 52.0                                         | 52.0                                         | 52.0                                         | 54.5                              | 54.0                              |
| Q1,Q3                        | 31.0, 73.0                               | 33.0, 62.0                               | 33.0, 69.0                               | 32.0, 67.0                                   | 35.0, 68.0                                   | 34.0, 67.0                                   | 42.0, 70.0                        | 41.0, 66.0                        |
| Min, Max                     | 21, 80                                   | 18,77                                    | 18,80                                    | 18.93                                        | 18,88                                        | 18,93                                        | 18,88                             | 18,89                             |

|              | Subjectswith≤12Monthsof ITP             | Subjectswith≤12Monthsof ITP             | Subjectswith≤12Monthsof ITP             | Subjectswith≤12Monthsof ITP               | Subjectswith≤12Monthsof ITP               | Subjectswith≤12Monthsof ITP               | Subjects with > 12 Months of ITP   | Subjects with > 12 Months of ITP   |
|--------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|------------------------------------|------------------------------------|
|              | Placebo/SOC (N =34) ITPDurationinMonths | Placebo/SOC (N =34) ITPDurationinMonths | Placebo/SOC (N =34) ITPDurationinMonths | Romiplostim (N = 277) ITPDurationinMonths | Romiplostim (N = 277) ITPDurationinMonths | Romiplostim (N = 277) ITPDurationinMonths | Placebo/SOC (N = 92)               | Romiplostim (N = 634)              |
|              | > (N = 15)                              | ≥3 to≤12 (N = 19)                       | Total (N = 34)                          | > (N = 140)                               | ≥3to≤12 (N = 137)                         | Total (N = 277)                           |                                    |                                    |
| Region-n (%) |                                         |                                         |                                         |                                           |                                           |                                           |                                    |                                    |
| Europe       | 4 (26.7)                                | 12 (63.1)                               | 16 (47.1)                               | 89 (63.6)                                 | 86 (62.8)                                 | 175 (63.2)                                | 27 (29.3)                          | 348 (54.9)                         |
| NorthAmerica | 9 (60.0)                                | 6 (31.6)                                | 15 (44.1)                               | 42 (30)                                   | 36 (26.3)                                 | 78 (28.2)                                 | 47 (51.1)                          | 212 (33.4)                         |
| Australia    | 2 (13.3)                                | 0 (0.0)                                 | 2 (5.9)                                 | 9 (6.4)                                   | 14 (10.2)                                 | 23 (8.3)                                  | 7 (7.6)                            | 53 (8.4)                           |
| Japan        | 0 (0.0)                                 | 1 (5.3)                                 | 1 (2.9)                                 | 0 (0.0)                                   | 1 (0.7)                                   | 1 (0.4)                                   | 11 (12)                            | 21 (3.3)                           |
| Total        | 15                                      | 19                                      | 34                                      | 140                                       |                                           | 277                                       | 92                                 | 634                                |

Adult subjects (age ≥18years at screening) who received at least one dose of investigalional product in any of ITP studies (20030105,20030212,20030213(exlension study),20040209,20060113(extensionstudy),20060131,20060216,20080009,and20080435)areincluded.Dataaftertreatmentswitchareexcluded. ITP duration is calculated from the time of ITPdiagnosis to the time of enrollment of the first ITPstudy. ITP=immunethrombocvtopenia:SoC=standardofcare.

Page 2of 2

<div style=\"page-break-after: always\"></div>

In  the  integrated  data  set,  among  subjects  with  ITP  &gt;  12  months  who  received  at  least  1  dose  of investigational product, 35.3% were men and 64.7% were women; most subjects were white (87.9%). Mean (standard deviation [SD], range) age was 53.5 (17.0, 18 to 89) years and the median (Q1, Q3) time since ITP diagnosis was 6.04 (2.80, 13.32) years. The mean (SD) baseline platelet count was also 21.0 (16.6) x 10 9 /L.

## Treatments

Subjects were assigned to the romiplostim group or placebo/SOC group based on the actual treatment received.

## Outcomes/endpoints

The integrated efficacy analysis evaluates the platelet response to romiplostim, rescue medication use, and on-study splenectomy.

- Platelet Response : The analysis of platelet response to romiplostim assess the proportion and magnitude  of  the  platelet  response  (defined  as  a  platelet  count  &gt;  50  10 9 /L)  by  the  following endpoints:
- -subject incidence of durable platelet response (6 or more weekly platelet responses during week 18 to 25),
- -subject incidence of monthly platelet response,
- -percentage of time with monthly with platelet response,
- -subject incidence of sustained platelet response (defined as having at least 9 weeks with weekly platelet responses in any 12-week interval),
- -percentage of subjects with monthly platelet response at least 75% of the time,
- -percentage of subjects with monthly platelet response at least 90% of the time
- -time to first platelet response.

*A weekly platelet response was achieved when the platelet count measurement during that week was ≥ 50 x 10 9 /L. Similarly, a monthly platelet response was achieved when the median of the platelet counts measured durin g that month was ≥ 50 x 10 9 /L.

- Rescue Medication usage-rate: defined as any medication or transfusion that was administered for  the  intended  purpose  of  raising  platelet  count.    The  administration  of  rescue  medication  is defined  according  to  each  individual  study  to  align  with  their  primary  endpoints.  Only  rescue medications  starting  after  the  first  dose  of  investigational  product  were  tabulated.  Multiple occurrences of using the same type of rescue medication for a subject were counted as multiple uses.  Study  20060131  had  a  different  approach  of  collecting  rescue  medication  use  which  is explained in detail in the following section (Statistical methods).

The following endpoints were summarized by treatment group and ITP subgroups:

- -subject incidence of rescue medication use by type and agent,
- -duration-adjusted rescue medication use
- -duration-adjusted rescue medication use by period (months)
- -duration-adjusted rescue medication use by reason,

<div style=\"page-break-after: always\"></div>

- -duration-adjusted rescue medication by closest platelet count in the prior 3 months
- On-study Splenectomy: Incidence of on-study splenectomy was summarized by treatment group and ITP subgroups.

## Statistical methods

The integrated ITP data set used in the integrated analysis consists of all adult subjects (≥ 18 years of age at screening) who received at least 1 dose of investigational product in any of the 7 parent ITP studies: 20030105, 20030212, 20040209, 20060131, 20060216, 20080009, and 20080435; and the subjects' data from  the  extension  studies  20030213  and  20060113.  All  subjects  were  analysed  based  on  the  actual treatment received, data after treatment switch in the extension studies were excluded. The integrated ITP data set was used to summarize the efficacy endpoints described above.

For results that were derived from an individual study, the integrated analysis refers to the results presented in the original clinical study report for that study; in general analyses and results for specific individual studies are not be reproduced in the integrated analysis.

Descriptive statistics  were  provided  with  number  (n),  mean,  standard  deviation  (SD),  median,  quartile range  (Q1,  Q3),  minimum,  and  maximum  for  continuous  variables,  and  number  and  percentage  for categorical variables.

For  all  platelet  response  and  on-study  splenectomy  endpoints,  the  integrated  ITP  set  consists  of  adult subjects ( ≥ 18 years of age at screening) who received at least 1 dose of investigational product in any of the following 7 parent ITP Studies 20030105, 20030212, 20040209, 20060131, 20060216, 20080009, and 20080435, and the subjects' data from the extension Studies 20030213 and 20060113.  Subjects were assigned to the romiplostim group or placebo/SOC group based on the actual treatment received.  For the data from Study 20060131, only data obtained during the initial treatment period were included in the analysis  set.    Data  from  extension  studies  were  summarized,  and  data  after  treatment  switch  in  the extension studies were excluded from the integrated analysis.

For rescue medication use endpoints, the integrated data set used 6 of the 7 parent ITP Studies 20030105, 20030212, 20040209, 20060216, 20080009, and 20080435, and the subjects' data from extension Studies 20030213 and 20060113.  This was because the SOC-controlled Study 20060131 had a different approach of reporting rescue medication use.  In Study 20060131, rescue medication use was allowed when platelet counts were &lt; 10 x 10 9 /L and/or there was bleeding or wet purpura.  Rescue medication was also allowed in any situation deemed medically necessary by the investigator.  In the SOC treatment arm, subjects were allowed  to  switch  medical  SOC  treatments  for  ITP  per  standard  institutional  practices  or  therapeutic guidelines and these SOC treatments were reported as treatment failure.  In the other studies, rescue medications were defined as any ITP therapies administered on study in addition to the investigational products (romiplostim or placebo) with the intention to raise platelet counts.  In these other studies, rescue medications were typically permitted for low platelet counts, bleeding or wet purpura, or any other situation deemed medically necessary by the investigator; and were allowed throughout the duration of the studies. For a comparable summary, Study 20060131 and corresponding data from the extension studies were excluded in the primary analysis of the rescue medication use endpoint.

Exploratory analyses were conducted using all data by re-categorizing the additional ITP treatments. In the exploratory analyses, additional ITP treatment was defined as rescue medication for subjects in the placebo and romiplostim treatment groups, and as rescue medication and/or postbaseline additional SOC medication for ITP (other than the first SOC) for the subjects in the SOC treatment group.

<div style=\"page-break-after: always\"></div>

## Imputation rule

For the platelet response endpoints, weekly/monthly platelet response were imputed for time points without a collected platelet count measurement. Imputations was done by using the following methods:

- -Monthly platelet measurement - 1) For the romiplostim group, if a month did not have platelet count measurements, then the neighboring platelet count imputation was used. If the month immediately prior h ad median platelet count ≥ 50 x 10 9  /L and the month immediately following had a median platelet  count  ≥  50  x  10 9   /L,  then  the  imputed  month  had  a  platelet  response.  2)  For  the placebo/SOC group, no monthly median platelet count imputation was used if no platelet data was collected for a month.
- -Weekly platelet measurement If the week immediately prior had a platelet count ≥ 50 x 10 9  /L and the week immediately following had a platelet count ≥ 50 x 10 9  /L, then the imputed week had a platelet response. Otherwise, the imputed week will have no platelet response. As a sensitivity analysis, analyses with no imputation will be conducted on the incidence of durable platelet response endpoint for subjects with ITP ≤ 12 months.

## Results

## Platelet Response

## · Subject Incidence of Platelet Response

A total of 239 of 277 subjects (86.3%; 95% CI: 81.7, 90.1) with ITP ≤ 12 months had at least 1 monthly platelet response, defined as the median of the platelet counts measured during that month ≥ 50 x 10 9 /L without any use of rescue medication within 8 weeks prior to date of the platelet measurement (Table 13). The percentage of subjects with ITP ≤ 12 months in the placebo/SOC group who achieved at least 1 monthly platelet response was 61.8% (95% CI: 43.6, 77.8; 21 of 34 subjects) (Table 14). Consistent with this, the percentage of subjects with at least 1 monthly platelet response was higher in the romiplostim group than the placebo/SOC group for each ITP duration subgroup (&lt; 3 months, ≥ 3 to ≤ 12 months, and &gt; 12 mon ths) (Table 13, Table 14).

Table  13.  Subject  Incidence  of  Platelet  Response  Romiplostim  Group  (Subjects  with  ≤ 12 Months of ITP Duration)

|                                                       | Romiplostim (N = 277) ITPDurationinMonths   | Romiplostim (N = 277) ITPDurationinMonths   | Romiplostim (N = 277) ITPDurationinMonths   |
|-------------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
|                                                       | <3 (N = 140)                                | ≥3to≤12 (N = 137)                           | Total (N = 277)                             |
| Subjectswhoachievedatleastonemonthlyplatelet response | 115 (82.1%)                                 | 124 (90.5%)                                 | 239 (86.3%)                                 |
| g5%exactbinomialconfidenceinterval                    | (74.8%, 88.1%)                              | (84.3%,94.9%)                               | (81.7%, 90.1%)                              |

Page 1of1

(extensionstudy),20040209,20060113(extensionstudy),20060131,20060216,20080009,and20080435)areincluded.Dataaftertreatmentswitchareexcluded. ITPdurationiscalculatedfromtheITPdiagnosistotheenrollmentoffirstITPstudy.

AmonthlyplateletresponseIsdefinedasthemedianoftheplateletcountsmeasuredduringthatmonthis≥50x1o9/L

Ifamonthdoesnothaveplateletcountmeasurements,thenneighboringplateletcountimputationwasused.Ifimmediatepriormonthhasmedianplatelet count≥50x109/Landimmediatefollowingmonthhasplateletcount≥50x109/L,thenimputedmonthlymedianplateletresponse=Yes,elseimputedmonthlymedian hasplateletresponse=No.

<div style=\"page-break-after: always\"></div>

Table 14. Subject Incidence of Platelet Response Placebo/SOC Group (Subjects with ≤ 12 Months of ITP Duration)

|                                                       | Placebo/SOC (N =34) ITPDurationinMonths   | Placebo/SOC (N =34) ITPDurationinMonths   | Placebo/SOC (N =34) ITPDurationinMonths   |
|-------------------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
|                                                       | <3 (N = 15)                               | 3≤to≤12 (N = 19)                          | Total (N = 34)                            |
| Subjectswhoachievedatleastonemonthlyplatelet response | 9 (60.0%)                                 | 12 (63.2%)                                | 21 (61.8%)                                |
| 95%exactbinomialconfidenceinterval                    | (32.3%, 83.7%)                            | (38.4%, 83.7%)                            | (43.6%, 77.8%)                            |

Page1of 1

Adultsubjecls(age&gt;=18yearsatscreening)whoreceivedatleastonedoseofinvestigationalproductinanyofITPstudies(20030105,20030212,20030213 (extensionstudy),20040209,20060113(exlensionstudy),20060131,20060216,20080009,and20080435)areincluded.Dataaflertreatmentswitchareexcluded. ITPdurationiscalculatedfromtheITPdiagnosistotheenrollmentoffirstITPstudy.

Amonthlyplateletresponseisdefinedasthemedianoftheplateletcountsmeasuredduringthatmonthis≥50x1o9/L.Nomonthlymedianplateletcountimputation wasusedifnoplateletdatacollectedforamonth.

Plateletcounlsmeasuredwithin8weeksfollowingarescuemedicationusewereexcludedfromtheanalysis.

SOC=StandardofCare.

These results were consistent with those seen with subjects for ITP &gt; 12 months duration, where 87.2% (95% CI:84.4%, 89.7%) of subjects in the romiplostim group and 32.6% (95% CI:23.2%, 43.2%) of subjects in the placebo group had a platelet response (ISE Table 14-4.2.3).

## · Time to First Platelet Response

Among subjects who had ≥ 1 weekly platelet response, the median time to first platelet response was lower in the romiplostim group compared with the placebo/SOC group for each ITP duration subgroup. Overall, among all subjects with ITP ≤ 12 months, the median time to first platelet response was 2.0 weeks in the romiplostim group and 3.1 weeks in the placebo/SOC group (Table 15).

Among subjects in the romiplostim group, the median time to first platelet response was 2.1 weeks for subjects who had &lt; 3 months ITP duration at study entry, 1.3 weeks for those who had ≥ 3 to ≤ 12 months ITP duration, and 2.0 weeks for subjects with &gt; 12 months duration.

Table 15. Time to First Platelet Response by ITP Duration and Treatment Group

|                                    | Romiplostim Group ITPDurationinMonths   | Romiplostim Group ITPDurationinMonths   | Romiplostim Group ITPDurationinMonths   | Romiplostim Group ITPDurationinMonths   | Placebo/SOC Group ITPDurationinMonths   | Placebo/SOC Group ITPDurationinMonths   | Placebo/SOC Group ITPDurationinMonths   | Placebo/SOC Group ITPDurationinMonths   |
|------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
|                                    | <3 (N = 140)                            | ≥3to ≤12 (N = 137)                      | All ≤ 12 (N = 277)                      | >12 (N =634)                            | 3 (N = 15)                              | ≥3tos12 (N = 19)                        | All ≤ 12 (N =34)                        | >12 (N = 92)                            |
| Timetofirstplateletresponse(weeks) |                                         |                                         |                                         |                                         |                                         |                                         |                                         |                                         |
| n                                  | 140                                     | 137                                     | 277                                     | 634                                     | 10                                      | 15                                      | 25                                      | 40                                      |
| Mean                               | 7.5                                     | 4.9                                     | 6.2                                     | 6.4                                     | 3.7                                     | 7.4                                     | 5.9                                     | 7.9                                     |
| SD                                 | 20.0                                    | 7.8                                     | 15.3                                    | 13.4                                    | 4.2                                     | 8.6                                     | 7.3                                     | 10.3                                    |
| Median                             | 2.1                                     | 1.3                                     | 2.0                                     | 2.0                                     | 2.6                                     | 3.1                                     | 3.1                                     | 2.2                                     |
| Q1, Q3                             | 1.1, 7.1                                | 1.1, 5.1                                | 1.1, 6.1                                | 1.1, 6.1                                | 1.3, 4.1                                | 1.3, 11.1                               | 1.3, 6.4                                | 1.1, 13.2                               |
| Min, Max                           | 0,213                                   | 0, 63                                   | 0,213                                   | 0, 155                                  | 0, 15                                   | 0, 27                                   | 0, 27                                   | 0, 44                                   |

ITP= immune thrombocytopenia;SoC = standard of care; n = number of subjects who had ≥ 1 weekly platelet response

Adult subjects(3ge ≥18 years at screening) who received atleast 1 dose ofinvestigational product in any ofITP studies (20030105, 20030212,20030213[extension study].20040209,20060113[extensionstudy].20060131,20060216,20080009,and20080435) areincluded.Dataaftertreatment switch wereexcluded.

Platelet counts without any use of rescue medication or ITP medication within 8 weeks prior to date of the platelet measurement were used.

ITP duration was celculated from the ITP diagnosis to the enrollment of first ITP study.

Source:ISETable14-4.7.1andISETable14-4.7.2

## · Durable Platelet Response

Durable platelet response was defined as ≥ 6 weekly platelet counts of ≥ 50 x 10 9 /L  during weeks 18 through 25 of treatment. In the analyses without imputation of platelet response (i.e. a weekly platelet response was considered to be 'no response' for timepoints without a platelet count measurement), among subjects with ITP ≤ 12 months in the integrated analysis set, the subject incidence of durable platelet response was 26.7% ( 95% CI: (21.6%, 32.3%) (74/277 subjects) in the romiplostim group compared with

<div style=\"page-break-after: always\"></div>

2.9% (95% CI: 0.1%, 15.3%) (1/34 subjects) in the placebo/SOC group. Among subjects with ITP &gt; 12 months in the integrated analysis set, the subject incidence of durable platelet response was 49.2% (95% CI:45.3%, 53.2%) (312/634 subjects) in the romiplostim group compared with 9.8% (95% CI: 4.6%, 17.8%) (9 of 92 subjects) in the placebo/SOC group.

Table 16. Subject Incidence of Durable Platelet Response (without imputation) - Romiplostim Group (Subjects with ≤ 12 Months of ITP Duration)

|                                                                                               | Romiplostim (N = 277) ITPDurationinMonths   | Romiplostim (N = 277) ITPDurationinMonths   | Romiplostim (N = 277) ITPDurationinMonths   |
|-----------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
|                                                                                               | <3 (N = 140)                                | ≥3to≤12 (N = 137)                           | Total (N = 277)                             |
| Subjectswhoachievedaplateletresponseforat least6ofthelast8weeksoftreatmentforthefirst 24weeks | 33 (23.6%)                                  | 41 (29.9%)                                  | 74 (26.7%)                                  |
| 95%exactbinomialconfidenceinterval                                                            | (16.8%, 31.5%)                              | (22.4%, 38.3%)                              | (21.6%, 32.3%)                              |

Page1of 1

(extensionstudy),20040209,20060113(extensionstudy),20060131,20060216,20080009,and20080435)areincluded.Dataaftertrealmentswitchareexcluded. ITPdurationiscalculatedfromtheITPdiagnosistotheenrollmentoffirstITPstudy.

Aweeklyplateletresponseisdefinedasthemedianoftheplateletcountsmeasuredduringthatweekis≥50x109/L.

Plateletcountsmeasuredwithin8weeksfollowingarescuemedicationusewereexcludedfromtheanalysis.

Durableplateletresponsewasdefinedasweeklyplateletcount≥50x109/Lfor6ormoretimesforWeeks18-25measurements.

Weekly platelet counts may not have been available due to either self-administration of romiplostim or other reasons.  Consistent  results  were  obtained  when  analyses  were  conducted  with  imputation  of  response status by using the response status of neighboring weeks before and after the missing timepoints. Weekly platelet response was imputed only when both neighboring weeks before and after had a platelet response. Among subjects with ITP ≤ 12 months in the integrated analysis set, the subject incidence of durable platelet response was 52.7% (146/277 subjects) in the romiplostim group compared with 23.5% (8/34 subjects) in the placebo/SOC group (Table 17).

Table 17. Subject Incidence of Du rable Platelet Response (after imputation) (Subjects with ≤ 12 Months of ITP Duration)

|                                              | Romiplostim (N = 277) ITPDurationinMonths   | Romiplostim (N = 277) ITPDurationinMonths   | Romiplostim (N = 277) ITPDurationinMonths   | Placebo/SOC (N =34) ITPDurationinMonths   | Placebo/SOC (N =34) ITPDurationinMonths   | Placebo/SOC (N =34) ITPDurationinMonths   |
|----------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
|                                              | <3 (N = 140)                                | ≥3to ≤12 (N = 137)                          | Total (N = 277)                             | 3 (N = 15)                                | ≥3to≤12 (N = 19)                          | Total (N=34)                              |
| Subjectswhoachieveda durableplateletresponse | 70 (50.0%)                                  | 76 (55.5%)                                  | 146 (52.7%)                                 | 4 (26.7%)                                 | 4 (21.1%)                                 | 8 (23.5%)                                 |
| 95%exactbinomialconfidence interval          | (41.4%, 58.6%)                              | (46.7%, 64.0%)                              | (46.6%, 58.7%)                              | (7.8%, 55.1%)                             | (6.1%, 45.6%)                             | (10.7%, 41.2%)                            |

ITP=immune thrombocytopenia;SoC=standardof care

Aweekly plateletresponse is definedasaplatelet count of ≥50x10/L

Adult subjects (age ≥ 18 years at screening) who received ≥1 dose of investigational product in any of ITP studies (20030105, 20030212, 20030213 (extension study). 20040209,20060113(extensionstudy).20060131,20060216,20080009,and20080435) wereincluded.Dataaftertreatment switchwereexcluded. ITP duration is calculated from the ITP diagnosis to the enrollment of first ITP study.

Platelet countsmeasured within8weeksfollowing a rescue medication use were excluded from the analysis.

Durable platelet response was defined as weekly platelet count ≥ 50x10°/L for 6 or more times for weeks 18 to 25 measurements.

If a week did not have a collected platelet count measurement, then neighboring platelet count logic was used.If any/most immediate prior week had a platelet count ≥ 50x10°/L and any/most immediate following week had a platelet count ≥ 50x107/L, then imputed week platelet response = Yes, otherwise the imputed week platelet response = No.

Source:ISETable14-4.1.4andISETable14-4.1.5

## · Number and Percentage of Months with Platelet Response

Among subjects with ITP ≤ 12 months, mean percent time with a platelet response was higher in the romiplostim  group  than  in  the  placebo/SOC  group  (77.1%  romiplostim,  34%  placebo/SOC),  and  this difference was apparent across all ITP duration subgroups (Table 18). Consistent with this, the percentage of subjects with a platelet response at least 75% of the time or at least 90% of the time across all integrated studies was higher in the romiplostim group than in the placebo/SOC group for each ITP duration subgroup.

<div style=\"page-break-after: always\"></div>

Overall, 60.6% of subjects in the romiplostim group achieved a platelet response 90% of the time, compared with 11.8% of subjects in the placebo/SOC group.

Similar results were seen for subjects with ITP &gt; 12 months in the integrated analysis set. Mean percent time with a platelet response (74.9% romiplostim, 17.0% placebo/SOC) and the percentage of subjects with a platelet response at least 75% of the time (71.0% romiplostim, 8.7% placebo/SOC) or at least 90% of the time (55.8% romiplostim, 6.5% placebo/SOC) was higher in the romiplostim group than in the placebo/SOC group.

Table 18. Percent Time (in Months) with Platelet Response (Subjects with ≤ 12 Months of ITP Duration)

|                                       | Romiplostim (N = 277) ITPDuration in Months   | Romiplostim (N = 277) ITPDuration in Months   | Romiplostim (N = 277) ITPDuration in Months   | Placebo/Soc (N=34) ITP Duration in Months   | Placebo/Soc (N=34) ITP Duration in Months   | Placebo/Soc (N=34) ITP Duration in Months   |
|---------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
|                                       | <3 (N = 140)                                  | ≥3to≤12 (N = 137)                             | Total (N = 277)                               | 3 (N= 15)                                   | ≥3to≤12 (N = 19)                            | Total (N = 34)                              |
| %Time (inMonths)withPlatelet Response |                                               |                                               |                                               |                                             |                                             |                                             |
| n                                     | 140                                           | 137                                           | 277                                           | 15                                          | 19                                          | 34                                          |
| Mean                                  | 75.2                                          | 79.0                                          | 77.1                                          | 42.8                                        | 27.0                                        | 34.0                                        |
| SD                                    | 38.3                                          | 31.4                                          | 35.0                                          | 41.3                                        | 28.2                                        | 34.9                                        |
| Median                                | 100.0                                         | 93.5                                          | 96.6                                          | 50.0                                        | 16.7                                        | 30.4                                        |
| Q1, Q3                                | 70.3, 100.0                                   | 72.2, 100.0                                   | 71.4, 100.0                                   | 0.0, 92.3                                   | 0.0, 54.5                                   | 0.0, 55.6                                   |
| Min, Max                              | 0, 100                                        | 0, 100                                        | 0, 100                                        | 0, 100                                      | 0, 85                                       | 0, 100                                      |

ITP=immune thrombocytopenia;SoC=standard ofcare

A monthly plateletresponse is defined as the median of the platelet counts measured during that month is ≥ 50x109/L.If a month does not have platelet count

Adult subjects (age ≥ 18 years at screening) who received at least 1 dose ofinvestigational product in any of ITP studies (20030105, 20030212, 20030213 (extension study).20040209,20060113 (extension study).20060131,20060216, 20080009,and 20080435) were included.Data aftertreatment switch were excluded.ITP duration was calculated from the ITP diagnosis to the enrollment of first ITP study.

measurements, then neighboring platelet count imputation was used. Ifimmediate prior month has median platelet count ≥ 50x10/L and immediate following month has platelet count ≥ 50x10/L, then imputed monthly median platelet response=Yes, else imputed monthly median has platelet response = No.

Source:ISETable14-4.3.1andISETable14-4.3.2

## · Sustained Platelet Response

Among subjects with ITP ≤ 12 months, the subjec t incidence of sustained platelet response (subjects who achieved a platelet response for at least 9 weeks within a 12-week period) was 74.4% (95% CI: 68.8, 79.4; 206 of 277 subjects) in the romiplostim group compared with 35.3% (95% CI: 19.7, 53.5; 12 of 34 subjects) in the placebo/SOC group (Table 19 and ISE Table 14-4.4.2).

Table 19. Subject Incidence of Sustained Platelet Response - Romiplostim Group (Subjects with ≤ 12 Months of ITP Duration)

|                                                                 | Romiplostim (N = 277) ITPDurationinMonths   | Romiplostim (N = 277) ITPDurationinMonths   | Romiplostim (N = 277) ITPDurationinMonths   |
|-----------------------------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
|                                                                 | <3 (N = 140)                                | 3≤to≤12 (N = 137)                           | Total (N = 277)                             |
| Subjectswhoachievedaplateletresponsefor9 weeksinany12weekperiod | 96 (68.6%)                                  | 110 (80.3%)                                 | 206 (74.4%)                                 |
| 95%exactbinomialconfidenceinterval                              | (60.2%, 76.1%)                              | (72.6%, 86.6%)                              | (68.8%, 79.4%)                              |

Page1of1

(extensionstudy),20040209,20060113(extensionstudy),20060131,20060216,20080009,and20080435)areincluded.Dataaftertreatmentswitchareexcluded ITPdurationiscalculatedfromtheITPdiagnosistotheenrollmentoffirstITPstudy.

Asustainedplateletresponseisdefinedashavingatleast9weekswithplateletcount≥50x109/Linany12weekinterval,withnouseofrescuemedicationduringthe 8weekspriortoeachqualifyingplateletcount.Thequalifyingperiodmuststartwithaplateletcount≥50x1o9/L.

Ifaweekdoesnothaveacollectedplateletcountmeasurement,thennelghboringplateletcountlogicwasused.Ifany/mostimmediatepriorweekhasplateletcount≥ response=No.

Among subjects with ITP &gt; 12 months in the integrated analysis set, the subject incidence of durable platelet response was 72.7% (461 of 634 subjects) in the romiplostim group compared with 19.6% (18 of 92 subjects) in the placebo/SOC group (Table 20).

<div style=\"page-break-after: always\"></div>

Table 20. Subject Incidence of Sustained Platelet Response (Subjects with &gt; 12 Months of ITP Duration)

|                                                                 | Placebo/Soc (N = 92)   | Romiplostim (N =634)   |
|-----------------------------------------------------------------|------------------------|------------------------|
| Subjectswhoachievedaplateletresponsefor9weeksinany12 weekperiod | 18 (19.6%)             | 461 (72.7%)            |
| 95%exactbinomialconfidenceinterval                              | (12.0%,29.1%)          | (69.1%, 76.1%)         |

Page1of 1

Adultsubjects（age&gt;=18yearsatscreening)whoreceivedatleastonedoseofinvesligationalproductinanyofITPstudies（20030105,20030212,20030213 (extensionstudy),20040209,20060113(extensionstudy),20060131,20060216,20080009,and20080435)areincluded.Dataaftertreatmentswitchareexcluded. ITPdurationiscalculatedfromtheITPdiagnosistotheenrollmentoffirstITPstudy.

Asustainedplateletresponseisdefinedashavingatleast9weekswithplateletcount≥50x109/Linany12weekinterval,withnouseofrescuemedicationduringthe

Ifaweekdoesnothaveacollectedplateletcountmeasurement,thenneighboringplateletcountlogicwasused.Ifany/mostimmediatepriorweekhasplateletcount2 50x109/Landany/mostimmediatefollowingweekhasplateletcount≥50x109/L,thenimputedweekhasplateletresponse=Yes,elseimputedweekhasplatelet response=No.

SOC=StandardofCare

## · Rescue Medication Use

In the primary analysis (where study 20060131 was excluded; see Method´s section), among all subjects with ITP ≤ 12 months, the subject incidence of rescue medication use at a ny time during treatment was 46.2% (102/221 subjects) in the romiplostim group and 71.4% (5/7 subjects) in the placebo group. Among subjects with ITP &gt; 12 months, the subject incidence of rescue medication use at any time during treatment was 54.5% (291/534 subjects) in the romiplostim group and 45.7% (21/46 subjects) in the placebo group (Table 21).

Table 21. Subject Incidence of Rescue Medication by ITP Duration and Treatment Group

|                                                   | Romiplostim Group ITPDurationinMonths   | Romiplostim Group ITPDurationinMonths   | Romiplostim Group ITPDurationinMonths   | Romiplostim Group ITPDurationinMonths   | PlaceboGroup ITPDurationinMonths   | PlaceboGroup ITPDurationinMonths   | PlaceboGroup ITPDurationinMonths   | PlaceboGroup ITPDurationinMonths   |
|---------------------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
|                                                   | <3 (N = 114) n (%)                      | ≥3to≤12 (N = 107) n (%)                 | AlI≤12 (N = 221) n (%)                  | >12 (N = 534) n (%)                     | <3 (N = 1) n (%)                   | ≥3to≤12 (N=6) n (%)                | AlII≤ 12 (N = 7) n (%)             | >12 (N = 46) n (%)                 |
| Totalnumberofsubjectswhoreceivedrescue medication | 54 (47.4)                               | 48 (44.9)                               | 102 (46.2)                              | 291 (54.5)                              | 1 (100.0)                          | 4 (66.7)                           | 5 (71.4)                           | 21 (45.7%)                         |

ITP=immunethrombocytopenia

Adult subjects (age ≥ 18 years at screening) who received ≥ 1 dose of investigational product in any of ITP studies 20030105, 20030212, 20030213 (exlension study), 20040209,20060113(extensionstudy),20060216,20080009,and20080435wereincluded.SubjeclsinStudy20060131wereexcluded.Dataaftertreatment switchwereexcluded.

ITPdurationwascalculatedfromtheITPdiagnosistotheenrollmentoffirstITPstudy.

Rescuemedicalionwasdefinedasanymedicationthatwasadministeredfortheintendedpurposeofraisingplateletcount.

Onlyrescuemedicationsstartingaflerthefirstdoseofinvestigationalproductweretabulated.

Source:Table14-8.3.2,Table14-8.3.3,Table14-8.4.2,Table14-1.2.2

Corticosteroids and/or immunoglobulins were the most commonly used rescue medications across all ITP subgroups for both the romiplostim and placebo treatment groups.

The total subject-years on study was higher in the romiplostim group than in the placebo group for both the subgroup of subjects with ITP ≤ 12 months (270.5 vs 2.8 subjects -years, respectively) and those with ITP &gt; 12 months (906.5 vs 18.8 subjects-years).

Among all subjects with ITP ≤ 12 months, the study duration -adjusted event rate (per 100 subject-years) for rescue medications received was 190.4 in the romiplostim group and 391.2 in the placebo group (ISE Tables 14-8.1.1 and 14-8.1.2.2). Among subjects with ITP &gt; 12 months, the study duration-adjusted event rate (per 100 subject-years) for rescue medications received was 251.0 in the in the romiplostim group and 754.3 in the placebo group.

An  exploratory  analysis  was  conducted  using  data  from  all  studies  (including  Study  20060131)  by re-categorising the additional ITP treatments (Table 22). In this analysis, additional ITP treatment was defined as rescue medication for subjects in the placebo and romiplostim treatment groups, and as rescue

<div style=\"page-break-after: always\"></div>

medication and/or postbaseline additional SOC medication for ITP (other than the first SOC) for the subjects in the SOC treatment group. Among all subjects with ITP ≤ 12 months, the subject incidence of additional ITP treatment use at any time during the treatment period was 45.8% (127/277 subjects) in the romiplostim group and 76.5% (26/34 subjects) in the placebo/SOC group. Across the ITP duration subgroups, the subject  incidence  for  additional  ITP  treatment  was  higher  for  subjects  who  had  received  placebo/SOC compared with those who had received romiplostim (Table 22). Among subjects with ITP &gt; 12 months, the subject incidence of additional ITP treatment use was 51.9% (329/634 subjects) in the romiplostim group and 55.4% (51/92 subjects) in the placebo/SOC group (Table 22).

Table 22. Subject Incidence of Additional ITP Treatments During Treatment Period (Integrated ITP Efficacy Set)

|             | ITP Duration (Months)   | ITP Duration (Months)   | ITP Duration (Months)   | ITP Duration (Months)   |
|-------------|-------------------------|-------------------------|-------------------------|-------------------------|
|             | 65 n/N (%)              | ≥ 3 to s 12 n/N (%)     | All ≤ 12 n/N (%)        | >12 n/N (%)             |
| Total       | 78/155 (50.3)           | 75/156 (48.1)           | 153/311 (49.2)          | 380/726 (52.3)          |
| Romiplostim | 66/140 (47.1)           | 61/137 (44.5)           | 127/277 (45.8)          | 329/634 (51.9)          |
| Placebo/SoC | 12/15 (80.0)            | 14/19 (73.7)            | 26/34 (76.5)            | 51/92 (55.4)            |

ITP =immune thrombocytopenia; SoC = standard of care

Adult subjects (age ≥ 18 years at screening) who received ≥ 1 dose of investigational product in any of ITP 20060131,20060216,20080009,and 20080435) were included.Dataaftertreatmentswitch were excluded.

ITP duration was calculated from the time of ITP diagnosis to the enrollment of first ITP study. Additional treatments were defined as either rescue medication or a post-baseline second ITPmedication in for subjects in the SoC treatment group. Source:Table14-8.3.2.1

## · On-study Splenectomy

Among  subjects  with  ITP  ≤  12  months  who  had  no  prior  splenectomy  (i .e.  prior  to  first  dose  of investigational product in the first ITP study), 5 of 252 subjects (2.0%) in the romiplostim group and 9 of 34 subjects (26.5%) in the placebo/SOC group had undergone a splenectomy or discontinued investigational product due to need for a splenectomy during the treatment period.

A total of 25 of 277 romiplostim subjects with ITP ≤ 12 months had a splenectomy prior to study entry (Table 23).

Table 23. Summary of On -Study Splenectomy by ITP duration Romiplostim (Subjects with ≤ 12 Months of ITP Duration)

|                                                  | Romiplostim (N =277) ITPDurationinMonths   | Romiplostim (N =277) ITPDurationinMonths   | Romiplostim (N =277) ITPDurationinMonths   |
|--------------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
|                                                  | ε> (N = 140)                               | ≥3to≤12 (N = 137)                          | Total (N = 277)                            |
| Subjectswhohadpriorsplenectomy                   | 6                                          | 19                                         | 25                                         |
| Subjectswhodidnothavepriorsplenectomy-N1         | 134                                        | 118                                        | 252                                        |
| Subjects who had on-study splenectomy - n/N1 (%) | 4/134 (3.0)                                | 1/118 (0.8)                                | 5/252 (2.0)                                |

## Comparison of Results in Subpopulations

A comprehensive clinical evaluation was performed to examine the efficacy of romiplostim in subjects with ITP &lt; 3, ≥ 3 to ≤ 12, and &gt; 12 months duration at study entry. No other subpopulations were examined for efficacy. Subject incidence of platelet response, time to first platelet response, subject incidence of durable platelet response, time spent with a platelet response, and subject incidence of sustained platelet response

<div style=\"page-break-after: always\"></div>

were in favour of romiplostim over placebo/SOC for all ITP durations studied (&lt; 3, ≥ 3 to ≤ 12, all ≤ 12 and &gt; 12 months). Subgroup analysis were conducted for safety endpoints.

In the original filing in 2007, no statistically significant differences were observed in efficacy outcomes when analys ed using the subgroups defined by sex, race (white vs black vs other), age at baseline (≤ 65 vs &gt; 65 years), and the number of prior ITP therapies (≤ 3 vs &gt; 3 therapies).

## Persistence of Efficacy and/or Tolerance Effects

## Long-term Efficacy Results

In the integrated analysis set, of the 277 subjects with a duration of ITP ≤ 12 months at study entry and who had  received  romiplostim,  101  subjects  (36.5%)  had  received  romiplostim  for  &gt;  12  months  (median exposure  time  51.86  weeks;  range  0.3  to  227.0).  Of  these  101  subjects  with  long-term  romiplostim exposures, 34 subjects (24.3%) had ITP &lt; 3 months duration at study entry and 67 subjects (48.9%) had ITP between 3 and 12 months.

## Effects of Treatment Withdrawal

The MAH acknowledges that thrombocytopenia could reoccur upon discontinuation of romiplostim, and, therefore,  a  warning  and  an  adverse  drug  reaction  has  been  included  this  in  the  core  data  sheet  for romiplostim.  In  addition,  the  MAH  continues  to  monitor  this  event  through  routine  and  additional pharmacovigilance activities.

## 2.4.2. Discussion on clinical efficacy

To justify the efficacy of romiplostim in patients with ITP ≤ 12 months, no new clinical trials have been submitted. Neither the controlled study 20130273 proposed in the AEMPS scientific advice in 2017 nor the planned non-interventional study that was the matter of EMA advice in 2018 has been initially submitted within the dossier.

The MAH has provided only an integrated analysis with data from 311 subjects with ITP ≤ 12 months from 7 parent clinical studies and 2 extension studies, already assessed in previous applications (Figure 8). Prior to integrating studies, data from the individual studies was examined to determine appropriateness of the integration. All the individual studies included patients ≥ 18 years with a platelet count ≤ 50 x 10 9 /L prior to study entry and have received at least 1 prior ITP treatment. Efficacy variables (various platelet response parameters,  incidence  of  splenectomy  and  remission,  use  of  rescue  therapies)  were  similar  in  the  key studies included, while supporting studies included other variables such as incidence of adverse events, antibody formation or bone marrow results, among others.

Individual  studies :  the  two  principals  controlled  individual  studies  were,  Study  20030105  and  Study 20030212, which were also the two pivotal studies for initial approval of romiplostim for the treatment of patients with chronic ITP. The company alleges that, since the definition of chronic ITP was revised, some subjects enrolled in these two main studies, would now be considered to have newly or persistent ITP. This is accepted. Accordingly, the MAH has realised, prior to the integrated analysis, for each main study, a post-hoc analysed of durable platelet response by ITP duration at study entry.

Both studies were phase 3, randomized, double blind, placebo controlled, 24-week study designed to assess the efficacy and safety of romiplostim in adult thrombocytopenic subjects with ITP. In Study 20030105 were enrolled subjects with ITP refractory to splenectomy, while in Study 20030212 were enrolled subjects prior to  splenectomy.  For  the  overall  population,  both  studies  showed  that  romiplostim  was  statistically significantly superior to placebo for the primary efficacy endpoint and for the key secondary endpoints.

<div style=\"page-break-after: always\"></div>

- -In Study 20030105, 5 of 63 (7.9%) subjects enrolled had a duration of ITP ≤ 12 months at study entry with a median (range) time from ITP diagnosis to the first dose of investigational product of  8.0  (0.6  to  44.8)  years.  When  a  post-hoc  analysed  of  durable  platelet  response  by  ITP duration at study entry had been realized, 40.0% (2/5) of subjects with ITP ≤ 12 months and 37.8% (14/37) of subjects with ITP &gt; 12 months treated with romiplostim, attained a durable platelet response, as compared with 0% (0/0) and 0% (0/21) of subjects treated with placebo, respectively (Tables 6 and 7).
- -In Study 20030212, 21 of 62 (33.9%) subjects enrolled, had a duration of ITP ≤ 12 months at study entry with a median time from ITP diagnosis to the first dose of investigational product of 2.10 years (range: 0.1 to 31.6).  In the post-hoc analysis 66.7% (10/15) of subjects with ITP ≤ 12 months and 57.7% (15/26) of subjects with ITP &gt; 12 months treated with romiplostim attained a durable platelet response, as compared with 16.7% (1/6) and (0/15), respectively, in placebo group. (Tables 6 and 7).

Although no notable differences were observed between subjects with ITP ≤ 12 months and subjects with ITP &gt; 12 regarding the achievement of a durable platelet response, it should be taken into consideration the reduced number of patients (26/125) and that it was a post-hoc analysis.

The other controlled studies, Study 20060131 and Study 20060216 were supportive and the MAH has not performed a post-hoc analysis regarding subjects with ITP ≤ 12 months ay study entry.

- -Study 20060131, a phase 3, multi-center, randomized, SOC-controlled, open-label, 52-week treatment study, showed that romiplostim administered weekly by SC injection significantly reduced the incidences of splenectomy and treatment failure in nonsplenectomized subjects with ITP ( ≥ 18 years of age and who had received at least 1 prior therapy for ITP) compared with the standard of care in the overall population. Overall, the median time since ITP diagnosis was 2.090 years range.
- -Study 20060216, a phase 3, multicenter, randomized, double-blind, placebo-controlled study, showed efficacy in raising and sustaining platelet counts in thrombocytopenic Japanese subjects with ITP (adults ≥ 20 years of age with a diagnosis of ITP at least 6 months before their first screening visit and who had received at least 1 prior treatment for ITP). Overall, the mean number of years since ITP diagnosis was 9 years.

Regarding single-arms studies, the study that provides the key efficacy data in subjects with ITP ≤ 12 months were Study 20080435 since all the subjects included (N=75) was diagnosed with primary ITP within 6 months of study entry.

Study 20080435 was a phase 2, interventional study in adult subjects with primary ITP diagnosed within 6 months of study entry who had an insufficient response to first-line therapy for treatment of ITP. The median time (range) from ITP diagnosis to the first dose of romiplostim was 2.2 months (0.1 to 6.6 months). Treatment with 12 months of romiplostim was associated with a mean of 9.2 (95% CI: 8.3, 10.1) months of platelet response during the 12-month treatment period and 93.3% of subjects had a platelet response, with a median time to first platelet response was 2.1 weeks. The subject incidence of ITP remission during the study was 32%, and the incidence of splenectomy during the 12-month treatment period was 1.3%. A post-hoc analysis of durable platelet response was carried out (after imputation of missing platelet counts due to self-administration or other reasons) where 73.3% (95% CI: 61.9, 82.9) of the subjects attained a durable platelet response (Table 8). After a sensitivity analysis was conducted (imputation of weekly platelet response was done only for subjects who had self-administered romiplostim); 64.0% of the subjects (95% CI: 52.1, 74.8) attained a durable platelet response.

<div style=\"page-break-after: always\"></div>

The remaining single-arms studies, study 20040209 and study 20080009 evaluated the safety and the changes in bone marrow morphology in adult subjects receiving romiplostim, respectively.

Finally, two extension studies were also included in the integrated analysis, study 20030213 and study 20060113,  whose  primary  objective  was  to  evaluate  the  safety  and  secondly,  long-term  efficacy  of romiplostim.

## Integrated analysis

Once the individual studies were examined, an integrated analysis was performed with data from 311 subjects with ITP ≤ 12 months included in the clinical trials stated above, with the aim of analyzing the platelet  response,  the  use  of  rescue  medication  and  the  incidence  on-study  splenectomy,  and  make  a comparison with subjects with ITP ≤ 12 months. Of the subjects enrolled, 726 had a duration of ITP &gt; 12 months a t  study  entry  and  311  subjects  had  a  duration  of  ITP  ≤  12  months  (277  romiplostim  and  34 placebo/SOC). Of these, 111 subjects (77 romiplostim, 34 placebo/SOC) had been enrolled in the controlled studies, while 200 subjects had been enrolled in single-arm s tudies. Of the 277 subjects with ITP ≤ 12 months who received romiplostim, approximately 50% (140 subjects) had a duration of ITP &lt; 3 months at study entry.

The  percentages  of  subjects  in  the  romiplostim  group  who  completed  the  parent  studies  were  equally distributed between subjects with ITP ≤ 12 months and subjects with &gt; 12 months duration (≈ 70%) . There were  no  notable  differences  between  the  two  subgroups  in  terms  of  baseline  and  demographic characteristics,  except  from  female  percentage  which  was  a  slight  superior  for  subjects  with  ITP  &gt;  12 months (64,7% vs 53,4%). Among subjects with ITP ≤ 12 months, the median (Q1, Q3) time since ITP diagnosis was 0.25 (0.10, 0.47) years, while in subjects with ITP &gt; 12 months, the median (Q1, Q3) time since ITP diagnosis was 6.04 (2.80, 13.32) years. The mean baseline platelet count was 21.0 (16.6) x 10 9  /L in both subgroups.

For the platelet response endpoints, weekly/monthly platelet response were imputed for time points without a collected platelet count measurement (please see Statistical Method`s section above).

When analysed platelet responses, the subject incidence of platelet response was 86.3% (CI: 81.7, 90.1; 239/277 subjects) in romiplostim group for ITP ≤ 12 months vs 61.8% (CI: 43.6, 77.8; 21/ 34 subjects) in the placebo/SOC group. In each ITP duration sub group (&lt; 3 months, ≥ 3 to ≤ 12 months, and &gt; 12 months) the results showed the same trend (the incidence of platelet response was higher in the romiplostim group than the placebo/SOC group). Similarly, in patients with ITP &gt; 12 months, the subject incidence of platelet response was 87.2% in romiplostim group vs 32.6% in the placebo group.

Regarding  time  to  first  platelet  response,  the  median  time  was  lower  in  the  romiplostim  group  when compared with the placebo/SOC group for each ITP duration subgroup. In s ubjects with ITP ≤ 12 months, the median time was 2.0 weeks in the romiplostim group vs 3.1 weeks in the placebo/SOC group. In &lt; 3 months ITP subgroup, the median time was 2.1 weeks vs 2.6 (placebo/SOC), in ≥ 3 to ≤ 12 months ITP subgroup, 1.3 weeks vs 3.1, and in &gt; 12 months subgroup, 2.0 weeks vs 2.2 .

Durable platelet response represents a key clinical outcome for ITP patients. Among subjects with ITP ≤ 12 months, data showed a subject incidence of durable platelet response (without imputation) of 26.7% (74/277  subjects)  in  the  romiplostim  group vs 2.9%  (1/34  subjects)  in  the  placebo/SOC  group.  After imputation of missing data, the same trend was observed, subject incidence of durable platelet response among subjects with ITP ≤ 12 months was 52.7% (146/277 subjects) in the romiplostim group vs 23.5% (8 of 34 subjects) in the placebo/SOC group. For ITP &gt; 12 months, it was 49.2% (312/634 subjects) in the romiplostim group vs 9.8% (9/92 subjects) in the placebo/SOC group.

When analyzed the number and percentage of months with platelet response, mean percent time with a platelet response was higher in the romiplostim group (77.1%) than in the placebo/SOC group (34%) and

<div style=\"page-break-after: always\"></div>

this  difference  was  apparent  across  all  ITP  duration  subgroups.  Percentage  of  subjects  with  a  platelet response at least 75% of the time or at least 90% of the time across all integrated studies was higher in the romiplostim  group  than  in  the  placebo/SOC  group  for  each  ITP  duration  subgroup.  Overall,  60.6% (romiplostim) vs 11.8% (placebo/SOC group) achieved a platelet response 90% of the time. The same trend was observed in ITP &gt; 12 months, where mean percent time with a platelet response (74.9% romiplostim, 17.0% placebo/SOC) and the percentage of subjects with a platelet response at least 75% of the time (71.0%  romiplostim,  8.7%  placebo/SOC)  or  at  least  90%  of  the  time  (55.8%  romiplostim,  6.5% placebo/SOC) was higher in the romiplostim group than in the placebo/SOC group.

The subject incidence of sustained platelet response (subjects who achieved a platelet response for at least 9 weeks within a 12week period), was 74.4% (206/277) of subjects with ITP ≤ 12 months, and 72.7% (461/634) of subjects with ITP &gt; 12 months in the romiplostim group vs 35.3% (12/34) and 19.6% (18/92 subjects) in the placebo/SOC group, respectively.

The subject incidence of rescue medication used at any time during treatment, showed a different trend between the two subgroups. In subjects with ITP ≤ 12 months, it was lower for romiplostim group in comparison with placebo group (46.2% (102/221) vs 71.4% (5/7); while in ITP &gt; 12 months, it was 54.5% (291/ 534) vs 45.7% (21/46), respectively, being the corticosteroids and /or immunoglobulins the most commonly used rescue medications across all ITP subgroups in both treatment groups. In this primary analysis the study 20060131 was excluded since the definition of rescue medication differs from the other studies.

The total subject-years on study was higher in the romiplostim group than in the placebo group for both the subgroup of subjects with ITP ≤ 12 months (270.5 vs 2.8 subjects-years, respectively) and those with ITP &gt; 12  months  (906.5  vs  18.8 subjects-years).  Among  all  subjects  with  ITP ≤ 12  months,  the  study duration-adjusted event rate (per 100 subjects-years) for rescue medications received was 190.4 in the romiplostim group and 391.2 in the placebo group, while among subjects with ITP &gt; 12 months, was 251.0 in the romiplostim group and 754.3 in the placebo group.

When an exploratory analysis was performed including study 20060131 (ITP additional treatment were recategorized), subjects with ITP ≤ 12 months showed a subject incidence of additional ITP treatment of 45.8% (127/277) for romiplostim vs 76.5% (26/34) for placebo/SOC group. When this was analyzed within the different subgroups (&lt; 3, ≥ 3 to ≤ 12, all ≤ 12 and &gt; 12 months) incidences for additional ITP treatment was  also  higher  for  subjects  who  had  received  placebo/SOC  compared  with  those  who  had  received romiplostim.  In  ITP  &gt;  12  months,  the  subject  incidence  of  additional  ITP  treatment  use  was  51.9% (329/634) in the romiplostim group and 55.4% (51/92) in the placebo/SOC group.

2.0% (5/252) subjects in  romiplostim  group  vs  26.5%  (9/34  subjects  in  the  placebo/SOC  group)  had undergone a splenectomy or disconti nued investigational product during the treatment period, in ITP ≤ 12 months subjects who had no prior splenectomy. 25/27 of romiplostim subject had a splenectomy prior to study entry.

## Conclusion

In summary, key results of the integrated analysis shows consistency in the efficacy profile between subjects with  ITP ≤ 12  months  and  subjects  with  ITP  &gt; 12 months,  with  all  the  endpoints  explored  favouring romiplostim over that placebo, being platelet response and durable platelet response the most relevant endpoints in the assessment of efficacy. The 3 studies included in the integrated study, that provides the greater evidence were, in first place, placebo-controlled pivotal phase 3 studies (20030105, 20030212) and in  second  place,  Study 20080435,  which  enrolled  adult  subjects  with  ITP  diagnosed  within  the  last 6 months. In Study 20080435 (N=75), 93.3% of subjects had a platelet response, and a 73.3% (95% CI: 61.9, 82.9) had durable platelet response when a post-hoc analysis was carried out. However, it is worth mentioning that study 20080435 was a phase 2, not controlled study, being the durable platelet response

<div style=\"page-break-after: always\"></div>

assessed  by  a  post-hoc  analysis;  therefore,  the  relevance  of  their  results  is  limited.  When  a  post-hoc analysis regarding two pivotal studies (20030105, 20030212) were performed, a 40.0% (2/5) and 66.7% (10/15) of subjects with ITP ≤ 12 months attained a durable platelet response, respectively, in comparison with 37.8% (14/37) and 57.7% (15/26) in subjects with ITP &gt; 12 months. In the integrated analysis set, the subject incidence of durable platelet response (without imputation) was 26.7% (74/277 subjects) in the romiplostim group compared with 2.9% (1/34 subjects) in the placebo/SOC group for ITP ≤ 12 months. After weekly platelet response was imputed, among subjects with ITP ≤ 12 months, it was 52.7% (146/277 subjects) in the romiplostim group compared with 23.5% (8/34 subjects) in the placebo/SOC group, while it was 49.2% (312/634) in the romiplostim group compared with 9.8% (9/92) in the placebo/SOC group among subjects with ITP &gt; 12 months.

When subgroups regarding time for diagnosis were explored ( &lt; 3 months, (N=140), ≥ 3 to ≤ 12 months (N=137), and &gt; 12 months) no significant differences were observed between them in terms of efficacy, and the results showed the same trend as for the overall population (favoring romiplostim overt placebo/SOC group). Specifically, 82.1% ( &lt; 3 months) and 90,5% (≥ 3 to ≤ 12 months) of subjects attained a platel et response, while 50.0% ( &lt; 3 months) and 55,5% (≥ 3 to ≤ 12 months) subjects attained a durable platelet response (after imputation) in the integrated analysis. No other subgroups were analyzed since in initial MAA,  no  statistically  significant  differences  were  observed  in  subgroups  defined  by  sex,  race,  age  at baseline, and the number of prior ITP therapies.

The MAH concludes that the efficacy of romiplostim has been sufficiently demonstrated in the randomized placebo-controlled pivotal phase 3 studies and continues to be seen with longer-term usage in 1024 subjects in adult ITP integrated analysis treated for up to 5.5 years. In the CHMP's opinion, in view of the data provided by the company, although it does not seem that romiplostim lacks efficacy in subjects with ITP ≤ 12 months regardless time from diagnosis, this has not been yet confirmed specifically by a controlled trial in this population, and, therefore, there is limited data with adequate robustness. It is accepted that, due to the revision in disease classification by the International Working Group (IWG) [Rodeghiero et al. 2009], based on the eligibility of the pivotal controlled studies, which provide the most robust efficacy data for romiplostim, there were included patients with ≤ 12 months, which cannot be currently categorised as having 'chronic' ITP.  Nevertheless, the number of subjects included in the pivotal trials is limited (26/125) and  although  the  integrated  analysis  increases  that  number  to  277  subjects,  it  should  be  taken  into consideration that many of the studies included where uncontrolled, hindering the assessment of causality of treatment effect. Specifically, if the number of subjects by subgroups is analysed in the pivotal studies, the number is even more limited, ( &lt; 3 months: 9 patients; ≥ 3 to ≤ 12 m onths: 17 patients) (Table 24). In addition, in a context of 10-year post-marketing experience, the data initially provided by the MAH were considered insufficient to reach any meaningful conclusion. In response to the CHMP RSI, the company has provided extensive real-world evidence (RWE) search from various sources. The evidence submitted show that romiplostim is frequently used -off label during clinical practice in both newly and persistent ITP, as it was expected and according to current guidelines. Although it must be taken into account that robust evidence that can be drawn from routine clinical settings is limited, and that, consequently, interpretation of data should be done with caution, results show the achievement of clinically relevant platelet responses in a considerable proportion of patients in patients with both newly and persistent IPT, in line with what has been observed in the integrated analysis and phase II Study 20080435 which provide the greatest evidence.

## 2.4.3. Conclusions on the clinical efficacy

Key results of the integrated analysis carried out by the MAH, which included 9 clinical trials previously assessed, showed consistency in the efficacy profile between subjects treated with romiplostim with ITP ≤ 12 months (N=277) and subjects with ITP &gt; 12 months (N=634), with all the endpoints explored favouring

<div style=\"page-break-after: always\"></div>

romiplostim over that placebo, being platelet response and durable platelet response the most relevant endpoints in the assessment of efficacy.

When subgroups regarding time for diagnos is were explored (&lt; 3 months, (N=140), ≥ 3 to ≤ 12 months (N=137), and &gt; 12 months), no significant differences were observed between them in terms of efficacy, and  the  results  showed  the  same  trend  as  for  the  overall  population  (favouring  romiplostim  overt placebo/SOC group).

Although it does not seem that romiplostim lacks efficacy in subjects with ITP ≤ 12 months refractory to other treatment, regardless time from diagnosis, this has not been confirmed specifically by a controlled trial in this population, and, therefore, there is limited data with the adequate robustness. It is accepted that, due to revision in disease classification, in pivotal studies, which provide the greatest evidence of romiplostim efficacy, there were included patients with ≤ 12 months, which cannot be currently categorized as having 'chronic' ITP. Nevertheless, the number of them is limited (26/125), and, although the integrated analysis increases that number to 277 subjects, many of the studies included where uncontrolled, hindering the assessment of causality of the treatment effect. Specifically, if the number of subjects by subgroups is analysed in the pivotal studies, the number is even more limited, ( &lt; 3 months: 9 patients; ≥ 3 to ≤ 12 months: 17 patients) (Table 24). In addition, in a context of 10-year post-marketing experience, the data initially provided by the MAH were considered insufficient to reach any meaningful conclusion. In response to the CHMP RSI, the Company has provided extensive real-world evidence (RWE) search from various sources (see Annex 2, RSI, Q1). The evidence submitted show that romiplostim is frequently used -off label during clinical practice in both newly and persistent ITP, as it was expected and according to current guidelines (Neunert et al, 2019; Provan et al, 2019). Although it must be taken into account that robust evidence that can be drawn from routine clinical settings is limited, and that, consequently, interpretation of data should be done with caution, results show the achievement of clinically relevant platelet responses in a considerable proportion of patients in patients with both newly and persistent IPT, in line with what has been observed in the integrated analysis and phase II Study 20080435 which provide the greatest evidence..

## 2.5. Clinical safety

## Introduction

Safety data of romiplostim in adult ITP were described in the original marketing authorisation. This variation application is based on a main integrated analysis.

As the basis of this application, the company provides an integrated analysis where safety was evaluated in 311 subjects (277 romiplostim, 34 placebo/standard of care [SOC]) with ITP ≤ 12 months across 7 parent clinical  studies  (20030105,  20030212,  20040209,  20060131,  20060216,  20080009,  20080435)  and  2 extension studies (20030213, 20060113) (Figure 8). Prior to integrating studies, the MAH has sent a very brief summary of each individual study. See Section 5.4.1.1 (-Summary on the main individual studies) for further details on study design and populations.

## Methods - analysis of data submitted

Nine  completed  studies  on  the  ITP  population  (Studies  20030105,  20030212,  20040209,  20060131, 20060216, 20080009, 20080435, 20030213 [extension study], 20060113 [extension study]) were pooled for integrated analysis for safety.

No hypothesis testing was intended in the integrated analysis of safety as the analysis was descriptive in nature. Categorical endpoints were summarised by the number and percentage of subjects in each category,

<div style=\"page-break-after: always\"></div>

while continuous endpoints were summarised by n, mean, standard deviation, median, Q1 (25th percentile), Q3 (75th percentile) and minimum and maximum values. Events were summarized by subject incidence and duration adjusted incidence event rate.

For comparison of subject incidence and duration-adjusted incidence event rates (per 100 subject-years) between treatment groups, anything &lt; 3% subject incidence or &lt; 3 adverse events per 100 subject-years is considered similar.

## Study participants

## Integrated Analysis Set

Data from all 9 studies in Figure 8 were pooled for the integrated analysis of safety. All adult subjects aged ≥ 18 years who received at least 1 dose of investigational product in the integrated dataset were included in the integrated analysis set. Data after treatment switch were excluded from the integrated analysis. Subject data were assigned to romiplostim group or placebo/SOC group based on the actual treatment received prior to any treatment switch. Subjects who received at least 1 dose of romiplostim were counted in romiplostim group and their corresponding safety data were also summarised under romiplostim group. Subjects in the placebo group and SOC group were pooled as the control group. Data collected for the same subject across multiple studies were concatenated over time.

The number of subjects by ITP duration ( &lt; 3, ≥ 3 to ≤ 12, &gt; 12 months) and by treatment group (romiplostim, placebo/SOC) in this integrated dataset is summarised in the following table (Table 24). ITP duration is calculated from the time of ITP diagnosis to the time of enrollment in the first romiplostim ITP study.

Table 24. Subjects by ITP Duration and by Study

|                                    | Total Number of Subjects Who Received IP by Treatment Group and ITP Duration (Months)   | Total Number of Subjects Who Received IP by Treatment Group and ITP Duration (Months)   | Total Number of Subjects Who Received IP by Treatment Group and ITP Duration (Months)   | Total Number of Subjects Who Received IP by Treatment Group and ITP Duration (Months)   | Total Number of Subjects Who Received IP by Treatment Group and ITP Duration (Months)   | Total Number of Subjects Who Received IP by Treatment Group and ITP Duration (Months)   | Total Number of Subjects Who Received IP by Treatment Group and ITP Duration (Months)   | Total Number of Subjects Who Received IP by Treatment Group and ITP Duration (Months)   |
|------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
|                                    | Romiplostim                                                                             | Romiplostim                                                                             | Romiplostim                                                                             | Romiplostim                                                                             | Placebo/SOC                                                                             | Placebo/SOC                                                                             | Placebo/SOC                                                                             | Placebo/SOC                                                                             |
| Individual Studies                 | <3                                                                                      | ≥3to≤ 12                                                                                | ≤12                                                                                     | >12                                                                                     | <3                                                                                      | ≥3to≤ 12                                                                                | ≤12                                                                                     | >12                                                                                     |
| Randomized, controlled ITP studies |                                                                                         |                                                                                         |                                                                                         |                                                                                         |                                                                                         |                                                                                         |                                                                                         |                                                                                         |
| 20030105                           | 0                                                                                       | 5                                                                                       | 5                                                                                       | 37                                                                                      | 0                                                                                       | 0                                                                                       | 0                                                                                       | 21                                                                                      |
| 20030212                           | 8                                                                                       | 7                                                                                       | 15                                                                                      | 27                                                                                      | 1                                                                                       | 5                                                                                       | 6                                                                                       | 14                                                                                      |
| 20060131                           | 26                                                                                      | 30                                                                                      | 56                                                                                      | 100                                                                                     | 14                                                                                      | 13                                                                                      | 27                                                                                      | 46                                                                                      |
| 20060216                           | 0                                                                                       | 1                                                                                       | 1                                                                                       | 21                                                                                      | 0                                                                                       | 1                                                                                       | 1                                                                                       | 11                                                                                      |
| Total                              | 34                                                                                      | 43                                                                                      | 77                                                                                      | 185                                                                                     | 15                                                                                      | 19                                                                                      | 34                                                                                      | 92                                                                                      |
| Open-label, single-arm studies     |                                                                                         |                                                                                         |                                                                                         |                                                                                         |                                                                                         |                                                                                         |                                                                                         |                                                                                         |
| 20040209                           | 45                                                                                      | 47                                                                                      | 92                                                                                      | 313                                                                                     | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       |
| 20080009                           | 16                                                                                      | 17                                                                                      | 33                                                                                      | 136                                                                                     | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       |
| 20080435                           | 45                                                                                      | 30                                                                                      | 75                                                                                      | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       |
| Total                              | 106                                                                                     | 94                                                                                      | 200                                                                                     | 449                                                                                     | 0                                                                                       | 0                                                                                       | 0                                                                                       | 0                                                                                       |
| Open-label, extension studies      |                                                                                         |                                                                                         |                                                                                         |                                                                                         |                                                                                         |                                                                                         |                                                                                         |                                                                                         |
| 20030213                           | 21                                                                                      | 35                                                                                      | 56                                                                                      | 145                                                                                     |                                                                                         |                                                                                         |                                                                                         |                                                                                         |
| 20060113                           | 0                                                                                       | 1                                                                                       | 1                                                                                       | 20                                                                                      |                                                                                         |                                                                                         |                                                                                         |                                                                                         |
| Total                              | 21                                                                                      | 36                                                                                      | 57                                                                                      | 165                                                                                     |                                                                                         |                                                                                         |                                                                                         |                                                                                         |

IP=investigationalproduct;ITP=immunethrombocytopenia;SoC=Standardof Care.

Adultsubjects(age≥18yearsatscreening)whoreceivedatleast1doseofinvestigationalproductinanyof

20060131,20060216,20080009,and20080435)areincluded.

ITP studies (20030105,20030212,20030213[extensionstudy],20040209,20060113[extension study],

ITP durationis calculatedfrom theITP diagnosis to the enrollmentoffirstITP study.

\" =Data aftertreatmentswitch were excludedfromthis analysis.

Subject disposition by ITP duration and treatment group and subject disposition by study, ITP duration and treatment group are presented in Table 10 and Table 11, respectively (please refer to the Efficacy Section).

<div style=\"page-break-after: always\"></div>

At time of enrolment, a total of 311 subjects had ITP for ≤ 12 months and a total of 726 subjects had ITP for &gt; 12 months. Of the 311 subjects  with  ITP  ≤  12  months,  277  received  romiplostim  and  34  received placebo/SOC and were included in the integrated data set for analysis of safety endpoints. Of the 277 subjects  with  ITP  ≤  12  months  who  received  romiplostim,  approximately  50%  of  these  subjects  (140 subjects) had a duration of ITP &lt; 3 months at study entry with the other half having a duration of ITP ≥ 3 to ≤ 12 months. The percentages of subjects in the romiplostim group who completed the parent study were similar between subjects with ITP ≤ 12 months duration at study entry (74.7%, 207/277 subjects) and those with ITP &gt; 12 months duration (74.6%, 473/634 subjects). Similar results were seen for completion of the open-label extension studies (71.9%, 41/57 subjects and 71.7%, 119 /166 subjects, respectively). Demographics and other baseline characteristics are already presented in Table 12 (please refer to the Efficacy Section). The following demographic and baseline characteristics were summarised by treatment groups (romiplostim; placebo/SOC) using descriptive statistics for the integrated data set by ITP subgroups using descriptive statistics: age, sex, race, months since ITP diagnosis, ITP treatment history, baseline bleeding status and baseline concurrent ITP therapy. Safety data was not summarized by prior splenectomy due to insufficient data (25 of 277 subjects) for analysis in subjects with ITP ≤ 12 months.

## Safety endpoints:

The safety endpoints included the following:

- Duration of treatment and dose intensity (average dose per week)
- Frequency, severity, seriousness, relationship to treatment of treatment-emergent adverse events and its subject incidence and duration adjusted incidence event rate
- Treatment-emergent adverse events leading to withdrawal from investigational product and/or study
- Events of interest (EOI
- Laboratory parameters and vital signs
- Antibody formation

In addition, subgroup analyses of the above safety endpoints were conducted for subjects who had ITP duration of &lt; 3 months, ≥ 3 to ≤ 12 months, and &gt; 12 months .

## Results

## Patient exposure

Exposure to romiplostim among the subjects with ITP for ≤ 12 months was compared to exposure among subjects with ITP for &gt; 12 months in the integrated analysis set (Table 25).

The median total duration of the treatment (51.86 weeks versus 70.93 weeks), median average weekly dose (3.03 μ g/kg/week versus 3.59 μ g/kg/week), and percent of subjects who received treatment for &gt; 12 months (36.5% versus 63.2%) were lower for subjects with ITP ≤ 12 months compared with subjects with ITP &gt; 12 months. The MAH argues that the difference in treatment duration result from different distribution of subjects among studies which had different treatment duration. For the ITP &gt; 12 months group, almost half of subjects were from Study 20040209 that had the longest follow-up duration.

<div style=\"page-break-after: always\"></div>

Table 25. Romiplostim Exposure by ITP Duration

<!-- image -->

|                                                           | RomiplostimOnly (N =277) ITPDurationinMonths              | RomiplostimOnly (N =277) ITPDurationinMonths              | RomiplostimOnly (N =277) ITPDurationinMonths              | Romiplostim (N=634) ITPDurationinMonths                   |
|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
|                                                           | <3 (N = 140)                                              | ≥3to≤12 (N = 137)                                         | ≤12 (N = 277)                                             | >12months                                                 |
| TotalDurationofTreatment(weeks)                           | TotalDurationofTreatment(weeks)                           | TotalDurationofTreatment(weeks)                           | TotalDurationofTreatment(weeks)                           | TotalDurationofTreatment(weeks)                           |
| n                                                         | 140                                                       | 137                                                       | 277                                                       | 634                                                       |
| Mean                                                      | 48.59                                                     | 74.31                                                     | 61.31                                                     | 84.52                                                     |
| SD                                                        | 43.16                                                     | 51.95                                                     | 49.34                                                     | 59.82                                                     |
| Median                                                    | 42.93                                                     | 52.14                                                     | 51.86                                                     | 70.93                                                     |
| Q1,Q3                                                     | 15.07,52.14                                               | 35.14,118.00                                              | 24.00,88.00                                               | 30.00,134.00                                              |
| Min, Max                                                  | 0.3,209.0                                                 | 3.0, 227.0                                                | 0.3, 227.0                                                | 1.9, 239.7                                                |
| NumberandPercentofSubjectsbyTotalDurationofTreatment-n(%) | NumberandPercentofSubjectsbyTotalDurationofTreatment-n(%) | NumberandPercentofSubjectsbyTotalDurationofTreatment-n(%) | NumberandPercentofSubjectsbyTotalDurationofTreatment-n(%) | NumberandPercentofSubjectsbyTotalDurationofTreatment-n(%) |
| ≤12months                                                 | 106 (75.7)                                                | 70 (51.1)                                                 | 176 (63.5)                                                | 233 (36.8)                                                |
| >12months                                                 | 34 (24.3)                                                 | 67 (48.9)                                                 | 101 (36.5)                                                | 401 (63.2)                                                |
| AverageWeeklyDose(μg/kg/week)                             | AverageWeeklyDose(μg/kg/week)                             | AverageWeeklyDose(μg/kg/week)                             | AverageWeeklyDose(μg/kg/week)                             | AverageWeeklyDose(μg/kg/week)                             |
| n                                                         | 140                                                       | 137                                                       | 277                                                       | 634                                                       |
| Mean                                                      | 3.418                                                     | 3.932                                                     | 3.672                                                     | 4.180                                                     |
| SD                                                        | 2.675                                                     | 2.382                                                     | 2.543                                                     | 2.719                                                     |
| Median                                                    | 2.450                                                     | 3.318                                                     | 3.028                                                     | 3.589                                                     |
| Q1,Q3                                                     | 1.270, 5.149                                              | 2.087,5.120                                               | 1.615, 5.120                                              | 1.992,6.071                                               |
| Min, Max                                                  | 0.11,14.39                                                | 0.62, 9.71                                                | 0.11,14.39                                                | 0.07,14.59                                                |

Adultsubjects(age≥18yearsatscreening)whoreceivedatleastonedoseofinvestigationalproductinany 20060131,20060216,20080009,and20080435)areincluded.Dataaftertreatmentswitchareexcluded. ITPdurationiscalculatedfromthetimeofITPdiagnosistothetimeofenrollmentof thefirstITPstudy. ITP=immunethrombocytopenia.n=Numberofsubjects.PercentagesarebasedonN.

## Adverse events

## Treatment-emergent Adverse Events

The subject incidence and duration-adjusted incidence event rate (per 100 subject-years) of treatment-emergent adverse events for the romiplostim group was lower in subjects with ITP ≤ 12 compared with subjects with ITP &gt; 12 months.

- -In subjects with ITP ≤ 12 months, the subject incidence and duration -adjusted incidence event rate (per 100 subject-years) were lower for the romiplostim group compared with the placebo/SOC group (92.8% versus 97.1%; 854.2 versus 1038.0), while among subjects with ITP &gt; 12 months, it was 94.2% versus 91.3% and 945.7 versus 1109.9, respectively (Table 26).

Table 26. Summary  of Subject Incidence and Duration Adjusted Incidence Rate of Treatment-emergent Adverse Events by ITP Duration (Subjects With ≤ 12 and &gt; 12 Months of ITP Duration)

<!-- image -->

|                                                           | Placebo/SOC (N =34) ITP Duration in Months                | Placebo/SOC (N =34) ITP Duration in Months                | Placebo/SOC (N =34) ITP Duration in Months                | Placebo/SOC ITP Duration in Months   | Romiplostim (N = 277) ITP Duration in Months                  | Romiplostim (N = 277) ITP Duration in Months                  | Romiplostim (N = 277) ITP Duration in Months                  | Romiplostim ITP Duration in Months   |
|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|--------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|--------------------------------------|
|                                                           | <3 (N = 15)                                               | 3to≤12 (N = 19)                                           | Total (N =34)                                             | >12 (N = 92)                         | <3 (N = 140)                                                  | 3to≤12 (N = 137)                                              | Total (N = 277)                                               | >12 (N =634)                         |
| Alltreatment-emergentadverseevents -n(%)                  | 14 (93.3)                                                 | 19 (100.0)                                                | 33 (97.1)                                                 | 84 (91.3)                            | 125 (89.3)                                                    | 132 (96.4)                                                    | 257 (92.8)                                                    | 597 (94.2)                           |
| Treatment-relatedtreatment-emergent adverseevents-n (%)   | 6 (40.0)                                                  | 5 (26.3)                                                  | 11 (32.4)                                                 | 34 (37.0)                            | 52 (37.1)                                                     | 57 (41.6)                                                     | 109 (39.4)                                                    | 323 (50.9)                           |
|                                                           | Placebo/SOC (Sbj-yr = 36.5) (N=34) ITP Duration in Months | Placebo/SOC (Sbj-yr = 36.5) (N=34) ITP Duration in Months | Placebo/SOC (Sbj-yr = 36.5) (N=34) ITP Duration in Months | Placebo/SOC ITPDuration in Months    | Romiplostim (Sbj-yr = 382.1) (N = 277) ITP Duration in Months | Romiplostim (Sbj-yr = 382.1) (N = 277) ITP Duration in Months | Romiplostim (Sbj-yr = 382.1) (N = 277) ITP Duration in Months | Romiplostim ITP Duration in Months   |
|                                                           | <3 (Sbj-yr = 16.8) (N = 15)                               | 3to≤12 (Sbj-yr = 19.7) (N = 19)                           | Total (Sbj-yr = 36.5) (N = 34)                            | >12 (Sbj-yr = 70.8) (76 = N)         | <3 (Sbj-yr = 167.3) (N = 140)                                 | 3to≤12 (Sbj-yr = 214.9) (N = 137)                             | Total (Sbj-yr = 382.1) (N = 277)                              | >12 (Sbj-yr = 1100.5) (N =634)       |
| (）u-                                                      |                                                           | 207 (1049.2)                                              | 379 (1038.0)                                              | 786 (1109.9)                         | 1432 (856.1)                                                  | 1832 (852.6)                                                  | 3264 (854.2)                                                  | 10407 (945.7)                        |
| AllTreatment-relatedtreatment- emergentadverseevents-n(r) | 39 (232.4)                                                | 10 (50.7)                                                 | 49 (134.2)                                                | 104 (146.9)                          | 128 (76.5)                                                    | 198 (92.1)                                                    | 326 (85.3)                                                    | 1123 (102.0)                         |

SOC=StandardofCare.Adultsubjects(age≥18yearsatscreening)whoreceivedatleast1doseofinvestigationalproductinanyoflTPstudies(20030105, 20030212,20030213[extensionstudy],20040209,20060113[extensionstudy],20060131,20060216,20080009,and20080435)areincluded.Data aftertreatment switchare excluded.

CTCAE=Common Terminology CriteriaforAdverse EventsGradingScale;ITP=immunethrombocytopenia;n=numberofevents;r=durationadjustedeventrate per 100 subject-years (n/Sbj-yr*100); Sbj-yr = Total subject years onstudy.

ITPdurationiscalculatedfromtheITPdiagnosistothe enrollmentoffirstITPstudy.Multipleoccurrencesofthe sameeventfora subjectarecountedasmultiple events.Only adverseeventsstartingafterthefirstdoseofinvestigationalproductaretabulated. Grades are based onCTCAE v3.0.

<div style=\"page-break-after: always\"></div>

The adverse events (by System Organ Class) with the highest subject incidence of treatment-emergent adverse events (&gt; 40%) were the same in subjects with ITP ≤ 12 months and in subjects with ITP &gt; 12 months:

- -For  subjects  with ≤ 12  months  were:  Infections  and  infestations  (59.9%  versus  52.9%), musculoskeletal and connective tissue disorders (48.0% versus 47.1%), gastrointestinal disorders (47.3% versus 50.0%), general disorders and administration site conditions (46.2% versus 44.1%), respiratory, thoracic, and mediastinal disorders (45.5% versus 52.9%), nervous system disorders (44.8% versus 38.2%), and skin and subcutaneous tissue disorders (42.2% versus 47.1%).
- -For  subject  ITP  &gt;  12  months  were:  Infections  and  infestations  (65.8%  versus  48.9%), musculoskeletal and connective tissue disorders (58.2% versus 35.9%), gastrointestinal disorders (55.7% versus 45.7%), nervous system disorders (51.6% versus 41.3%), skin and subcutaneous tissue  disorders  (51.1%  versus  52.2%),  general  disorders  and  administration  site  conditions (50.6% versus 41.3%), and respiratory, thoracic, and mediastinal disorders (46.2% versus 38.0%).

The  adverse  events  (by  preferred  terms)  reported  with  highest  subject  incidence  (&gt;  15%)  and/or duration-adjusted incidence event rate (&gt; 15 adverse events per 100 subject-years) and with higher subject incidence and/or event rate in the romiplostim group compared with the placebo/SOC group, were similar in subjects with ITP ≤ 12 months and in subjects with ITP &gt; 12 months.

- -For patients ≤ 12 months, the adverse events (by preferred term) with highest subject incidence and/or duration-adjusted incidence event rate and with higher subject incidence and/or event rate in  the  romiplostim  group  compared  with  the  placebo/SOC  group  were  similar  across  all  ITP subgroups (Tables 27 and 28).

Table  27.  Subject  Incidence  of  Treatment-emergent  Adverse  Events  by  Preferred  Term  in Descending Order of Frequency (Subjects with ≤ 12 Months of ITP Duration)

|                                   |                           | Romiplostim-ITPDurationinMonths   | Romiplostim-ITPDurationinMonths   | Romiplostim-ITPDurationinMonths   |
|-----------------------------------|---------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| Preferred Tem                     | Placebo/SOC (N = 34) n(%) | 3 (N = 140) n (%)                 | ≥3tos12 (N = 137) n (%)           | (N = 277) n (%)                   |
| Headache                          | 7 (20.6)                  | 31 (22.1)                         | 47 (34.3)                         | 78 (28.2)                         |
| Arthralgia                        | 4 (11.8)                  | 22 (15.7)                         | 33 (24.1)                         | 55 (19.9)                         |
| Fatigue                           | 7 (20.6)                  | 28 (20.0)                         | 27 (19.7)                         | 55 (19.9)                         |
| Epistaxis                         | 11 (32.4)                 | 20 (14.3)                         | 29 (21.2)                         | 49 (17.7)                         |
| Diarrhoea                         | 3 (8.8)                   | 29 (20.7)                         | 19 (13.9)                         | 48 (17.3)                         |
| Nasopharyngitis                   | 10 (29.4)                 | 16 (11.4)                         | 31 (22.6)                         | 47 (17.0)                         |
| Upper respiratory tract infection | 2 (5.9)                   | 20 (14.3)                         | 26 (19.0)                         | 46 (16.6)                         |
| Cough                             | 2 (5.9)                   | 24 (17.1)                         | 19 (13.9)                         | 43 (15.5)                         |
| Petechiae                         | 7 (20.6)                  | 22 (15.7)                         | 21 (15.3)                         | 43 (15.5)                         |
| Contusion                         | 5 (14.7)                  | 17 (12.1)                         | 25 (18.2)                         | 42 (15.2)                         |
| Nausea                            | 2 (5.9)                   | 20 (14.3)                         | 18 (13.1)                         | 38 (13.7)                         |
| Pain in extremity                 | 4 (11.8)                  | 19 (13.6)                         | 14 (10.2)                         | 33 (11.9)                         |
| Dizziness                         | 1 (2.9)                   | 11 (7.9)                          | 21 (15.3)                         | 32 (11.6)                         |
| Back pain                         | 4 (11.8)                  | 14 (10.0)                         | 17 (12.4)                         | 31 (11.2)                         |
| Oropharyngeal pain                | 1 (2.9)                   | 9 (6.4)                           | 22 (16.1)                         | 31 (11.2)                         |
| Rash                              | 4 (11.8)                  | 14 (10.0)                         | 16 (11.7)                         | 30 (10.8)                         |
| Thrombocytopenia                  | 4 (11.8)                  | 12 (8.6)                          | 15 (10.9)                         | 27 (9.7)                          |

Adult subjects (age ≥ 18 years at screening) who received at least one dose ofinvestigational product in any 20060131,20060216,20080009,and20080435)areincluded.

Data after treatment switch are excluded.

ITPduration iscalculatedfrom the ITPdiagnosisto the enrollment of first ITPstudy.

Only adverse events starting after the first dose of investigational product are tabulated.

ITP = immune thrombocytopenia;MedDRA = Medical Dictionary for Regulatory Activities; SOC = Standard of Care.

Coded using the MedDRA version 21.0.

Events with subject incidence of &lt; 10% in the romiplostim group are not included in this table.

<div style=\"page-break-after: always\"></div>

Table  28.  Study  Duration  Adjusted  Incidence  Event  Rates  of  Treatment-emergent  Adverse Events by Preferred Term in Descending Order of Incidence Rate (Subjects with ≤ 12 Months of ITP Duration)

<!-- image -->

|                                   | Placebo/SOC -ITP Duration in Months   | Placebo/SOC -ITP Duration in Months   | Placebo/SOC -ITP Duration in Months   | Romiplostim - ITP Duration in Months   | Romiplostim - ITP Duration in Months   | Romiplostim - ITP Duration in Months   |
|-----------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| Preferred Tem                     | 3 (Sbj- yr=16.8) (N= 15) n (n)        | ≥3to≤12 (Sbj- yr=19.7) (N= 19) n(n)   | Total (Sbj- yr=36.5) (N= 34) n(n)     | <3 (Sbj- yr=167.3) (N= 140) n(n)       | 23to≤ 12 (Sbj- yr=214.9) (N= 137) n(n) | Total (Sbj- yr=382.1) (N = 277) n(n)   |
| Headache                          | 2 (11.9)                              | 11 (55.8)                             | 13 (35.6)                             | 51 (30.5)                              | 98 (45.6)                              | 149 (39.0)                             |
| Contusion                         | 4 (23.8)                              | 3 (15.2)                              | 7 (19.2)                              | 34 (20.3)                              | 62 (28.9)                              | 96 (25.1)                              |
| Fatigue                           | 7 (41.7)                              | 4 (20.3)                              | 11 (30.1)                             | 46 (27.5)                              | 46 (21.4)                              | 92 (24.1)                              |
| Petechiae                         | 3 (17.9)                              | 9 (45.6)                              | 12 (32.9)                             | 49 (29.3)                              | 34 (15.8)                              | 83 (21.7)                              |
| Arthralgia                        | 3 (17.9)                              | 3(15.2)                               | 6 (16.4)                              | 34 (20.3)                              | 47 (21.9)                              | 81 (21.2)                              |
| Epistaxis                         | 4 (23.8)                              | 16 (81.1)                             | 20 (54.8)                             | 33 (19.7)                              | 40 (18.6)                              | 73 (19.1)                              |
| Nasopharyngitis                   | 1 (6.0)                               | 15 (76.0)                             | 16 (43.8)                             | 24 (14.3)                              | 49 (22.8)                              | 73 (19.1)                              |
| Cough                             | 1 (6.0)                               | 2 (10.1)                              | 3 (8.2)                               | 42 (25.1)                              | 29 (13.5)                              | 71 (18.6)                              |
| Upper respiratory tract infection | 1 (6.0)                               | 1 (5.1)                               | 2 (5.5)                               | 27 (16.1)                              | 44 (20.5)                              | 71 (18.6)                              |
| Diarrhoea                         | 0 (0.0)                               | 5 (25.3)                              | 5 (13.7)                              | 43 (25.7)                              | 26 (12.1)                              | 69 (18.1)                              |
| Nausea                            | 3 (17.9)                              | 0 (0.0)                               | 3(8.2)                                | 29 (17.3)                              | 35 (16.3)                              | 64 (16.7)                              |
| Thrombocytopenia                  | 2 (11.9)                              | 2 (10.1)                              | 4 (11.0)                              | 28 (16.7)                              |                                        | 30 (14.0)58 (15.2)                     |

Adult subjects (age 2 18 years at screening) who received at least one dose of investigational product in any of ITP studies (20030105, 20030212, 20030213 (extension study).20040209, 20060113 (extension study).20060131,20060216,20080009,and 20080435) are included.Data after treatment switch are excluded. ITP duration is calculated from the ITP diagnosis to the enrollment of first ITP study. Only adverse events starting after the first dose of investigational product are tabulated. Multiple occurrences of the same event for a subject are counted as multiple events. Sbj-yr = Total subject years on study. n = number of events. r = duration adjusted event rate per 100 subject-years (n/Sbj-yr*100). Preferred terms are presented in descending order of duration adjusted incidence rate in total romiplostim group. Events with event rate of &lt; 15 per 100 sub-yrs in the romiplostim group are not included in this table. ITP = immune thrombocytopenia; MedDRA = Medical Dictionary for Regulatory Activities; SOC = Standard of Care. Coded using MedDRA version 21.0. Source:Modified from /SSTable14-6.1.5.1,ISSTable 14-6.1.5.2.

- -For patients with ITP &gt; 12 months, adverse events (by preferred term) in romiplostim group versus placebo/SOC  reported  with  the  highest  subject  incidence,  and/or  highest  duration-adjusted incidence event rates and with higher subject incidence and/or event rate in the romiplostim group compared with the placebo/SOC group were:

-Headache (35.3% versus 25.0%; 42.4 versus 62.1) - Nasopharyngitis (26.5% versus 17.4%; 30.2 versus 29.7) - Arthralgia (24.9% versus 10.9%; 21.5 versus 16.9) Epistaxis (22.9% 19.6%; 32.0 versus 45.2) - Nausea (20.3% versus 9.8%; 18.1 versus 19.8) - Diarrhoea (17.5% versus 9.8%; 18.9 versus 24.0) - Pain in extremity (16.6% versus 4.3%; 14.4 versus 11.3) - Back pain (15.5% versus 4.3%; 11.1 versus 5.6) - Cough (15.5% versus 9.8%; 12.1 versus 15.5) - Upper respiratory tract infection (15.5% versus 9.8%; 17.5 versus 15.5) - Thrombocytopenia (11.2% versus 4.3%; 16.0 versus 5.6).

## Treatment-related Adverse Events

In the integrated analysis set, for both subgroups, subjects with ITP ≤ 12 months and subjects with ITP &gt; 12 months, the subject incidence of treatment-related adverse events for the romiplostim group was higher for romiplostim group compared with the placebo/SOC, and the duration-adjusted incidence event rate (per 100 subject-years) was lower (Table 26).

<div style=\"page-break-after: always\"></div>

The  adverse  events  (by  System  Organ  Class)  with  the  highest  subject  incidence  of  treatment-related adverse events (&gt; 10%) was higher in subjects with ITP &gt; 12 months compared with subjects with ITP ≤ 12 months.

- -For  subjects  with  ITP  ≤  12  months  the  adverse  events  (by  SOC)  in  romiplostim  group  versus placebo/SOC  were  nervous  system  disorders  (13.7%  versus  8.8%),  and  musculoskeletal  and connective tissue disorders (13.0% versus 2.9%)
- -For  subjects  with  ITP  &gt;  12  months  the  adverse  events  (by  SOC)  in  romiplostim  group  versus placebo/SOC were nervous system disorders (22.1% versus 9.8%), musculoskeletal and connective tissue disorders (18.3% versus 3.3%), general disorders and administration site conditions (17.2% versus 13.0%), skin and subcutaneous tissue disorders (10.4% versus 8.7%), and gastrointestinal disorders (10.3% versus 8.7%).

Headache and arthralgia had the highest subject incidence of treatment-related adverse events (by PT) in the romiplostim group compared with the placebo/SOC group in both ITP duration groups (subjects with ITP ≤ 12 months and subjects with ITP &gt; 12 months).

- -For subjects with ≤ 12 months the treatment -related adverse events (by PT) with highest subject incidence ( &gt; 3%) and/or event rate ( &gt; 3 events per 100 subject-years) and with higher subject incidence and/or event rate in the romiplostim group compared with the placebo/SOC group were similar across all ITP subgroups (Tables 29 and 30).

Table  29.  Subject  Incidence  of  Treatment-related  Adverse  Events  by  Preferred  Term  in Descending Order of Frequency (Subjects with ≤ 12 Months of ITP Duration)

|                   |                            | Romiplostim (N = 277) ITP Duration in Months   | Romiplostim (N = 277) ITP Duration in Months   | Romiplostim (N = 277) ITP Duration in Months   |
|-------------------|----------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Preferred Term    | Placebo/SoC (N = 34) n (%) | 3 (N = 140) n(%)                               | 2 3 to ≤ 12 (N = 137) n (%)                    | Total (N = 277) n (%)                          |
| Headache          | 2 (5.9)                    | 16 (11.4)                                      | 12 (8.8)                                       | 28 (10.1)                                      |
| Arthralgia        | 0 (0.0)                    | 11 (7.9)                                       | 8 (5.8)                                        | 19 (6.9)                                       |
| Fatigue           | 2 (5.9)                    | 6 (4.3)                                        | 7 (5.1)                                        | 13 (4.7)                                       |
| Myalgia           | 0 (0.0)                    | 4 (2.9)                                        | 4 (2.9)                                        | 8 (2.9)                                        |
| Nausea            | 0 (0.0)                    | 4 (2.9)                                        | 4 (2.9)                                        | 8 (2.9)                                        |
| Pain in extremity | 0 (0.0)                    | 7 (5.0)                                        | 0 (0.0)                                        | 7 (2.5)                                        |

Adult subjects (age 2 18 years at screening) who received at least one dose of investigational product in any of ITP studies (20030105, 20030212, 20030213 (extension study). 20040209, 20060113 (extension study). 20060131,20060216,20080009,and 20080435) are included.

Data after treatment switch are excluded.

ITP duration is calculated from the ITP diagnosis to the enrolment of first ITP study.

Only adverse events starting after the first dose of investigational product are tabulated.

of Care. Coded using the MedDRA version 21.0.

Descending order of frequency is sorted by romiplostim (total) group.

Only events with subject incidence &gt; 2% in the romiplostim group are included in this table.

Source: Modiied from ISS Table 14-6.1.1.5.

<div style=\"page-break-after: always\"></div>

Table 30. Duration Adjusted Event Rate of Treatment-related Adverse Events by Preferred Term in Descending Order of Incidence Rate (S ubjects with ≤ 12 Months of ITP Duration)

|                |                                          | Romiplostim (N = 277) ITP,Duration in Months   | Romiplostim (N = 277) ITP,Duration in Months   | Romiplostim (N = 277) ITP,Duration in Months   |
|----------------|------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Preferred Term | Placebo/SOC (Sbj-yr=36.5) (N = 34) n (n) | 3 (sbj- yr=167.3) (N = 140) n0                 | 23to≤12 (Sbj- yr=214.9) (N = 137) n(n)         | Total (Sbj- yr=382.1) (N = 277) n (r)          |
| Headache       | 3 (8.2)                                  | 23 (13.8)                                      | 19 (8.8)                                       | 42 (11.0)                                      |
| Arthralgia     | D (0.0)                                  | 16 (9.6)                                       | 9 (4.2)                                        | 25 (6.5)                                       |
| Fatigue        | 5 (13.7)                                 | 7 (4.2)                                        | 15 (7.0)                                       | 22 (5.8)                                       |
| Myalgia        | D (0.0)                                  | 4 (2.4)                                        | 16 (7.4)                                       | 20 (5.2)                                       |
| Nausea         | D (0.0)                                  | 6 (3.6)                                        | 14 (6.5)                                       | 20 (5.2)                                       |
| Bone pain      | 0 (0.0)                                  | 1 (0.6)                                        | 7 (3.3)                                        | 8 (2.1)                                        |
| Dehydration    | D (0.0)                                  | 0 (0.0)                                        | 8 (3.7)                                        | 8 (2.1)                                        |
| Insomnia       | 0 (0.0)                                  | 0 (0.0)                                        | 8 (3.7)                                        | 8 (2.1)                                        |

<!-- image -->

|                   |                                         | Romiplostim (N = 277) ITP Duration in Months   | Romiplostim (N = 277) ITP Duration in Months   | Romiplostim (N = 277) ITP Duration in Months   |
|-------------------|-----------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Preferred Term    | Placebo/SOC (Sbj-yr=36.5) (N = 34) n(n) | 3 (Sbj- yr=167.3) (N= 140) n(c)                | 23to≤12 (sbj- yr=214.9) (N = 137) n()          | Total (Sbj- yr=382.1) (N = 277) n(c)           |
| Diarrhoea         | 0 (0.0)                                 | 3 (1.8)                                        | 4 (1.9)                                        | 7 (1.8)                                        |
| Pain in extremity | 0 (0.0)                                 | 7 (4.2)                                        | 0 (0.0)                                        | 7 (1.8)                                        |

Page 2of 2

Adult subjects (age 2 18 years at screening) who received at least one dose of investigational product in any of ITP studies (20030105, 20030212, 20030213 (extension study). 20040209, 20060113 (extension study).

20060131, 20060216, 20080009, and 20080435) are included.

Data after treatment switch are excluded.

ITP duration is calculated from the ITP diagnosis to the enrollment of first ITP study.

Only adverse events starting after the first dose of investigational product are tabulated.

ITP = immune thrombocytopenia; MedDRA = Medical Dictionary for Regulatory Activities; SOC = Standard

of Care. Coded using the MedDRA version 21.0.

Sbj-yr = Total subject years on study.

n = number of events. r = duration adjusted event rate per 100 subject-years (n/Sbj-yr*100).

Preferred terms are presented in descending order of duration adjusted incidence rate in total romiplostim

group.

Only events with event rate of &gt; 2 per 100 sub-yrs in the romiplostim group are included in this table.

Source:Modified fromISS Table 14-6.1.13.3.

- -For subjects with ITP &gt; 12 months, adverse events (by preferred term) in romiplostim group versus placebo/SOC  reported  with  the  highest  subject  incidence,  and/or  highest  duration-adjusted incidence event rates and with higher subject incidence and/or event rate in the romiplostim group compared with the placebo/SOC group were similar:

-

Headache (16.6% versus 6.5%; 16.2 versus 15.5) - Arthralgia (6.9% versus 1.1%; 4.6 versus

1.4) - Nausea (4.3% versus 1.1%; 4.1 versus 1.4) - Myalgia (4.1% versus 1.1%; 3.3 versus 1.4)

- Pain in extremity (3.5% versus 0%; 2.8 versus 0)

A summary of common treatmentemergent adverse events in subjects with ITP &lt; 3 months and &gt; 3 to ≤ 12 months is provided in Table 46.

## Grade 4 or above adverse events

Among subjects treated with romiplostim, the subject incidence and duration-adjusted incidence event rate of  grade ≥ 4  adverse events were lower in subjects with ITP ≤ 12 months compared with subjects with ITP &gt; 12 months (Table 31).

<div style=\"page-break-after: always\"></div>

In  subjects  with  ITP ≤ 12 months,  the  subject  incidence  and  duration-adjusted  incidence  event  rate  of grade ≥ 4 adverse events were lower in the romiplostim group compared with placebo/SOC, 10.1% versus 14.7% ; 11.0 events per 100 subject-years versus 16.4 events per 100 subject-years; while in subjects with ITP &gt; 12 months, were 13.4% versus 13.0%; 14.8 versus 24.0 events per 100 subject-years (Table 31).

Table 31. Summary of Subject Incidence and Duration Adjusted Incidence Rate of Grade ≥ 4 Treatmentemergent  Adverse  Events  (Subjects  with  ≤  12  Months  and  &gt;  12  Months  of  ITP Duration)

<!-- image -->

|                                                          | Placebo/SoC ITPDurationinMonths          | Placebo/SoC ITPDurationinMonths          | Placebo/SoC ITPDurationinMonths          | Placebo/SoC ITPDurationin Months   | Romiplostim ITPDurationinMonths              | Romiplostim ITPDurationinMonths              | Romiplostim ITPDurationinMonths              | Romiplostim ITP Duration in Months   |
|----------------------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|--------------------------------------|
|                                                          | > (N = 15)                               | 3 to≤12 (N = 19)                         | Total (N = 34)                           | >12 (N = 92)                       | > (N = 140)                                  | 3to≤12 (N =137)                              | Total (N = 277)                              | >12 (N=634)                          |
| Alltreatment-emergentadverseevents n(%)                  | 5 (33.3)                                 | 0 (0.0)                                  | 5 (14.7)                                 | 12 (13.0)                          | 14 (10.0)                                    | 14 (10.2)                                    | 28 (10.1)                                    | 85 (13.4)                            |
| Treatment-related treatment-emergent adverse events-n(%) | 2 (13.3)                                 | 0 (0.0)                                  | 2 (5.9)                                  | 1 (1.1)                            | 0 (0.0)                                      | 0 (0.0)                                      | 0(0.0)                                       | 12 (1.9)                             |
|                                                          | Placebo/Soc (N = 34) ITPDurationinMonths | Placebo/Soc (N = 34) ITPDurationinMonths | Placebo/Soc (N = 34) ITPDurationinMonths | Placebo/SoC ITP Duration in Months | Romiplostim (N = 277) ITP Duration in Months | Romiplostim (N = 277) ITP Duration in Months | Romiplostim (N = 277) ITP Duration in Months | Romiplostim ITP Duration in Months   |
|                                                          | > (Sbj-yr = 16.8) (N = 15)               | ≥3to≤12 (Sbj-yr = 19.7) (N = 19)         | Total (Sbj-yr = 36.5) (N =34)            | >12 (Sbj-yr = 70.8) (N = 92)       | > (Sbj-yr = 167.3) (N = 140)                 | 23to≤12 (Sbj-yr= 214.9) (N = 137)            | Total (Sbj-yr= 382.1) (N = 277)              | >12 (Sbj-yr = 1100.5) (N = 634)      |
| Alltreatment-emergentadverseevents n(n)                  | 6 (35.8)                                 | 0 (0.0)                                  | 6 (16.4)                                 | 17 (24.0)                          | 18 (10.8)                                    | 24 (11.2)                                    | 42 (11.0)                                    | 163 (14.8)                           |
| AllTreatment-related treatment-emergentadverseevents n() | 2 (11.9)                                 | 0 (0.0)                                  | 2 (5.5)                                  | 2 (2.8)                            | 0 (0.0)                                      | 0 (0.0)                                      | 0 (0.0)                                      | 17 (1.5)                             |

ITP = immune thrombocytopenia; n= number of events.r= duration adjustedevent rate per 100 subject-years(n/Sbj-yr'1o0). Sbj-yr= Total subject years on study. SOC=Standardof Care.

s ITPdurationiscalculatedfrom theITPdiagnosistotheenrollmentoffirstITPstudy.Multipleoccurrencesof thesameeventforasubjectarecountedasmultiple events. Only adverse events starting after the first dose of investigational product are tabulated.

GradesarebasedonCTCAEv3.0.CTCAE=CommonTerminologyCriteriaforAdverseEventsGradingScale.

Source:ModifiedfromISSTable14-6.1.1.1,ISSTable14-6.1.1.2,ISSTable14-6.1.2.1,ISSTable14-6.1.2.2,ISSTable14-6.1.3.1,ISSTable14-6.1.3.2,ISS Table14-6.1.3.3,1SSTable14-6.1.4.2.

The adverse events by preferred term with highest event rate ( &gt; 0.5 events per 100 subject-years) were similar between ITP ≤ 12 months and ITP &gt; 12 months and were mostly reported by subjects from the romiplostim group (Table 32 and table 33).

Table 32. Study Duration Adjusted Incidence Event Rates of Grade ≥ 4 Treatm ent-emergent Adverse Events by Preferred Term in Descending Order of Incidence Rate - Romiplostim Group (Subjects with ≤ 12 Months of ITP Duration)

|                                 | Romiplostim - ITP Duration in Months   | Romiplostim - ITP Duration in Months        | Romiplostim - ITP Duration in Months   |
|---------------------------------|----------------------------------------|---------------------------------------------|----------------------------------------|
| Preferred Term                  | <3 (Sbj- yr=167.3) (N = 140) n (n)     | ≥ 3 to ≤ 12 (Sbj- yr=214.9) (N = 137) n (c) | Total (Sbj- yr=382.1) (N = 277) n (n)  |
| Thrombocytopenia                | 3 (1.8)                                | 7 (3.3)                                     | 10 (2.6)                               |
| Immune thrombocytopenic purpura | 0 (0.0)                                | 5 (2.3)                                     | 5 (1.3)                                |
| Myocardlal infarction           | 2 (1.2)                                | 0 (0.0)                                     | 2 (0.5)                                |
| Renal failure                   | 1 (0.6)                                | 1 (0.5)                                     | 2 (0.5)                                |

20060131,20060216,20080009,and 20080435) are included.Data after treatment switch are excluded.

ITP duration is calculated from the ITP diagnosis to the enrollment of first ITP study.

Only adverse events starting after the first dose of investigalional product are tabulated.

Multiple occurrences of the same event for a subject are counted as multiple events.

100 subject-years (n/Sbj-yr*100).

Sbj-yr = Total subject years on study. n = number of events. r = duralion adjusted event rate per

Preferred terms are presented in descending order of duration adjusted incidence rale In total Romlplostim group. Coded using MedDRA verslon 21.0. Grade is based on CTCAE v3.0.

ITP = Immune thrombocytopenia; MedDRA = Medical Dictionary for Regulatory Activities;

CTCAE = Common Terminology Criteria for Adverse Events Grading Scale.

Events with &lt; 0.5 per 100 sub-yrs in the romiplostim group are not included in this table.

Source:Modiffed from ISS Table14-6.1.9.1.

<div style=\"page-break-after: always\"></div>

Table 33. Study Duration Adjusted Incidence Event Rates of Treatmentemergent Grade ≥ 4 Adverse Events by Preferred Term in Descending Order of Incidence Rate - Romiplostim Group (Subjects with &gt; 12 Months of ITP Duration)

| Preferred Tem                       | Romiplostim ITP Duration in Months >12 (Sbj-yr=1100.5) (N = 634) n ()   |
|-------------------------------------|-------------------------------------------------------------------------|
| Thrombocytopenia                    | 44 (4.0)                                                                |
| Immune thrombocytopenic purpura     | 28 (2.5)                                                                |
| Pulmonary embolism                  | 5 (0.5)                                                                 |
| Anaemia                             | 4 (0.4)                                                                 |
| Hyperuricaemia                      | 3 (0.3)                                                                 |
| Platelet count decreased            | 3 (0.3)                                                                 |
| Respiratory failure                 | 3 (0.3)                                                                 |
| Acute kidney injury                 | 2 (0.2)                                                                 |
| Acute respiratory distress syndrome | 2 (0.2)                                                                 |
| Cardiac failure congestive          | 2 (0.2)                                                                 |
| Cholecystitis acute                 | 2 (0.2)                                                                 |
| Deep vein thrombosis                | 2 (0.2)                                                                 |
| Epistaxis                           | 2 (0.2)                                                                 |
| Fungal sepsis                       | 2 (0.2)                                                                 |
| Myocardial infarction               | 2 (0.2)                                                                 |

Adult subjects (age ≥ 18 years at screening) who received at least one dose of investigational product in any 20060131,20060216,20080009,and 20080435)are included.Dataaftertreatment switchare excluded.

ITP duration is calculated from the ITP diagnosis to the enrollment of first ITP study.

Only adverse events starting after the first dose of investigational product are tabulated.

Multiple occurrences of the same event for a subject are counted as multiple events.

Sbj-yr = Total subject years on study.

n = number of events. r = duration adjusted event rate per 100 subject-years (n/Sbj-yr*100).

Preferred terms are presented in descending order of duration adjusted incidence rate in total Romiplostim

group.

Events with event rate of &lt; 0.2 per 100 sub-yrs are not included in this table.

Coded using MedDRA version 21.0.

Grade is based on CTCAE v3.0.

CTCAE= Common Terminology Criteria for Adverse Events Grading Scale: ITP =immune

thrombocytopenia; MedDRA = Medical Dictionary for Regulatory Activities.

Source:Modified from /SS Table 14-6.1.10.1.

Treatment-related adverse events of grade ≥ 4 were reported by subjects with ITP &gt; 12 months only and the subject incidence were similar in the romiplostim group compared with the placebo/SOC group (1.9% versus 1.1%) (Table 31).

## Grade 3 or Higher Treatment-emergent Adverse Events and Grade 3 Treatment-related Grade 3 or Higher Adverse Events

The subject incidence and duration-adjusted inci dence event rate of grade ≥ 3 adverse events (per 100 subjectyears) was lower in the romiplostim group compared with placebo/SOC group in subjects with ITP ≤ 12 months and ITP &gt; 12 months (Table 34).

In subjects with ITP ≤ 12 months, the subject incidence and duration-adjusted incidence event rate were lower in the romiplostim group compared with the placebo/SOC group (37.2% versus 47.1%; 75.6 versus 101.3), while in subjects with ITP &gt; 12 months, the subject incidence was higher for the romiplostim group compared with the placebo/SOC group (42.7% versus 34.8%), and the duration-adjusted incidence event rate was lower for the romiplostim group compared with the placebo/SOC group (84.0 versus 134.2) (Table 34)

<div style=\"page-break-after: always\"></div>

Table 34. Summary of Subject I ncidence and Duration Adjusted Incidence Rate of Grade ≥ 3 Treatmentemergent  Adverse  Events  (Subjects  with  ≤  12  Months  and  &gt;  12  Months  of  ITP Duration)

<!-- image -->

|                                                               | Placebo/SOC ITPDurationinMonths          | Placebo/SOC ITPDurationinMonths          | Placebo/SOC ITPDurationinMonths          | Placebo/SoC ITP Duration in Months   | Romiplostim ITP Duration in Months           | Romiplostim ITP Duration in Months           | Romiplostim ITP Duration in Months           | Romiplostim ITP Duration in Months   |
|---------------------------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|--------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|--------------------------------------|
|                                                               | <3 (N = 15)                              | 23 to≤12 (N= 19)                         | Total (N =34)                            | >12 (N = 92)                         | > (N = 140)                                  | 23to≤12 (N= 137)                             | Total (N = 277)                              | >12 (N =634)                         |
| Alltreatment-emergentadverseevents -n (%)                     | 8 (53.3)                                 | 8 (42.1)                                 | 16 (47.1)                                | 32 (34.8)                            | 50 (35.7)                                    | 53 (38.7)                                    | 103 (37.2)                                   | 271 (42.7)                           |
| Treatment-related treatment-emergent adverse events -n (%)    | 3 (20.0)                                 | 0(0.0)                                   | 3(8.8)                                   | 6 (6.5)                              | 6 (4.3)                                      | 11 (8.0)                                     | 17 (6.1)                                     | 68 (10.7)                            |
|                                                               | Placebo/SOC (N =34) ITPDuration inMonths | Placebo/SOC (N =34) ITPDuration inMonths | Placebo/SOC (N =34) ITPDuration inMonths | Placebo/SOC ITP Duration in Months   | Romiplostim (N = 277) ITP Duration in Months | Romiplostim (N = 277) ITP Duration in Months | Romiplostim (N = 277) ITP Duration in Months | Romiplostim ITP Duration in Months   |
|                                                               | > (Sbj-yr = 16.8) (N = 15)               | ≥3to≤12 (Sbj-yr= 19.7) (N= 19)           | Total (Sbj-yr = 36.5) (N =34)            | >12 (Sbj-yr = 70.8) (N = 92)         | 3 (Sbj-yr = 167.3) (N = 140)                 | 23to≤12 (Sbj-yr= 214.9) (N = 137)            | Total (Sbj-yr = 382.1) (N = 277)             | >12 (Sbj-yr = 1100.5) (N = 634)      |
| All treatment-emergent adverseevents (）u-                     | 27 (160.9)                               | 10 (50.7)                                | 37 (101.3)                               | 95 (134.2)                           | 143 (85.5)                                   | 146 (67.9)                                   | 289 (75.6)                                   | 924 (84.0)                           |
| AllTreatment-relatedtreatment- emergent adverse events -n (r) | 12 (71.5)                                | 0 (0.0)                                  | 12 (32.9)                                | 13 (18.4)                            | 12 (7.2)                                     | 13 (6.1)                                     | 25 (6.5)                                     | 117 (10.6)                           |

ITPdurationis calculated from the ITPdiagnosis to the enrollment of first ITPstudy. Multiple occurrences of the same event for a subject are counted as multiple events.Onlyadverseeventsstartingafterthefirst doseof investigationalproductaretabulated. ITP=immune thrombocytopenia; n =numberof events.r= duration adjusted event rateper100subject-years(n/Sbj-yr100).Sbj-yr=Total subject years onstudy.

SOC=StandardofCare.

GradesarebasedonCTCAEv3.0.CTCAE=CommonTerminologyCriteriaforAdverseEventsGradingScale.

For subjects with ITP ≤ 12 months, among subjects treated with romiplostim, the adverse events (by PT s), in romiplostim group versus placebo/SOC, reported with the highest duration-adjusted incidence event rates (≥ 2.0 adverse events per 100 subject -years) were:

- Thrombocytopenia (10.7 vs 11.0). • Immune thrombocytopenic purpura (3.7 vs 2.7).

For subjects with ITP &gt; 12 months were:

- Thrombocytopenia (11.0 vs 5.6). · Immune thrombocytopenic purpura (6.2 vs 0) · Headache (2.9 vs 2.8). · Platelet count decreased (2.4 vs 11.3).

Treatment-related  adverse  events  of  grade ≥ 3: the subject incidence and  event  rate  (per  100 subject-years) were lower for subjects with ITP ≤ 12 months compared with ITP &gt; 12 months (6.1% versus 10.7%; 6.5 versus 10.6) (Table 34).

## Serious adverse event/deaths/other significant events

Among subjects treated with romiplostim, the subject incidence and duration-adjusted incidence event rate (per 100 subjectyears) event rate of serious adverse events were lower in subjects with ITP ≤ 12 months compared with ITP &gt; 12 months (Table 35).

In subjects with ITP ≤ 12 months, the subject incidence and event rate of serious adverse events were lower in the romiplostim group compared with the placebo/SOC group (30.3% versus 41.2%; 51.0 events per subject-years versus 90.4 events per subject-years), while in subjects with ITP &gt; 12 months, the subject incidence was higher and event rate was lower in the romiplostim group compared with the placebo/SOC group (34.2% versus 27.2%; 56.4 events per subject-years versus 98.8 events per  subject-years (Table 35).

<div style=\"page-break-after: always\"></div>

Table  35.  Summary  of  Subject  Incidence  and  Duration  Adjusted  Incidence  Rate  of  Serious Treatmentemergent  Adverse  Events  (Subjects  with  ≤  12  Months  and  &gt;  12  Months  of  ITP Duration)

|                                                           | Placebo/SOC ITP Duration in Months     | Placebo/SOC ITP Duration in Months     | Placebo/SOC ITP Duration in Months     | Placebo/SOC ITPDurationin Months   | Romiplostim ITP Duration in Months                         | Romiplostim ITP Duration in Months                         | Romiplostim ITP Duration in Months                         | Romiplostim ITPDuration in Months   |
|-----------------------------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|-------------------------------------|
|                                                           | <3 (N = 15)                            | ≥3to≤12 (N = 19)                       | Total (N= 34)                          | >12 (N = 92)                       | <3 (N = 140)                                               | ≥3 to≤12 (N = 137)                                         | Total (N = 277)                                            | >12 (N = 634)                       |
| All treatment-emergent adverseevents -n (%)               | 8 (53.3)                               | 6 (31.6)                               | 14 (41.2)                              | 25 (27.2)                          | 40 (28.6)                                                  | 44 (32.1)                                                  | 84 (30.3)                                                  | 217 (34.2)                          |
| Treatment-relatedtreatment-emergent adverse events -n (%) | 3 (20.0)                               | 1 (5.3)                                | 4 (11.8)                               | 2 (2.2)                            | 5 (3.6)                                                    | 10 (7.3)                                                   | 15 (5.4)                                                   | 46 (7.3)                            |
|                                                           | Placebo/SOC (N=34) ITPDurationinMonths | Placebo/SOC (N=34) ITPDurationinMonths | Placebo/SOC (N=34) ITPDurationinMonths | Placebo/SOC ITPDuration in Months  | Romiplostim (Sbj-yr = 382.1) (N = 277) ITPDurationinMonths | Romiplostim (Sbj-yr = 382.1) (N = 277) ITPDurationinMonths | Romiplostim (Sbj-yr = 382.1) (N = 277) ITPDurationinMonths | Romiplostim ITPDuration in Months   |
|                                                           | <3 (Sbj-yr = 16.8) (N = 15)            | ≥3to≤12 (Sbj-yr = 19.7) (N= 19)        | Total (Sbj-yr = 36.5) (N = 34)         | >12 (Sbj-yr = 70.8) (N = 92)       | <3 (Sbj-yr = 167.3) (N = 140)                              | ≥3to≤12 (Sbj-yr = 214.9) (N = 137)                         | Total (Sbj-yr = 382.1) (N = 277)                           | >12 (Sbj-yr = 1100.5) (N =634)      |
| Alltreatment-emergentadverseevents -n()                   | 26 (154.9)                             | 7 (35.5)                               | 33 (90.4)                              | 70 (98.8)                          | 80 (47.8)                                                  | 115 (53.5)                                                 | 195 (51.0)                                                 | 621 (56.4)                          |
| AllTreatment-relatedtreatment- emergentadverseevents-n(r) | 11 (65.5)                              | 1 (5.1)                                | 12 (32.9)                              | 6 (8.5)                            | 5 (3.0)                                                    | 11 (5.1)                                                   | 16 (4.2)                                                   | 81 (7.4)                            |

(extensionstudy),20040209,20060113(extensionstudy),20060131,20060216,20080009,and20080435)areincluded.Dataaftertrealmentswitchareexcluded. ITPdurationiscalculatedfromtheITPdiagnosistotheenrollmentoffirstITPstudy.Multipleoccurrencesofthesameeventforasubjectarecountedasmultiple events.Onlyadverseeventsstartingafterthefirstdoseofinvestigationalproductaretabulated.

ITP=immune thrombocytopenia;n=numberof events.r=duration adjustedevent rateper100 subject-years(n/Sbj-yr*100).Sbj-yr=Totalsubject years on study. SOC=Standard of Care.

GradesarebasedonCTCAEv3.0.CTCAE=CommonTerminologyCriteriaforAdverseEventsGradingScale.

## Treatment-related serious adverse events

Among subjects treated with romiplostim, the subject incidence was similar between ITP ≤ 12 months and ITP &gt; 12 months  subgroups  (5.4%  versus  7.3%),  while  the  event  rate  was  lower  in  ITP ≤ 12 months compared with the ITP &gt; 12 months subgroup (4.2 versus 7.4 events per 100 subject-years) (Table 35).

-  In  subjects  with  ITP ≤ 12 months,  the  subject  incidence  and  event  rate  of  treatment-related  serious adverse events were lower in the romiplostim group compared with the placebo/SOC group (5.4% versus 11.8%; 4.2 versus 32.9 events per 100 subject-years); while in subjects with ITP &gt; 12 months, the subject incidence was higher and event rate was similar in the romiplostim group compared with the placebo/SOC group (7.3% versus 2.2%; 7.4 versus 8.5 events per 100 subject-years) (Table 35).

Adverse events (by PTs) (romiplostim versus placebo/SOC) reported with highest subject incidence (≥ 0.4%) and/or highest durationadjusted incidence event rates (≥ 0.4 adverse events per 100 subject -years) for patients with ITP ≤ 12 months and ITP &gt; 12 months are provided in Table 36 and Table 37, respectively:

<div style=\"page-break-after: always\"></div>

Table 36. Subject Incidence of Treatment-related Serious Adverse Events by Preferred Term in Descending Order of Frequency (Subjects with ≤ 12 Months of ITP Duration)

|                                           |                            | Romiplostim (N = 277) ITP Duration in Months   | Romiplostim (N = 277) ITP Duration in Months   | Romiplostim (N = 277) ITP Duration in Months   |
|-------------------------------------------|----------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Preferred Term                            | Placebo/SOC (N = 34) n (%) | 3 (N = 140) n (%)                              | ≥ 3 to ≤ 12 (N = 137) n (%)                    | Total (N = 277) n (%)                          |
| Pulmonary embolism                        | 0 (0.0)                    | 1 (0.7)                                        | 1 (0.7)                                        | 2 (0.7)                                        |
| Thrombocytopenia                          | (0'0) 0                    | 1 (0.7)                                        | 1 (0.7)                                        | 2 (0.7)                                        |
| Amnesia                                   | 0 (0.0)                    | 1 (0.7)                                        | 0 (0.0)                                        | 1 (0.4)                                        |
| Angina unstable                           | 0 (0.0)                    | 0 (0.0)                                        | 1 (0.7)                                        | 1 (0.4)                                        |
| Bicytopenia                               | 0 (0.0)                    | 0 (0.0)                                        | 1 (0.7)                                        | 1 (0.4)                                        |
| Cerebrovascular accident                  | (0°0) 0                    | 0 (0.0)                                        | 1 (0.7)                                        | 1 (0.4)                                        |
| Gastritis                                 | 0 (0.0)                    | 0 (0.0)                                        | 1 (0.7)                                        | 1 (0.4)                                        |
| Generalised oedema                        | 0 (0.0)                    | 0 (0.0)                                        | 1 (0.7)                                        | 1 (0.4)                                        |
| Lichenoid keratosis                       | 0 (0.0)                    | 0 (0.0)                                        | 1 (0.7)                                        | 1 (0.4)                                        |
| Musculoskeletal chest pain                | 0 (0.0)                    | 1 (0.7)                                        | 0 (0.0)                                        | 1 (0.4)                                        |
| Myelofibrosis                             | 0 (0.0)                    | 0 (0.0)                                        | 1 (0.7)                                        | 1 (0.4)                                        |
| Reversible ischaemic neurological deficit | (0:0) 0                    | 1 (0.7)                                        | 0 (0.0)                                        | 1 (0.4)                                        |
| Transaminasesincreased                    | 0 (0.0)                    | 0 (0.0)                                        | 1 (0.7)                                        | 1 (0.4)                                        |
| Venous thrombosis limb                    | (0:0) 0                    | 0 (0.0)                                        | 1 (0.7)                                        | 1 (0.4)                                        |
| Acute kidney injury                       | 1 (2.9)                    | 0 (0.0)                                        | 0 (0.0)                                        | 0 (0.0)                                        |
| Atrial fibrillation                       | 1 (2.9)                    | 0 (0.0)                                        | 0 (0.0)                                        | 0 (0.0)                                        |
| Bacteraemia                               | 1 (2.9)                    | 0 (0.0)                                        | 0 (0.0)                                        | 0 (0.0)                                        |
| Cardiac failure congestive                | 1 (2.9)                    | 0 (0.0)                                        | 0 (0.0)                                        | 0 (0.0)                                        |
| Immune thrombocytopenic purpura           | 1 (2.9)                    | 0 (0.0)                                        | 0 (0.0)                                        | 0 (0.0)                                        |
| Liver function test increased             | 1 (2.9)                    | 0 (0.0)                                        | 0 (0.0)                                        | 0 (0.0)                                        |
| Malnutrition                              | 1 (2.9)                    | 0 (0.0)                                        | 0 (0.0)                                        | 0 (0.0)                                        |
| Pancreatic fistula                        | 1 (2.9)                    | 0 (0.0)                                        | 0 (0.0)                                        | 0 (0.0)                                        |
| Pancreatitis                              | 1 (2.9)                    | 0 (0.0)                                        | 0 (0.0)                                        | 0 (0.0)                                        |
| Pneumonia                                 | 1 (2.9)                    | 0 (0.0)                                        | 0 (0.0)                                        | 0 (0.0)                                        |
| Sepsis                                    | 1 (2.9)                    | 0 (0.0)                                        | 0 (0.0)                                        | 0 (0.0)                                        |
| Subdiaphragmatic abscess                  | 1 (2.9)                    | 0 (0.0)                                        | 0 (0.0)                                        | 0 (0.0)                                        |

Adult subjects (age ≥ 18 years at screening) who received at least one dose of investigational product in any of ITP studies (20030105, 20030212, 20030213 (extension study). 20040209, 20060113 (extension study). 20060131, 20060216, 20080009, and 20080435) are included. Dafaafor troomronf euiteh. owclmclod

None of these adverse events were fatal.

Table 37. Subject Incidence of Treatment-related Serious Adverse Events by Preferred Term in Descending Order of Frequency (Subjects with &gt; 12 Months of ITP Duration)

| Preferred Term                  | Placebo/SoC (N = 92) n (%)   | Romiplostim (N = 634) n (%)   |
|---------------------------------|------------------------------|-------------------------------|
| Pulmonary embolism              | 0 (0.0)                      | 5 (0.8)                       |
| Bonemarrowdisorder              | 0 (0.0)                      | 4 (0.6)                       |
| Deep Vein thrombosis            | (00)0                        | 4 (0.6)                       |
| Bone: marrow reticulin fibrosis | 0 (0.0)                      | 3 (0.5)                       |
| Myocardialinfarction            | 0 (0.0)                      | 3 (0.5)                       |

of ITP studies (20030105, 20030212, 20030213 (extension study). 20040209, 20060113 (extension study). 20060131,20060216,20080009,and 20080435) are included.

Data after treatment switch are excluded.

ITP duration is calculated from the ITP diagnosis to the enrollment of first ITP study.

Only adverse events starting after the first dose of investigational product are tabulated.

SoC = Standard of Care. Coded using the MedDRA. version 21.0.

Descending order of frequency is sorted by romiplostim (total) group.

Events with subject incidence of &lt;0.4% are not included in this table.

<div style=\"page-break-after: always\"></div>

Two  cases  of  pulmonary  embolism  and  one  case  of  bone  marrow  reticulin  fibrosis  was  considered life-threatening while one case of myocardial infarction was fatal.

## Deaths

Among subjects treated with romiplostim, the subject incidence and duration-adjusted incidence event rate of fatal adverse events were similar in subjects with ITP ≤ 12 months and ITP &gt; 12 months (4.7% versus 4.1%; 3.4 events per 100 subject-years versus 2.4 events per 100 subject-years) (Table 38).

- For subjects with ITP ≤ 12 months, the subject incidence and the duration -adjusted incidence event rate (per 100 subject-years) were similar for romiplostim group compared with the placebo/SOC group (4.7% versus 5.9%; 3.4 versus 5.5 events per 100 subjects-years). In subjects with ITP &gt; 12 months, the subject incidence was similar and event rate was lower in the romiplostim group compared with the placebo/SOC group (4.1% versus 6.5%; 2.4 versus 8.5 events per 100 subject-years).

-  For  subjects  with  ITP ≤ 12 months,  the  PTs  (romiplostim  versus  placebo/SOC)  reported  with  highest subject incidence (≥ 0.4%) and/or highest duration -adjusted incidence event rates (≥ 0.3 adverse events per 100 subject-years) were provided in Table 37 below. With respect to subjects with ITP &gt; 12 months, no fatal adverse events were reported with the mentioned subject incidence and/or duration-adjusted incidence event rates.

Regarding treatment-related deaths, none was reported in subjects with ITP ≤ 12 months. Among subjects with  ITP &gt; 12 months,  treatment-related  fatal  adverse  events  were  reported  by  subjects  from  the romiplostim group only (and the subject incidence and duration-adjusted incidence event rate were similar in the romiplostim group compared with the placebo/SOC group (0.8% versus 0%; 0.5 versus 0) (Table 38). Preferred  terms  for  the  treatment-related  fatal  adverse  events  were  intestinal  ischaemia,  haemolysis, aplastic anaemia, myocardial infarction, and angina unstable.

## Table  38.  Summary  of  Subject  Incidence  and  Duration  Adjusted  Incidence  Rate  of  Fatal Treatmentemergent  Adverse  Events  (Subjects  with  ≤  12  Months  and &gt;  12  Months  of  ITP Duration).

|                                                                | Placebo/SOC (N=34) ITP Duration in Months                 | Placebo/SOC (N=34) ITP Duration in Months                 | Placebo/SOC (N=34) ITP Duration in Months                 | Placebo/SOC ITP Duration in Months   | Romiplostim (N = 277) ITP Duration in Months                  | Romiplostim (N = 277) ITP Duration in Months                  | Romiplostim (N = 277) ITP Duration in Months                  | Romiplostim ITP Duration in Months   |
|----------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|--------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|--------------------------------------|
|                                                                | 3 (N=15)                                                  | 23to≤12 (N =19)                                           | Total (N=34)                                              | >12 (N=92)                           | 3 (N = 140)                                                   | 23to≤12 (N= 137)                                              | Total (N = 277)                                               | >12 (N = 634)                        |
| Alltreatment-emergent adverseevents -n (%)                     | 2 (13.3)                                                  | 0 (0.0)                                                   | 2(5.9)                                                    | 6 (6.5)                              | 7 (5.0)                                                       | 6 (4.4)                                                       | 13 (4.7)                                                      | 26 (4.1)                             |
| Treatment-related treatment-emergent adverse events -n (%)     | 0 (0.0)                                                   | 0 (0.0)                                                   | 0 (0.0)                                                   | 0 (0.0)                              | 0 (0.0)                                                       | 0 (0.0)                                                       | 0 (0.0)                                                       | 5 (0.8)                              |
|                                                                | Placebo/SOC (Sbj-yr = 36.5) (N=34) ITP Duration in Months | Placebo/SOC (Sbj-yr = 36.5) (N=34) ITP Duration in Months | Placebo/SOC (Sbj-yr = 36.5) (N=34) ITP Duration in Months | Placebo/SOC ITP Duration in Months   | Romiplostim (Sbj-yr = 382.1) (N = 277) ITP Duration in Months | Romiplostim (Sbj-yr = 382.1) (N = 277) ITP Duration in Months | Romiplostim (Sbj-yr = 382.1) (N = 277) ITP Duration in Months | Romiplostim ITP Duration in Months   |
|                                                                | 3 (Sbj-yr = 16.8) (N= 15)                                 | 23to≤12 (Sbj-yr = 19.7) (N=19)                            | Total (Sbj-yr = 36.5) (N = 34)                            | >12 (Sbj-yr = 70.8) (N = 92)         | 3 (Sbj-yr = 187.3) (N =140)                                   | 23to≤12 (Sbj-yr= 214.9) (N = 137)                             | Total (Sbj-yr= 382.1) (N = 277)                               | >12 (Sbj-yr= 1100.5) (N = 634)       |
| Alltreatment-emergent adverse events -n()                      |                                                           | 0 (0.0)                                                   | 2 (5.5)                                                   | 6 (8.5)                              | 7 (4.2)                                                       | 6 (2.8)                                                       | 13 (3.4)                                                      | 26 (2.4)                             |
| All Treatment-relatedtreatment- emergent adverse events -n (r) | 0 (0.0)                                                   | 0 (0.0)                                                   | 0(0.0)                                                    | 0 (0.0)                              | 0(0.0)                                                        | 0 (0.0)                                                       | 0 (0.0)                                                       | 5 (0.5)                              |

(extensionstudy),20040209,20060113(extension study),20060131,20060216,20080009,and20080435)areincluded.Dataaftertreatmentswitchareexcluded. ITP duration is calculated from the ITP diagnosis to the enrollment of first ITP study. Multiple occurrences of the same event for a subject are counted as multiple events. Only adverse events starting after the first dose of investigational product are tabulated.

ITP = immune thrombocytopenia; n = number of events.r = duration adjusted event rate per 100 subject-years (n/Sbj-yr 100). Sbj-yr = Total subject years on study. SOC = Standard of care. Grades are based on CTCAE v3.0. CTCAE = Common Teminology Criteria for Adverse Events Grading Scale.

<div style=\"page-break-after: always\"></div>

Table  39.  Subject  Incidence  and  Duration-Adjusted  Event  Rate  of  Fatal  (Grade  =  5) Treatment-emergent  Adverse  Events  by  Preferred  Term  in  Descending  Order  of  Frequency (Subjects with ≤ 12 Months of ITP Duration)

|                            |                                    | Romiplostim (N = 277) ITP Duration in Months              | Romiplostim (N = 277) ITP Duration in Months   | Romiplostim (N = 277) ITP Duration in Months   |
|----------------------------|------------------------------------|-----------------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Preferred Term             | Placebo/SOC (N = 34) n (%)         | 3 (N = 140) n (%)                                         | 2 3 to 5 12 (N = 137) n (%)                    | Total (N = 277) n (%)                          |
| Myocardial infarction      | 0 (0.0)                            | 2(1.4)                                                    | 0 (0.0)                                        | 2 (0.7)                                        |
| Renal failure              | 0 (0.0)                            | 1 (0.7)                                                   | 1 (0.7)                                        | 2 (0.7)                                        |
| Acule kidney injury        | 0 (0.0)                            | 1 (0.7)                                                   | 0 (0.0)                                        | 1 (0.4)                                        |
| Cardiac failure            | 0 (0.0)                            | 1 (0.7)                                                   | 0 (0.0)                                        | 1 (0.4)                                        |
| Cerebral haemorrhage       | 0 (0.0)                            | 1 (0.7)                                                   | 0 (0.0)                                        | 1 (0.4)                                        |
| Haemorrhage intracranial   | 0 (0.0)                            | 0 (0.0)                                                   | 1 (0.7)                                        | 1 (0.4)                                        |
| Ischaemic slroke           | 0 (0.0)                            | 0 (0.0)                                                   | 1 (0.7)                                        | 1 (0.4)                                        |
| Lung neoplasm malignant    | 0 (0.0)                            | 0 (0.0)                                                   | 1 (0.7)                                        | 1 (0.4)                                        |
| Pneumococcal sepsis        | 0 (0.0)                            | 0 (0.0)                                                   | 1 (0.7)                                        | 1 (0.4)                                        |
| Pneumonia                  | 0 (0.0)                            | 0 (0.0)                                                   | 1 (0.7)                                        | 1 (0.4)                                        |
| Sudden dealh               | 0 (0.0)                            | 1 (0.7)                                                   | 0 (0.0)                                        | 1 (0.4)                                        |
| Cardio-respiralory arrest  | 1 (2.9)                            | 0 (0.0)                                                   | 0 (0.0)                                        | 0 (0.0)                                        |
| Hepalocellular carcinoma   | 1 (2.9)                            | 0 (0.0)                                                   | 0 (0.0)                                        | 0 (0.0)                                        |
|                            |                                    | Romiplostim - ITP Duration in Months                      | Romiplostim - ITP Duration in Months           | Romiplostim - ITP Duration in Months           |
|                            | Placebo/SoC (Sbj-yr=36.5) (N = 34) | 23 (Sbj-yr=167.3) (Sbj-yr=214.9) (Sbj-yr=382.1) (N = 140) | 2 3 1o s 12 (N = 137)                          | Tolal (N = 277)                                |
|                            | n(c)                               | n(n)                                                      | n(n)                                           | n(t)                                           |
| Myocardial infarclion      | 0 (0.0)                            | 2 (1.2)                                                   | 0 (0.0)                                        | 2 (0.5)                                        |
| Renal failure              | 0 (0.0)                            | 1 (0.6)                                                   | 1 (0.5)                                        | 2 (0.5)                                        |
| Acute kidney injury        | 0 (0.0)                            | 1 (0.6)                                                   | 0 (0.0)                                        | 1 (0.3)                                        |
| Cardiac failure            | 0 (0.0)                            | 1 (0.6)                                                   | 0 (0.0)                                        | 1 (0.3)                                        |
| Cerebral haemorrhage       | 0 (0.0)                            | 1 (0.6)                                                   | 0 (0.0)                                        | 1 (0.3)                                        |
| Haemorrhage intracranial   | 0 (0.0)                            | 0 (0.0)                                                   | 1 (0.5)                                        | 1 (0.3)                                        |
| Ischaemic stroke           | 0 (0.0)                            | 0 (0.0)                                                   | 1 (0.5)                                        | 1 (0.3)                                        |
| Lung neoplasm malignant    | 0 (0.0)                            | 0 (0.0)                                                   | 1 (0.5)                                        | 1 (0.3)                                        |
| Pneumococcal sepsis        | 0 (0.0)                            | 0 (0.0)                                                   | 1 (0.5)                                        | 1 (0.3)                                        |
| Pneumonia                  | 0 (0.0)                            | 0 (0.0)                                                   | 1 (0.5)                                        | 1(0.3)                                         |
| Sudden death               | 0 (0.0)                            | 1 (0.6)                                                   | 0 (0.0)                                        | 1 (0.3)                                        |
| Cardio-respiralory alrrest | 1 (2.7)                            | 0 (0.0)                                                   | 0 (0.0)                                        | 0 (0.0)                                        |
| Hepalocellular carcinoma   | 1 (2.7)                            | 0 (0.0)                                                   | 0 (0.0)                                        | 0 (0.0)                                        |

## Adverse Events of Interest

Adverse  EOI  were  defined  for  romiplostim  based  upon  events  identified  in  emerging  clinical  data,  the mechanism of action of the product, potential risks as defined by nonclinical data, and events identified with other TPO-RA products, and include important potential and important identified risks that are established for romiplostim in the overall adult ITP population.

The subject incidences and duration-adjusted subject incidences for adverse events of special interest in both subgroups are provided in Table 40.  In both ITP duration analysis sets ( ≤ 12 and &gt; 12 months), the adverse  events  of  special  interest  with  the  highest  subject  incidence  were  pulmonary  disorders, haemorrhages  [AMQ],  and  hypersensitivity  and/or  angioedema  and/or  anaphylactic  reactions  and/or anaphylactic-anaphylactoid  shock  conditions  [SMQs].  For  the  latter,  no  events  were  reported  for  the preferred terms anaphylaxis or angioedema in any subject.

<div style=\"page-break-after: always\"></div>

Table 40.  Overall Summary of Adverse Events of Interest

|                                                                                                                               | ITP≤ 12 months                                                                                    | ITP≤ 12 months                                                 | ITP > 12 months                                                                                   | ITP > 12 months                                                |
|-------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|----------------------------------------------------------------|---------------------------------------------------------------------------------------------------|----------------------------------------------------------------|
| Events of Interest                                                                                                            | Placebo/SOC (N = 34) n (%) [duration- adjusted incidence rate in incidence rate in subject-years] | Romiplostim (N = 277) n (%) [duration- adjusted subject-years] | Placebo/SOC (N = 92) n (%) [duration- adjusted incidence rate in incidence rate in subject-years] | Romiplostim (N = 634) n (%) [duration- adjusted subject-years] |
| Hypersensitivity/angioedema/anaphylactic reactions/anaphylactic- anaphylactoid shock conditions (SMQs)                        | 11 (32.4) [38.3]                                                                                  | 63 (22.7) [27.7]                                               | 18 (19.6) [42.4]                                                                                  | 172 (27.1) [30.8]                                              |
| Cardiac disorders (SMQ)                                                                                                       | 3 (8.8) [11.0]                                                                                    | 15 (5.4) [6.5]                                                 | 3 (3.3) [9.9]                                                                                     | 39 (6.2) [6.2]                                                 |
| Drug related hepatic disorders (SMQ)                                                                                          | 3 (8.8) [19.2]                                                                                    | 7 (2.5) [3.1]                                                  | 4 (4.3) [9.9]                                                                                     | 26 (4.1) [3.0]                                                 |
| Thrombotic/thromboembolic events (SMQ)                                                                                        | 2 (5.9) [8.2]                                                                                     | 15 (5.4) [4.4]                                                 | 2 (2.2) [2.8]                                                                                     | 46 (7.3) [6.1]                                                 |
| Haewowhages (SMQ)                                                                                                             | 18 (52.9) [191.7]                                                                                 | 140 (50.5) [129.5]                                             | 52 (56.5) [265.5]                                                                                 | 374 (59.0) [182.2]                                             |
| Haewatoloaicalmalignant tuwous(SMQ),haematolagical.tumoursof unspecified malignancy (SMQ), and myelodysplastic syndrome (SMQ) | 0 (0.0) [0.0]                                                                                     | 4 (1.4) [1.0]                                                  | 3 (3.3) [4.2]                                                                                     | 2 (0.3) [0.3]                                                  |
| Immunogenicity (AMQ)                                                                                                          | 0 (0.0) [0.0]                                                                                     | 1 (0.4) [0.3]                                                  | [00] (00) 0                                                                                       | 0 (0.0) [0.0]                                                  |
| Pulmonary disorders (AMQ)                                                                                                     | 23 (67.6) [161.6]                                                                                 | 175 (63.2) [145.2]                                             | 53 (57.6) [182.2]                                                                                 | 422 (66.6) [161.6]                                             |
| Renal and urinary disorders (system organ class)                                                                              | 4 (11.8) [24.6]                                                                                   | 22 (7.9) [8.9]                                                 | 7 (7.6) [12.7]                                                                                    | 72 (11.4) [9.5]                                                |
| Thrombocytosis (AMQ)                                                                                                          | [00] (00) 0                                                                                       | 8 (2.9) [3.1]                                                  | 1 (1.1) [1.4]                                                                                     | 17 (2.7) [2.1]                                                 |
| Malignancies (SMQ)                                                                                                            | 4 (11.8) [13.7]                                                                                   | 11 (4.0) [4.4]                                                 | 4 (4.3) [5.6]                                                                                     | 29 (4.6) [3.4]                                                 |
| Myelofibrosis (AMQ)                                                                                                           | 0 (0.0) [0.0]                                                                                     | 1 (0.4) [0.3]                                                  | [00] (0°0) 0                                                                                      | 6 (0.9) [0.5]                                                  |
| Hematopoietic cxtopenias affecting more than one type of blood cell (SMQ)                                                     | [00] (00) 0                                                                                       | 1 (0.4) [0.3]                                                  | 0 (0.0) [0.0]                                                                                     | 1 (0.2) [0.1]                                                  |
| Concurrent haematonoietic ervthropenia (SMQ) and leukocytosis (AMQ)a                                                          | 1 (2.9)                                                                                           | 12 (4.3)                                                       | 9 (9.8)                                                                                           | 61 (9.6)                                                       |
| Medication errors (SMQ)                                                                                                       | 0 (0.0) [0.0]                                                                                     | 0 (0.0) [0.0]                                                  | [0°0] （0°0) 0                                                                                     | 0 (0.0) [0.0]                                                  |

AMQ = Amgen MedDRA query; ITP = immune thrombocytopenia; MedDRA = Medical Dictionary for Regulatory Activity; n = number of adverse events; SMQ = Standardized MedDRA query; SOC = standard of care a  Haematopoietic erythropenia (SMQ) is identified by MedDRA terms or lab values (hemoglobin &lt; Lower limit of normal, which is age and gender dependent).

Leukocytosis (AMQ) is defined by MedDRA terms or lab values (white blood cells &gt; 11 x 10 9 /L).  Concurrent event is defined as both haematopoietic erythropenia and leukocytosis events occurring within a 4-week window.

## Medication Errors (SMQ):

No subjects with ITP ≤ 12 months or ITP &gt; 12 months treated with romiplostim in the integrated analysis set reported medication errors adverse events.

## Myelofibrosis (AMQ)

For subjects treated with romiplostim, the subject incidence and corresponding duration adjusted rates (per 100 subjectyears) were similar between subjects with ITP ≤ 12 months and subjects with ITP &gt; 12 months (0.4% versus 0.9%; 0.3 versus 0.5).

- -In subjects with ITP ≤ 12 months the myelofibrosis adverse events were reported by subjects from the romiplostim group only. The PT of the only event was observed was myelofibrosis in one subject with ITP ≥ 3 to ≤ 12 months. This event was serious, treatment-related, and the subject was discontinued from the study.

- In subjects with ITP &gt; 12 months, the myelofibrosis adverse events were also reported by subjects from the romiplostim group only. The myelofibrosis adverse events with highest subject incidence by PT in the romiplostim group were bone marrow reticulin fibrosis (0.8%, 5 of 6 subjects) and reticulin increased (0.2%, 1 of 6 subjects).

<div style=\"page-break-after: always\"></div>

## Haematological Malignancy (SMQ)

For subjects treated with romiplostim, the subject incidence and duration-adjusted incidence event rate (per 100 subjectyears) were similar between subjects with ITP ≤ 12 months and subjects with ITP &gt; 12 months (1.4% versus 0.3%; 1.0 versus 0.3).

- -For subjects with ITP ≤ 12 months, haematological malignant adverse ev ents were reported by subjects from the romiplostim group only. The duration-adjusted incidence event rate was 1.0 (4 events)  in  the  romiplostim  group.  The  haematological  malignant  adverse  events  with  highest subject incidence by PT in the romiplostim group were B-cell lymphoma (0.4%, 1/277 subjects), lymphoma  (0.4%,  1/277  subjects),  metastases  to  lymph  nodes  (0.4%,  1/277  subjects),  and non-Hodgkin's  lymphoma  (0.4%,  1/277  subjects).  Neither  of  them  was  considered  related  to romiplostim treatment by the investigator.
- -For  subjects  with  ITP  &gt;  12  months  incidence  of  subjects  was  similar  in  the  romiplostim  group compared with the placebo/SOC group (0.3% versus 3.3%). The duration-adjusted incidence event rate was lower in the romiplostim group compared with the placebo/SOC group (0.3 [3 events] versus 4.2 [3 events]). There were no haematological malignancy adverse events by PT with a subject incidence of ≥ 1% in the romiplostim group.

## Thrombocytosis (AMQ)

For subjects treated with romiplostim, the subject incidence and corresponding duration-adjusted rates of events ( per 100 subject-years) from the thrombocytosis AMQ were similar between subjects with ITP ≤ 12 months and subjects with ITP &gt; 12 months (2.9% versus 2.7%; 3.1 versus 2.1).

- -In subjects with the ITP ≤ 12 months in the integrated analysis set, events were reported in the romiplostim group only. The duration-adjusted event incidence rate was 3.1 (12 events) in the romiplostim group. The events with highest subject incidence by PT in the romiplostim group were thrombocytosis  (1.8%,  5/277  subjects),  platelet  count  decreased  (0.7%,  2/277  subjects), erythromelalgia (0.4%, 1/277 subjects), and platelet count abnormal (0.4%, 1/277 subjects).
- -In subjects with ITP &gt; 12 months the incidence of subjects was similar in the romiplostim group compared with the placebo/SOC group (2.7% versus 1.1%). The duration-adjusted incidence event rate) was also similar for the romiplostim group compared with the placebo/SOC group (2.1 [23 events] versus 1.4 [1 event]). The event wi th the highest subject incidence (≥ 1%) by PT in the romiplostim group was thrombocytosis (1.9%, 12 /634 subjects).
- Search Results by Platelet Count &gt; 450 × 10 9  /L:

For subjects treated with romiplostim, the incidence of subjects who had platelet counts &gt; 450 x 10 9 /L was similar between subjects with ITP ≤ 12 months and subjects with ITP &gt; 12 months (35.4% versus 36.9%). For both subgroups, the incidence of subjects with platelet counts &gt; 450 x 10 9  /L was  higher  in  the  romiplostim  group  compared  with  the  placebo/SOC  group  (35.4%  [98/277 subjects] versus 20.6% [7/34 subjects]) and 36.9% [234/634 subjects] versus 5.4% [5 of 92 subjects]).

## Thrombotic/Thromboembolic Events (SMQ)

For subjects treated with romiplostim, the subject incidence and duration-adjusted incidence rate from the thrombotic/thromboembolic SMQ were similar between subjects with ITP ≤ 12 months versus subjects with ITP &gt; 12 months (5.4% versus 7.3%; 4.4 versus 6.1.)

- -In subjects with ITP ≤ 12 months the incidence of subjects was similar in t he romiplostim group compared with the placebo/SOC group (5.4% versus 5.9%). The duration-adjusted event incidence rate was lower in the romiplostim group compared with the placebo/SOC group (4.4 [17 events]

<div style=\"page-break-after: always\"></div>

versus 8.2 [3 events]). The events with highest subject incidence (≥ 1%) by PT in the romiplostim group with corresponding duration-adjusted incidence event rate were cerebrovascular accident (1.1%, 3/277 subjects [0.8, 3 events]), and pulmonary embolism (1.1%, 3/277 subjects [0.8, 3 events]); these events were not reported by subjects from the placebo/SOC group.

- -In subjects with the ITP &gt; 12 months, the incidence of subjects was higher in the romiplostim group compared with the placebo/SOC group (7.3% [46/634 subjects] versus 2.2% [2/92 subjects]). The duration-adjusted event incidence rate was also higher in the romiplostim group compared with the placebo/SOC  group  (6.1  [67  events]  versus  2.8  [2  events]).  The  adverse  events  with  highest subject incidence by PT in the romiplostim group with corresponding duration-adjusted incidence event rate were deep vein thrombosis (1.9% [12/634 subjects]; 1.5 [16 events]), and pulmonary embolism (1.4% [9/634 subjects]; 0.9 [10 events]). Except for pulmonary embolism (1.1% [1/92 subjects]) all other adverse events were not reported by subjects from the placebo/SOC group.

## Haemorrhages (SMQ)

For subjects treated with romiplostim, the subject incidence and corresponding duration adjusted rate (e (per 100 subject-years) of haemorrhages adverse events were lower in subjects with ITP ≤ 12 months compared with subjects with ITP &gt; 12 months (50.5% versus 59.0%; 129.5 versus 182.2) (Table 41 and Table 42).

- -In subjects with ITP ≤ 12 months, the incidence of subjects was similar for the romiplostim group compared with the placebo/SOC group (50.5% [140/277 subjects] versus 52.9% [18/34 subjects]) (Table 41). The corresponding duration-adjusted incidence rate (per 100 subject-years) was lower for romiplostim group compared with the placebo/SOC group (129.5 [495 events] versus 191.7 [70 events]) (Table 42).

The events from the haemorrhages SMQ with highest subject incidence (≥ 10%) with corresponding duration-adjusted  incidence  event  rate  by  PT  in  the  romiplostim  group  and  placebo  group  for subjects  with  ITP  ≤  12  months  were  epistaxis (17.7%,  49/277  subjects  [19.1,  73  events]), petechiae (15.5%, 43/277 subjects [21.7, 83 events])  and contusion ((15.2%, 42/277 subjects [25.1, 96 events]). Except for contusion, the subject incidence and event rate of the above adverse events were lower in the romiplostim group compared with the placebo/SOC group.

<div style=\"page-break-after: always\"></div>

Table 41. Subject Incidence of Haemorrhages (SMQ) Treatment-emergent Adverse Events by Preferred Term in Descending Order of Frequency ( ≥ 1%) (Subjects with ≤ 12 Months of ITP Duration)

|                                                                         |                           | Romiplostim - ITP Duration in Months   | Romiplostim - ITP Duration in Months   | Romiplostim - ITP Duration in Months   |
|-------------------------------------------------------------------------|---------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| Preferred Term                                                          | Placebo/SOC (N= 34) n (%) | 3 (N = 140) n (%)                      | 2 3 to ≤ 12 (N = 137) n (%)            | Total (N= 277) n (%)                   |
| Subjects reporting Haemorrhages (SMQ) treatment-emergent adverse events | 18 (52.9)                 | 62 (44.3)                              | 78 (56.9)                              | 140 (50.5)                             |
| Epistaxis                                                               | 11 (32.4)                 | 20 (14.3)                              | 29 (21.2)                              | 49 (17.7)                              |
| Petechiae                                                               | 7 (20.6)                  | 22 (15.7)                              | 21 (15.3)                              | 43 (15.5)                              |
| Contusion                                                               | 5 (14.7)                  | 17 (12.1)                              | 25 (18.2)                              | 42 (15.2)                              |
| Haematoma                                                               | 6 (17.6)                  | 9 (6.4)                                | 12 (8.8)                               | 21 (7.6)                               |
| Immune thrombocytopenic purpura                                         | 3 (8.8)                   | 8 (5.7)                                | 8 (5.8)                                | 16 (5.8)                               |
| Mouth haemorrhage                                                       | 0 (0.0)                   | 6 (4.3)                                | 7 (5.1)                                | 13 (4.7)                               |
| Gingival bleeding                                                       | 3 (8.8)                   | 6 (4.3)                                | 5 (3.6)                                | 11 (4.0)                               |
| Ecchymosis                                                              | 2 (5.9)                   | 1 (0.7)                                | 7 (5.1)                                | 8 (2.9)                                |
| Rectalhaemorrhage                                                       | 1 (2.9)                   | 2 (1.4)                                | 6 (4.4)                                | 8 (2.9)                                |
| Vaginal haemorrhage                                                     | 1 (2.9)                   | 4 (2.9)                                | 4 (2.9)                                | 8 (2.9)                                |
| Blood blister                                                           | 0 (0.0)                   | 3 (2.1)                                | 4 (2.9)                                | 7 (2.5)                                |
| Injection site bruising                                                 | 0 (0.0)                   | 0 (0.0)                                | 6 (4.4)                                | 6 (2.2)                                |
| Mucosal haemorrhage                                                     | 0 (0.0)                   | 3 (2.1)                                | 2 (1.5)                                | 5 (1.8)                                |
| eundind                                                                 | 1 (2.9)                   | 1 (0.7)                                | 4 (2.9)                                | 5 (1.8)                                |
| Haematochezia                                                           | 0 (0.0)                   | 3 (2.1)                                | 1 (0.7)                                | 4 (1.4)                                |
| Haemorrhoidal haemorrhage                                               | 0 (0.0)                   | 2 (1.4)                                | 2 (1.5)                                | 4 (1.4)                                |
| Conjunctival haemorrhage                                                | 0 (0.0)                   | 1 (0.7)                                | 2 (1.5)                                | 3 (1.1)                                |
| Eye haemorrhage                                                         | 0 (0.0)                   | 3 (2.1)                                | 0 (0.0)                                | 3 (1.1)                                |
| Haematuria                                                              | 1 (2.9)                   | 1 (0.7)                                | 2 (1.5)                                | 3 (1.1)                                |
| Haemorrhage                                                             | 1 (2.9)                   | 2 (1.4)                                | 1 (0.7)                                | 3 (1.1)                                |
| Menorrhagia                                                             | 1 (2.9)                   | 2 (1.4)                                | 1 (0.7)                                | 3 (1.1)                                |
| Post procedural haemorrhage                                             | 0 (0.0)                   | 2 (1.4)                                | 1 (0.7)                                | 3 (1.1)                                |

Adult subjecls (age ≥ 18 years at screening) who received at least one dose of investigalional product in any 20060131,20060216,20080009,and20080435)areincluded.

ITPdurationiscalculatedfromtheITPdiagnosistotheenrollmentoffirstITPstudy.

Dataaftertrealmentswitchareexcluded.

Onlyadverseeventsstartingafterthefirstdoseofinvestigalionalproductaretabulated.

SOC=Slandard of Care.Coded using theMedDRAverslon 21.0.

Events were identified using narrowsearchof pre-defined listofpreferred termsfor Haemorrhages (SMQ).

Source:ModifiedfromISSTable14-6.1.16.3.

<div style=\"page-break-after: always\"></div>

Table 42. Duration Adjusted Event Rate of Haemorrhages (SMQ) Treatment-emergent Adverse Events by Preferred Term in Descending Order of Incidence Rate (Subjects with ≤ 12 Months of ITP Duration)

|                                                                   |                                           | Romiplostim -ITP Duration in Months   | Romiplostim -ITP Duration in Months   | Romiplostim -ITP Duration in Months   |
|-------------------------------------------------------------------|-------------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
| PreferredTem                                                      | Placebo/SOC (Sbj-yr = 36.5) (N = 34) n(c) | <3 (Sbj-yr = 167.3) (N = 140) n(c)    | ≥3to≤12 (Sbj-yr = 214.9) (N= 137) n() | Total (Sbj-yr = 382.1) (N = 277) n(c) |
| Total numberof Haemorrhages (SMQ) treatment-emergentadverseevents | 70 (191.7)                                | 228 (136.3)                           | 267 (124.3)                           | 495 (129.5)                           |
| Contusion                                                         | 7 (19.2)                                  | 34 (20.3)                             | 62 (28.9)                             | 96 (25.1)                             |
| Petechiae                                                         | 12 (32.9)                                 | 49 (29.3)                             | 34 (15.8)                             | 83 (21.7)                             |
| Epistaxis                                                         | 20 (54.8)                                 | 33 (19.7)                             | 40 (18.6)                             | 73 (19.1)                             |
| Haematoma                                                         | 11 (30.1)                                 | 11 (6.6)                              | 17 (7.9)                              | 28 (7.3)                              |
| Immune thrombocytopenic purpura                                   | 3 (8.2)                                   | 13 (7.8)                              | 11 (5.1)                              | 24 (6.3)                              |
| Gingival bleeding                                                 | 3 (8.2)                                   | 11 (6.6)                              | 11 (5.1)                              | 22 (5.8)                              |
| Mouth haemorhage                                                  | 0 (0.0)                                   | 11 (6.6)                              | 10 (4.7)                              | 21 (5.5)                              |
| Vaginal haemorrhage                                               | 2 (5.5)                                   | 12 (7.2)                              | 6 (2.8)                               | 18 (4.7)                              |
| Ecchymosis                                                        | 3 (8.2)                                   | 2 (1.2)                               | 11 (5.1)                              | 13 (3.4)                              |
| Blood blister                                                     | 0 (0.0)                                   | 4 (2.4)                               | 8 (3.7)                               | 12 (3.1)                              |
| endind                                                            | 1 (2.7)                                   | 3 (1.8)                               | 9 (4.2)                               | 12 (3.1)                              |
| Mucosal haemorhage                                                | 0 (0.0)                                   | 6 (3.6)                               | 3 (1.4)                               | 9 (2.4)                               |
| Rectal haemorrhage                                                | 1 (2.7)                                   | 2 (1.2)                               | 6 (2.8)                               | 8 (2.1)                               |
| Injection site bruising                                           | 0 (0.0)                                   | 0 (0.0)                               | 6 (2.8)                               | 6 (1.6)                               |
| Conjunctival haemorhage                                           | 0 (0.0)                                   | 1 (0.6)                               | 4 (1.9)                               | 5 (1.3)                               |
| Haemorrhoidal haemorhage                                          | 0 (0.0)                                   | 3 (1.8)                               | 2 (0.9)                               | 5 (1.3)                               |
| Skin haemorrhage                                                  | 0 (0.0)                                   | 1 (0.6)                               | 4 (1.9)                               | 5 (1.3)                               |
| Eye haemorrhage                                                   | 0 (0.0)                                   | 4 (2.4)                               | 0 (0.0)                               | 4 (1.0)                               |
| Haematochezia                                                     | 0 (0.0)                                   | 3 (1.8)                               | 1 (0.5)                               | 4 (1.0)                               |
| Haematuria                                                        | 1 (2.7)                                   | 2 (1.2)                               | 2 (0.9)                               | 4 (1.0)                               |
| Haemorrhagic anaemia                                              | 0 (0.0)                                   | 4 (2.4)                               | 0 (0.0)                               | 4 (1.0)                               |

-  In  subjects with ITP subjects with the ITP &gt; 12 months, the incidence of subjects was similar in the romiplostim group compared with the placebo/SOC group (59.0% [374/634 subjects] versus 56.5% [52/92 subjects]). The duration-adjusted event incidence rate was lower for the romiplostim group compared with the  placebo/SOC  group  (182.2  [2005  events]  versus  265.5  [188  events]).  The  events  from  the haemorrhages SMQ with highest subject in cidence (≥ 10%) with corresponding duration -adjusted incidence event rate by PT in the romiplostim group and placebo/SOC group for subjects with ITP &gt; 12 months were epistaxis (22.9%, 145/634 subjects [32.0, 352 events] versus 19.6%, 18/92 subjects [45.2, 32 events]), contusion (21.5%, 136/634 subjects [32.8, 361 events] versus 21.7%, 20 /92 subjects [56.5, 40 events]), petechiae (19.1%, 121 of 634 subjects [21.6, 238 events] versus 17.4%, 16 of 92 subjects [29.7, 21 events]), and gingival bleeding (10.1%, 64 of 634 subjects [9.9, 109 events] versus 7.6%, 7 of 92 subjects [12.7, 9 events.

- Haemorrhages  in  subjects  with  consistently  low  platelet  counts:  For  subjects  treated  with romiplostim, the subject incidence and duration-adjusted rates of events from the haemorrhages SMQ in subjects with consistently low platelet counts were lower in subjects with ITP ≤ 12 months compared with subjects with ITP &gt; 12 months (75% versus 78.2%; 198.6 versus 248.1).
- -In subjects with ITP ≤ 12, 16 subjects (5.8%) in the romiplo stim group and 2 subjects (5.9%) in the placebo group had consistently low platelet counts defined as a platelet count of &lt; 20 × 10 9 /L with dose  ≥  10 ìg/kg  for  4  consecutive  weeks.  Among  these  subjects  with  low  platelet  counts,  the incidence of subjects reporting events from the haemorrhages SMQ was lower for the romiplostim group compared with the placebo/SOC group (75% [12/16 subjects] versus 100% [2/2 subjects]). The duration-adjusted incidence event rate was also lower for the romiplostim group compared with the placebo/SOC group (198.6 [44 events] versus 1300.6[12 events]).

<div style=\"page-break-after: always\"></div>

- -In subjects with ITP &gt; 12 months, 55 subjects (8.7%) in the romiplostim group and 11 (12.0%) subjects in the placebo group had consistently low platelet counts defined as a platelet count of &lt; 20 × 10 9 /L with dose ≥ 10 ìg/kg for 4 consecutive weeks. The incidence of subjects reporting events from the haemorrhages SMQ was higher for the romiplostim group compared with the placebo/SOC group (78.2% [43/55 subjects] versus 63.6% [7/11 subjects]). The corresponding duration-adjusted event incidence rate (per 100 subject-years) was lower for the romiplostim group compared with the placebo/SOC group (248.1 [251 events] versus 416.3[19 events]).
- Subjects with Variable Platelet Counts: for those subjects treated with romiplostim, the subject incidence  and  corresponding  duration-adjusted  rates  of  events  from  the  haemorrhages  SMQ  in subjects with variable platelet counts were lower in subjects with ITP ≤ 12 months compared with subjects with ITP &gt; 12 months (69.0% versus 72.6%; 267.3 versus 278.5).
- -In su bjects with ITP ≤ 12 months, a total of 42 subjects (15.2%) in the romiplostim group and 1 subject (2.9%) in the placebo/SOC group had variable platelet counts, defined as platelet counts increased or decreased by &gt; 100 × 10 9  /L in 2 consecutive weeks while also crossing 50 × 10 9  /L, and that changed in the opposite direction by &gt; 100 × 10 9  /L while crossing 50 × 10 9  /L in the following consecutive week. Among these subjects, the incidence of subjects was lower for the romiplostim group compared with the placebo/SOC group (69.0% [29/42 subjects] versus 100.0%. The duration-adjusted event incidence rate was also lower for the romiplostim group compared with the placebo/SOC group (267.3 [162 events] versus 432.2 [2 events]).
- -In subjects with the ITP &gt; 12 months, a total of 164 subjects (25.9%) in the romiplostim group and 3 subjects (3.3%) in the placebo/SOC group had variable platelet counts. Among these subjects, the incidence of subjects was higher for the romiplostim group compared with the placebo/SOC group (72.6% [119/164 subjects] versus 66.7% [2/3 subjects]). The duration-adjusted event incidence rate was also higher for the romiplostim group compared with the placebo/SOC group (278.5 [914 events] versus 211.5 [3 events]).

## Hypersensitivity/Angioedema/Anaphylactic Reactions/Anaphylactic-Anaphylactoid Shock Conditions (SMQ)

For subjects treated with romiplostim, the subject incidence and the duration-adjusted event rate of events from the hypersensitivity reaction search were lower in subjects with ITP ≤ 12 months compared with subjects with ITP &gt; 12 months (22.7% versus 27.1%; 27.7 versus 30.8). The types of events from the hypersensitivity reaction search with highest subject incidence (≥ 1%) by PT in the romiplostim group and placebo/SOC group in subjects with ITP ≤ 12 months were similar to those report in subjects with ITP &gt; 12 months (rash, immune thrombocytopenic purpura, eczema, hypersensitivity and urticaria).  In patients with ITP ≤ 12 months t here were no events reported with the PT of anaphylaxis or angioedema.

## Immunogenicity (AMQ)

- -In  subjects  with  ITP  ≤  12  months,  the  incidence  of  subjects  reporting  events  from  the immunogenicity  AMQ  was  0.4%  (1/277  subjects)  in  the  romiplostim  group  compared  with  no subjects  in  the  placebo/SOC  group.  The  duration-adjusted  event  incidence  rate  (per  100 subject-years) was 0.3 (1 event) in the romiplostim group versus 0.0 in the placebo/SOC group. The PT of the only event in the romiplostim group was Therapy non-responder. The event was serious, not treatment-related, and the subject was discontinued from the study.
- -In subjects with ITP &gt; 12 months there were no events from the immunogenicity AMQ reported.

## Renal and Urinary Disorders (System Organ Class)

For subjects treated with romiplostim, the subject incidence of renal and urinary disorder adverse events was lower in subjects with ITP ≤ 12 months compared with subjects with ITP &gt; 12 months (7.9% versus

<div style=\"page-break-after: always\"></div>

11.4%); however, the duration-adjusted incidence rate (per 100 subject-years) was similar between these subject groups (8.9 versus 9.5).

## Concurrent Haematopoietic Erythropenia (SMQ) with Leukocytosis (AMQ)

In summary, for those subjects treated with romiplostim, subject incidence of concurrent events from the erythropenia SMQ and the leukocytosis AMQ search was lower in subjects with ITP ≤ 12 months compared with  ITP  &gt;  12  months  (4.3%  versus  9.6%).  In  both  subgroups  subject  incidence  was  similar  in  the romiplostim group compared with the placebo/SOC group.

## Cardiac Disorders (SMQ)

For subjects treated with romiplostim, the subject incidence and corresponding duration-adjusted rates (per 100 subjectyears) of events from the cardiac disorder SMQ search were similar in subjects with ITP ≤ 12 months compared with subjects with ITP &gt; 12 months (5.4% versus 6.2%; 6.5 versus 6.2).

## Drug Related Hepatic Disorders (SMQ)

For subjects treated with romiplostim, the subject incidence and corresponding duration-adjusted incidence rate (per 100 subject years) of events from the drug-related hepatic disorder SMQ were similar in subjects with ITP ≤ 12 months compared with subjects with ITP &gt; 12 months (2.5% versus 4.1%; 3.1 versus 3.0).

## Pulmonary Disorders (AMQ)

For subjects treated with romiplostim, the subject incidence and duration-adjusted incidence rate (per 100 subject years) of events from the pulmonary disorder AMQ were lower in subjects with ITP ≤ 12 months compared with subjects with ITP &gt; 12 months (63.2% versus 66.6%; 145.2 versus 161.6). The events from the pulmona ry disorder AMQ with highest subject incidence (≥ 10%) by PT in the romiplostim group and placebo/SOC group (epistaxis, nasopharyngitis, upper respiratory tract infection, and cough) were similar between two subgroups.

## Malignancies (SMQ)

In  summary,  for  those  subjects  treated  with  romiplostim,  the  subject  incidence  and  duration-adjusted incidence rate (per 100 subject years) of events from the malignancies SMQ were similar between subjects with ITP ≤ 12 months and subjects with ITP &gt; 12 months (4.0% versus 4.6%; 4.4 versus 3.4). There were no events from the malignancies SMQ by PT with subject incidence of ≥ 1% in the romiplostim treatment group in neither of the two subgroups.

## Haematopoietic Cytopenias Affecting More Than One Type of Blood Cells (SMQ)

For subjects treated with romiplostim, the subject incidence and duration-adjusted incidence event rate (per 100 subject-years) of haematopoietic cytopenias affecting more than one type of blood cell were similar in subjects with ITP ≤ 12 months and subjects w ith ITP &gt; 12 months (0.4% versus 0.2%; 0.3 versus 0.1).

## Laboratory findings

In the studies included in this submission, low baseline platelet values are expected for subjects with ITP which is an autoimmune disorder characterised by a low circulating platelet count (thrombocytopenia).  The use of rescue medications was allowed during romiplostim studies and may have had an effect on platelet counts.

For  serum  chemistry,  the  maximum  postbaseline  increase  from  baseline  grade 0  to  2  to  most  severe on-treatment grade 3 to 4 of total bilirubin, AST, and ALT occurred less frequently in subjects with ITP ≤ 12 months compared with subjects with ITP &gt; 12 months, while that of creatinine occurred in 1 subject each with ITP ≤ 12 months and ITP &gt; 12 months (Table 44).

<div style=\"page-break-after: always\"></div>

For hematology parameters, the maximum postbaseline increase from baseline grade 0 to 2 to most severe on-treatment grade 3 to 4 of hemoglobin, absolute neutrophil count, platelets count, and leukocyte count occurred less frequently in subjects with ITP ≤ 12 months compared with subjects with ITP &gt; 12 months.

Table 44. Maximum Post Baseline Shift in Serum Chemistry and Hematology in Romiplostim Treated Subjects With ≤ 12 Months and &gt; 12 Months of ITP Duration

| Baseline        | Subjects with s 12 Months of ITP Duration   | Subjects with s 12 Months of ITP Duration   | Subjects with > 12 Months of ITP Duration   | Subjects with > 12 Months of ITP Duration   |
|-----------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Grade           | Romiplostim (N = 277)                       | Romiplostim (N = 277)                       | Romiplostim (N=634)                         | Romiplostim (N=634)                         |
|                 | Grade 3                                     | Grade 4                                     | Grade 3                                     | Grade 4                                     |
| Creatinine      |                                             |                                             |                                             |                                             |
| GradeD          | 0 (0.0%)                                    | 0 (0.0%)                                    | 1 (0.3%)                                    | 0 (0.0%)                                    |
| Grade 1         | 0 (0.0%)                                    | 1 (0.6%)                                    | 0 (0.0%)                                    | 0 (0.0%)                                    |
| Grade 2         | 0 (0.0%)                                    | 0 (0.0%)                                    | 0 (0.0%)                                    | 0 (0.0%)                                    |
| Total Bilinubin |                                             |                                             |                                             |                                             |
| Grade D         | 0 (0.0%)                                    | 0 (0.0%)                                    | 1 (0.3%)                                    | 0 (0.0%)                                    |
| Grade 1         | 0 (0.0%)                                    | 0 (0.0%)                                    | 0 (0.0%)                                    | 0 (0.0%)                                    |
| Grade 2         | 1 (0.6%)                                    | 0 (0.0%)                                    | 0 (0.0%)                                    | 1 (0.3%)                                    |
| SGOT            |                                             |                                             |                                             |                                             |
| Grade 0         | 1 (0.6%)                                    | 0 (0.0%)                                    | 1 (0.3%)                                    | 0 (0.0%)                                    |
| Grade 1         | 0 (0.0%)                                    | 0 (0.0%)                                    | 0 (0.0%)                                    | 0 (0.0%)                                    |
| Grade 2         | 0 (0.0%)                                    | 0 (0.0%)                                    | 2 (0.6%)                                    | 0 (0.0%)                                    |
| SGPT            |                                             |                                             |                                             |                                             |
| Grade D         | 0 (0.0%)                                    | 0 (0.0%)                                    | 2 (0.6%)                                    | 0 (0.0%)                                    |
| Grade 1         | 2 (1.1%)                                    | 0 (0.0%)                                    | 2 (0.6%)                                    | 0 (0.0%)                                    |
| Grade 2         | 0 (0.0%)                                    | 0 (0.0%)                                    | 3 (0.9%)                                    | 0 (0.0%)                                    |

| Baseline                  | Subjects with ≤ 12 Months of ITP Duration   | Subjects with ≤ 12 Months of ITP Duration   | Subjects with > 12 Months of ITP Duration   | Subjects with > 12 Months of ITP Duration   |
|---------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Grade                     | Romiplostim (N = 277)                       | Romiplostim (N = 277)                       | Romiplostim (N=634)                         | Romiplostim (N=634)                         |
|                           | Grade 3                                     | Grade 4                                     | Grade 3                                     | Grade 4                                     |
| Hemoglobin                |                                             |                                             |                                             |                                             |
| Grade 0                   | 1 (0.4%)                                    | 0 (0.0%)                                    | 2 (0.3%)                                    | 3 (0.5%)                                    |
| Grade 1                   | 3 (1.1%)                                    | 0 (0.0%)                                    | 7 (1.1%)                                    | 0 (0.0%)                                    |
| Grade 2                   | 1 (0.4%)                                    | 0 (0.0%)                                    | 3 (0.5%)                                    | 3 (0.5%)                                    |
| Absolute neutrophil count |                                             |                                             |                                             |                                             |
| Grade 0                   | 3 (1.7%)                                    | 4 (2.3%)                                    | 7 (1.9%)                                    | 8 (2.2%)                                    |
| Grade 1                   | 0 (0.0%)                                    | 0 (0.0%)                                    | 0 (0.0%)                                    | 1 (0.3%)                                    |
| Grade 2                   | 1 (0.6%)                                    | 0 (0.0%)                                    | 0 (0.0%)                                    | 1 (0.3%)                                    |
| Platelets                 |                                             |                                             |                                             |                                             |
| Grade 0                   | 1 (0.4%)                                    | 0 (0.0%)                                    | 0 (0.0%)                                    | 1 (0.2%)                                    |
| Grade 1                   | 0 (0.0%)                                    | 1 (0.4%)                                    | 3 (0.6%)                                    | 5 (1.0%)                                    |
| Grade 2                   | 3 (1.2%)                                    | 1 (0.4%)                                    | 2 (0.4%)                                    | 7 (1.4%)                                    |
| Leukocytes                |                                             |                                             |                                             |                                             |
| Grade 0                   | 2 (0.7%)                                    | 1 (0.4%)                                    | 6 (0.9%)                                    | 2 (0.3%)                                    |
| Grade 1                   | 0 (0.0%)                                    | 0 (0.0%)                                    | 0 (0.0%)                                    | 0 (0.0%)                                    |
| Grade 2                   | 2 (0.7%)                                    | 0 (0.0%)                                    | 0 (0.0%)                                    | 0 (0.0%)                                    |

Adult subjects (age ≥ 18 years at screening) who received at least one dose of investigational product in any 20060131,20060216,20080009,and20080435)areincluded.

Data after treatment switchare excluded.

ITPduration is calculated from the ITPdiagnosis to the enrollment of first ITPstudy.

Only subjects who had both baseline and at least one post-baseline measurement were included in the summary.

NotethatStudy20040209didnotcollect liverorrenalfunctiontests.

Onlylaboratory data collected after thefirst dose ofinvestigational product are tabulated.

Grade is based on CTCAE version 3.0

CTCAE =CommonTerminology Criteria forAdverseEvents GradingScale,ITP=immune

Page 2of2

thrombocytopenia,SGOT=serumglutamicoxaloacetictransaminase,SGPT=serumglutamicpyruvic transaminase.

No  clinically  significant  changes  in  vital  signs  were  observed  in  subjects  with  ITP ≤ 12 or &gt; 12  months Clinically significant changes from baseline to the end-of-treatment in liver and spleen ultrasound were observed for 3 romiplostim-treated subjects with ITP &gt; 12 months in Study 20030105 and 1 subject in Study 20030212.

<div style=\"page-break-after: always\"></div>

## Safety in special populations

Subgroup analyses by age, sex, race, baseline bleeding status, baseline haemoglobin value, and prior ITP therapies were done for only the romiplostim group with ITP ≤ 12 months as there were only 34 subjects in the  placebo/SOC  group  and  its  subgroup  analysis  would  be  less  meaningful  due  to  smaller  numbers. Subgroup analysis was also not done for subjects with ITP &gt; 12 months. Safety data was not summarized by prior splenectomy due to insufficient data (25 of 277 subjects) for analysis in subjects with ITP ≤ 12 months.

## Subgroup Analyses by Age

Among subjects with ITP ≤ 12 months, the median age was higher for the romiplostim group compared with the placebo/SOC group (52 [18-93] years versus 47.5 [18-80] years) (Table 12).  The incidence of subjects reporting adverse events in the romiplostim group was lower for subjects aged &lt; 65 years compared with subjects aged ≥ 65 years (91.2% versus 96.4%). The duration-adjusted incidence event rate was also lower for  subjects  aged &lt; 65 years compared with subjects aged ≥ 65 years (762.5 versus 1089.9 events per 100 subject-years) (Table 45).

- -The adverse events (romiplostim versus placebo/SOC) with the highest subject incidence by PT in the romiplostim group (&gt; 15%) had a higher incidence in subjects aged &lt; 65 years compared with subjects aged ≥ 65 years for headache (29.4% versus 25.3%); whi le there was a lower incidence in subjects  aged  ≥  65  years  compared  with  subjects  aged  &lt;  65  years  for  fatigue  (18.6%  versus 22.9%) and nasopharyngitis (14.9% versus 21.7%).
- -Adjusted  for  duration,  the  adverse  events  with  the  highest  incidence  event  rates  (romiplostim versus placebo/SOC) (&gt; 15 number of adverse events per 100 subject-years in the romiplostim group) by PT in the romiplostim group, had a higher incidence event rate in subjects aged &lt; 65 years compared with subjects aged ≥ 65 years for headache (40.3 versus 35.5); while incidence event rate was lower in subjects aged &lt; 65 years compared with subjects aged ≥ 65 years for contusion (22.5 versus 31.8) and nasopharyngitis (16.4 versus 26.2)

Among subjects with ITP &gt; 12 months in the integrated analysis set, the median age was almost equal for the romiplostim and the placebo/SOC groups (54 years [range: 18-89] versus 54.5 years [range: 18-88]).

## Subgroup Analyses by Sex

Among subjects with ITP ≤ 12 months, there were more females compared with males in the romiplostim group  (53.4%  versus  46.6%),  while  subjects  were  equally  split  between  males  and  females  in  the placebo/SOC groups (50% versus 50%) (Table 12). The incidence of subjects reporting adverse events in the romiplostim group was higher for females compared with males (95.3% versus 89.9%); however, the duration-adjusted incidence event rate (per 100 subject-years) was lower for females compared with males (830.9 versus 880.7) (Table 45)

- -The adverse events (romiplostim versus placebo/SOC) with the highest subject incidence by PT in the romiplostim group (&gt; 15%) had a higher subject incidence in females compared with males for arthralgia (23.0% versus 16.3%), and nasopharyngitis (18.9% versus 14.7%); while there was a lower incidence in the females compared with males for fatigue (14.2% versus 26.4%).
- -Adjusted  for  duration,  the  adverse  events  (romiplostim  versus  placebo/SOC)  with  the  highest incidence event rates (&gt; 15 number of adverse events per 100 subject-years in the romiplostim group) by PT in the romiplostim group) had a higher incidence event rate in females compared with males for headache (41.7 versus 35.9), arthralgia (26.5 versus 15.1), epistaxis (21.1 versus 16.8), and nasopharyngitis (21.6versus 16.3 ); while there was a lower incidence in females compared with males for fatigue (16.7versus 32.5).

<div style=\"page-break-after: always\"></div>

Among subjects with ITP &gt; 12 months in the integrated analysis set, there were more females compared with males in both the romiplostim (64.2% versus 35.8%) and the placebo/SOC (68.5% versus 31.5%) groups (Table 12).

## Subgroup Analysis by Race

The  subjects  in  the  integrated  analysis  set  were  predominantly  white  in  the  romiplostim  and  the placebo/SOC groups for ITP ≤ 12 months (90.3% versus 94.1%), and ITP &gt; 12 months (87.9% versus 77.2%). Among sub jects with ITP ≤ 12 months, the incidence of subjects reporting adverse events in the romiplostim  group  was  lower  for  white  compared  with  non-white  (92.0%  versus  100%)  subjects.  The duration-adjusted incidence event rate (per 100 subject-years) was also lower for white compared with non-white (833.5 versus 1014.5) subjects (Table 45).

- -The adverse events (romiplostim versus placebo/SOC) with the highest subject incidence by PT in the romiplostim group (&gt; 15%) had a lower subject incidence in whites compared with non-white for fatigue  (19.2%  versus  25.9%),  epistaxis  (16.0%  versus  33.3%)  and  diarrhoea  (16.8%  versus 22.2%); while there was higher incidence in white compared with non-white for nasopharyngitis (17.2% versus 14.8%).
- -Adjusted  for  duration,  the  adverse  events  (romiplostim  versus  placebo/SOC)  with  the  highest incidence event rates (&gt; 15 number of adverse events per 100 subject-years in the romiplostim group) by PT in the romiplostim group had a lower incidence event rate in whites compared with non-white for headache (38.1 versus 45.9), contusion (24.2 versus 32.1), arthralgia (20.1 versus 29.8), and epistaxis (16.8 versus 36.7); while there was a higher incidence in white compared with non-white for petechiae (22.4 versus 16.1), and nasopharyngitis (19.5 versus 16.1).

Table 45. Summary of Subject Incidence and Duration Adjusted Event Rate of Treatment-emergent  Adverse  Events  by  Baseline  Age  (years)  Sex  and  Race  (Romiplostim Treated Subjects with ≤ 12 Months of ITP Duration)

|                                                                           | Romiplostim (N = 277) Baseline Age (years)   | Romiplostim (N = 277) Baseline Age (years)   |
|---------------------------------------------------------------------------|----------------------------------------------|----------------------------------------------|
|                                                                           | <65 (Sb]-yr=275.1) (N = 194) n()             | 265 (Sb]-yr=107.0) (N = 83) n()              |
| Number and percent of subjects reporting                                  | 177 (91.2%)                                  | 80 (96.4%)                                   |
| treatment-emergent adverse events                                         |                                              |                                              |
| Total number of treatment-emergent adverse evenis                         | 2098 (762.5)                                 | 1166 (1089.9)                                |
|                                                                           | Romiplostim (N = 277) Sex                    | Romiplostim (N = 277) Sex                    |
|                                                                           | Female                                       | Male (Sb)-yr=178.3) (N = 129) n(0)           |
|                                                                           | (Sb]-yr=203.9) (N = 148)                     |                                              |
| Number and percent of sublects reporting treatment-emergent adverseevents | n() 141 (95.3%)                              | 116 (89.9%)                                  |
| Total number of treatment-emergent adverse evenis                         | 1694 (830.9)                                 | 1570 (880.7)                                 |
|                                                                           | Romiplostim (N = 277) Race                   | Romiplostim (N = 277) Race                   |
|                                                                           | White                                        | Non-white                                    |
|                                                                           | (Sb]-yr=338.6)                               | (Sb)-yr=43.6) (N = 27)                       |
|                                                                           | (N = 250)                                    |                                              |
|                                                                           | n(0)                                         | n()                                          |
| Number andpercentof subjectsreporting treatment-emergent adverseevents    | 230 (92.0%)                                  | 27 (100.0%)                                  |
| Total number of treatment-emergent adverse events                         | 2822 (833.5)                                 | 442 (1014.5)                                 |

Adult subjects (age≥18 years at screening) whoreceived atleast one dose of investigational product in any of ITP studies(20030105,20030212,20030213(extension study),20040209,20060113(extension study), 20060131,20060216,20080009,and20080435)areincluded. Dataaftertreatmentswitchareexcluded. ITPdurationiscalculatedfrom theITPdiagnosistotheenrollmentoffirstITPstudy. Onlyadverseeventsstartingafterthefirstdoseofinvestigationalproductaretabulated. Coded using theMedDRA version 21.0. Sbj-yr=Total subject years onstudy. n=numberofevents.r=durationadjustedeventrateper100subject-years(n/Sbj-yr100).

<div style=\"page-break-after: always\"></div>

## Subgroup Analyses by Months Since ITP Diagnosis

Among subjects treated with romiplostim, the subject incidence of treatment-emergent adverse events was similar and event rate was lower in subjects with ITP ≤ 12 months compared with ITP &gt; 12 months (92.8% versus 94.2%; 854.2 versus 945.7) (Table 26).

- For subjects with ITP ≤ 12 months, the subject incidence and duration-adjusted incidence event rate of adverse events were lower in the romiplostim group compared with the placebo/SOC group in subjects with ITP ≤ 12 months (92.8% versus 97.1%; 854.2 versus 1038.0 events per 100 subject-years).

- For subjects with ITP &gt; 12 months, the incidence of subjects reporting adverse events was similar for the romiplostim  group  compared  with  the  placebo/SOC  group  (94.2%  versus  91.3%);  however,  the duration-adjusted  incidence  event  rate  (per  100 subject-years)  was  lower  for  the  romiplostim  group compared with the placebo/SOC group (945.7 versus 1109.9 events per 100 subject-years).

A summary of common treatmentemergent adverse events in subjects with ITP &lt; 3 months and &gt; 3 to ≤ 12 months is provided in Table 46.

Table  46.  Summary  of  subject  incidence  of  treatment-emergent  adverse  events-romiplostim group (subjects with ≤ 12 months of ITP duration)

|                                                      | Romlplostlm (N - 277) ITP Duratlon In Months   | Romlplostlm (N - 277) ITP Duratlon In Months   | Romlplostlm (N - 277) ITP Duratlon In Months   |
|------------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
|                                                      | 33 (N - 140)                                   | 2 3 to ≤ 12 (N - 137)                          | Total [N - 277]                                |
| All treatment-emergent adverse events - n (%6)       | 125 (89.3)                                     | 132 (96.4)                                     | 257 (92.8)                                     |
| Grades2                                              | 102 (72.9)                                     | 103 (75.2)                                     | 205 (74.0)                                     |
| Grade g3                                             | 50 (35.7)                                      | 53 (38.7)                                      | 103 (37.2)                                     |
| Grade 4                                              | 14 (10.0)                                      | 14 (10.2)                                      | 28 (10.1]                                      |
| Serlous adverse evenis                               | 40 (28.6)                                      | 44 (32.1)                                      | 84 (30.3)                                      |
| Leadng to dlscontinuallon of Investigatlonal product | 11 (7.9)                                       | 13 (9.5)                                       | 24 (8.7)                                       |
| Leadlng to dlscontinuation from study                | 9 (6.4)                                        | 13 (9.5)                                       | 22 (7.9)                                       |
| Falal adverse events                                 | 715.01                                         | 6(4.4)                                         | 13 (4.7)                                       |

|                                                              | Romlplostim (N - 277] ITPDuratlon InMonths   | Romlplostim (N - 277] ITPDuratlon InMonths   | Romlplostim (N - 277] ITPDuratlon InMonths   |
|--------------------------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
|                                                              | (N - 140)                                    | 2 3 to ≤ 12 (N - 137]                        | Total IN - 277]                              |
| Treatment-related treatment-emergent adverse events - n (%6) | 52 (37.1)                                    | 57 (41.6)                                    | 109 (39.4)                                   |
| Grades2                                                      | 21 (15.0)                                    | 29 (21.2)                                    | 50 (18.1)                                    |
| Grade3                                                       | 6 [4.3)                                      | 11 (8.0)                                     | 17 (6.1)                                     |
| Grade4                                                       | D (0.0)                                      | 0 (0.0)                                      | D(0.0)                                       |
| Serlous adverse events                                       | 5 (3.6)                                      | 10 (7.3)                                     | 15 (5.4)                                     |
| Leadng to dlsoontinuatlon ot Investigatlonal product         | 0 (0.0)                                      | 6 [4.4]                                      | 6 (2.2)                                      |
| Leading to discontinuation from study                        | D (0.0)                                      | 6(4.4)                                       | 6(2.2)                                       |
| Fatal adverse events                                         | 0 (0.0)                                      | 0(0.0)                                       | 0 (0.0)                                      |

## Subgroup Analyses by Bleeding Status

Overall, among 277 romiplostimtreated subjects with ITP ≤ 12 months in the integrated analysis set, 133 subjects had bleeding at baseline ( ≈50%). The incidence of subjects reporting adverse events was higher for subjects with bleeding at baseline compared with subjects with no bleeding at baseline (96.2% versus 89.6%). The duration-adjusted incidence event rate (per 100 subject-years in the romiplostim group) was

<div style=\"page-break-after: always\"></div>

also higher for subjects with bleeding at baseline compared with subjects with no bleeding at baseline (1074.4 versus 659.5) (Table 47).

- -Most adverse events (romiplostim versus placebo/SOC) with the highest subject incidence by PT in the romiplostim group (&gt; 15%) had a higher subject incidence in subjects bleeding at baseline compared  with  subjects  not  bleeding  at  baseline  for  headache  (30.8%  versus  25.7%),  fatigue (27.1% versus 13.2%), epistaxis (24.8% versus 11.1%), diarrhoea (22.6% versus 12.5%), upper respiratory  tract  infection  (20.3%  versus  13.2%)  contusion  (17.3%  versus  13.2%),  and thrombocytopenia (12.8% versus 6.9%).
- -Most  adverse  events  (romiplostim  versus  placebo/SOC)  with  the  highest  duration-adjusted incidence  event  rate  (&gt;  15  number  of  adverse  events  per  100  subject-years)  by  PT  in  the romiplostim group had a higher event rate in subjects bleeding at baseline compared with subjects not bleeding at baseline for headache (43.0 versus 35.5), contusion (32.9 versus 18.2), fatigue (31.2 versus 17.7), petechiae (24.5 versus 19.2), epistaxis (30.1 versus 9.4), cough (24.0 versus 13.8), and upper respiratory tract infection (22.3 versus 15.3).

The incidence of subjects reporting events from the haemorrhages SMQ was similar for the romiplostim group compared with the placebo/SOC group (50.5% [140/277 subjects] versus 52.9% [18/34 subjects]). The  corresponding  duration-adjusted  incidence  rate  (per  100 subject-years)  was  lower  for  romiplostim group compared with the placebo/SOC group (129.5 [495 events] versus 191.7 [70 events]) (Table 42).

## Subgroup Analyses by Baseline Hemoglobin

Among romiplostim-treated subjects with ITP ≤ 12 months, the incidence of subjects reporting adverse events was similar for subjects with baseline hemoglobin value of 8 to &lt; 12 g/dL compared with subjects with baseline hemoglobin value of 12 to &lt; 18 g/dL (95.2% versus 92.5%).  The duration-adjusted incidence event  rate  (per  100  subject-years  in  the  romiplostim  group)  was  higher  for  subjects  with  baseline hemoglobin  value  of  8  to &lt; 12 g/dL  compared  with  subjects  with  baseline  hemoglobin  value  of  12  to &lt; 18 g/dL (1181.4 versus 793.8 events per 100 subject-years) (Table 47).

- -The adverse events (romiplostim versus placebo/SOC) with the highest subject incidence by PT in the romiplostim group (&gt; 15%) had a lower subject incidence in subjects with baseline hemoglobin value of 8 to &lt; 12 g/dL compared with 12 to &lt; 18 g/dL for headache (27.0% versus 28.8%), arthralgia  (15.9%  versus  21.1%),  fatigue  (11.1%  versus  22.5%),  and  nasopharyngitis  (11.1% versus 18.8%).
- -Adjusted  for  duration,  the  adverse  events  (romiplostim  versus  placebo/SOC)  with  the  highest incidence  event  rates  (&gt;  15  number  of  adverse  events  per  100  subject-years)  by  PT  in  the romiplostim group had a lower incidence event rate in subjects with baseline hemoglobin value of 8 to &lt; 12 g/dL compared with 12 to &lt; 18 g/dL for contusion (21.0 versus 26.0), fatigue (21.0 versus 24.8), and nasopharyngitis (14.5 versus 20.1); while those with a higher incidence event rate were arthralgia  (24.2  versus  20.7),  epistaxis  (29.1  versus  17.2),  cough  (24.2  versus  17.5),  upper respiratory tract infection (25.9 versus 17.2), diarrhoea (30.7 versus 15.7), nausea (22.6 versus 15.7), and thrombocytopenia (40.4 versus 10.2).

## Subgroup Analyses by Prior ITP Therapy

Among romiplostim-treated subjects with ITP ≤ 12 months in the integrated analysis set, the incidence of subjects reporting adverse events and the duration-adjusted incidence event rate (per 100 subject-years in the  romiplostim  group)  were  lower  for  subjects  who  received &lt; 3  prior  ITP  treatments  compared  with subjects  who  received ≥ 3  prior  ITP  treatments  (91.7%  versus  95.1%;  716.1 versus  933.9 events  per subject-years) (Table 47).

<div style=\"page-break-after: always\"></div>

Table 47. Summary of Subject Incidence and Duration-Adjusted Event Rate of Treatment-emergent Adverse Events by Baseline Bleeding Status, Baseline Hemoglobin Value, and Number of Prior ITP Treatment (Romiplostim-Treated Subjects with ≤ 12 Months of ITP Duration)

|                                                                            | Romiplostim (N = 277) Baseline Bleeding Slalus      | Romiplostim (N = 277) Baseline Bleeding Slalus      |
|----------------------------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                                                                            | Yes (Sbj-yr=179.3) (N= 133) n (n)                   | No (Sbj-yr=202.9) (N= 144) n (0)                    |
| Number and percent of subjecls reporling trealment-emergent adverse evenls | 128 (96.2%)                                         | 129 (89.6%)                                         |
| Tolal number of treatment-emergent adverse evenls                          | 1926 (1074.4)                                       | 1338 (659.5)                                        |
|                                                                            | Romiplostim (N = 277) Baseline hemoglobin value     | Romiplostim (N = 277) Baseline hemoglobin value     |
|                                                                            | 8 to ≤ 12 g/dL (Sbj-yr=61.9) (N = 63) n (n)         | 12 to ≤ 18 g/dL (Sbj-yr=319.1) (N= 213) n(m)        |
| Number and percent of subjecls reporting trealmenl-emergent adverse evenls | 60 (95.2%)                                          | 197 (92.5%)                                         |
| Tolal number of treatment-emergent adverse evenls                          | 731 (1181.4)                                        | 2533 (793.8)                                        |
|                                                                            | Romiplostim (N = 277) Number of Prior ITP Trealment | Romiplostim (N = 277) Number of Prior ITP Trealment |
|                                                                            | 33 (Sbj-yr=233.3) (N= 144) n (n)                    | 23 (Sbj-yr=74.1) (N= 41) n ()                       |
| Number and percent of subjecls reporting trealment-emergent adverse evenls | 132 (91.7%)                                         | 39 (95.1%)                                          |
| Total number of treatment-emergent adverse evenls                          | 1671 (716.1)                                        | 692 (933.9)                                         |

Adult sublects (age ≥ 18 years at screening) who recelived at least one dose of invesllgational product in any of ITP studles (20030105, 20030212, 20030213 (extenslon study), 20040209, 20060113 (extenslon study). 20060131, 20060216, 20080009, and 20080435) are incuded.

Data after treatment switch are excluded.

ITP duratlon is calculated from the ITP diagnosis to the enrollment of flrst ITP study.

Coded uslng the MedDRA werslon 21.0.

Only adverse events starting after the first dose of Investigatlonal product are tabulated.

Sbj-yr = Total subject years on study.

Study 20040209 dld not collect prior ITP Therapy.

n = number of events. r = duration adjusted event rate per 100 subject-years (n/Sbj-yr*100).

Source: Modlfied from ISS Table 14-6.1.5.6, ISS Table 14-6.1.5.7, 1SS Table 14-6.1.5.8.

## Use in Pregnancy and Lactation

The safety and efficacy of romiplostim in pregnant women has not been established.

## Antibody formation

Among subjects with ITP ≤ 12 months in the integrated analysis set (Table 43):

- the incidence of non-neutralizing binding antibody positive to romiplostim at any time during romiplostim treatment was 5.5% (15/272 subjects with an on-study antibody result). Of the 15 subjects, 7 subjects had pre-existing positive result at or before baseline and 8 subjects developed a post-baseline positive result.
- The incidence of neutralizing antibody positive to romiplostim at any time during romiplostim treatment was  0.7%  (2/272  subjects  with  an  on-study  antibody  result).  No  subjects  were  positive  at  or  before baseline. Both subjects developed a post-baseline positive persistent (at last time point tested) antibody result.

<div style=\"page-break-after: always\"></div>

-  The  incidence  of  non-neutralizing  binding  antibody  positive  to  TPO  at  any  time  during  romiplostim treatment was 5.6% (15/270 subjects with an on-study antibody result). Of the 15 subjects, 6 subjects had pre-existing binding non-neutralizing antibodies to TPO at or before baseline and 9 subjects developed a post-baseline positive result. No subjects were neutralizing antibody positive to TPO at any time during romiplostim treatment.

Table 43. Summary of immunogenicity in subjects with ITP ≤ 12 months and subjects with ITP &gt; 12 Months

<!-- image -->

| Antibodyresult                                            | ITP≤12 months (Romiplostim N = 277 or 270[TPO]or272 [romiplostim]withon-study result) n (%) [number of subjects with a positive result post-baseline]   | ITP >12 months (Romiplostim N =634 or 612[TPO] or 615 [romiplostim] with on-studyresult) n (%) [numberofsubjectswitha positiveresult post-baseline]   | Source                                  |
|-----------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| non-neutralizing binding antibody positive to romiplostim | 15 (5.5) [8]                                                                                                                                            | 51 (8.3) [27]                                                                                                                                         | ISS Table 14-10.1.1 ISSTable 14-10.1.3  |
| neutralizing antibody positive to romiplostim             | 2 (0.7) [2]                                                                                                                                             | 1 (0.2) [0]                                                                                                                                           | ISS Table 14-10.1.1 ISS Table 14-10.1.3 |
| non-neutralizing binding antibody positive to TPO         | 15 (5.6) [6]                                                                                                                                            | 34 (5.6) [18]                                                                                                                                         | ISS Table 14-10.2.1 ISSTable 14-10.2.3  |
| neutralizing antibodypositiveto TPO                       | 0 [0]                                                                                                                                                   | 1 (0.2) [0]                                                                                                                                           | ISS Table 14-10.2.1 ISS Table 14-10.2.3 |

ITP =immune thrombocytopenia;n=numberof subjectspositiveto TPO orromiplostim atanytimepoint; TPO= thrombopoietin

percentageswerecalculatedwiththenumberofsubjectswithanon-studyantibodyresultasthe denominator.

## Safety related to drug-drug interactions and other interactions

The potential effects of drug interactions on the activity of romiplostim were not evaluated in the adult population. No formal drug-drug interaction studies of romiplostim have been performed.

A total of 4 out of 277 subjects (1.4%, 5.46 adverse events per 100 subject-years) exposed to romiplostim concurrently received rituximab and/or alkylating agents in the ITP ≤ 12 months integrated analysis set.; while    total  of  6  out  of  634  subjects  (0.9%,  7.14  adverse  events  per  100  subject-years)  exposed  to romiplostim concurrently received rituximab and/or alkylating agents in the ITP &gt; 12 months integrated analysis set.

The potential interactions of romiplostim with co-administered medicinal products due to binding to plasma proteins remain unknown. Medicinal products used in the treatment of ITP in combination with romiplostim in clinical studies included corticosteroids, danazol, and/or azathioprine, intravenous immunoglobulin, and anti-D  immunoglobulin.  Platelet  counts  should  be  monitored  when  combining  romiplostim  with  other medicinal products for the treatment of ITP in order to avoid platelet counts outside of the recommended range.

<div style=\"page-break-after: always\"></div>

## Withdrawal and Rebound

Withdrawal and/or rebound has not been specifically evaluated in a romiplostim study.  Subjects reporting reoccurrence of thrombocytopenia after cessation of romiplostim were identified using the laboratory values and haematopoietic thrombocytopenia SMQ (broad search) after cessation of romiplostim.

Among subjects with ITP ≤ 12 months in the integrated analysis set, 14 of 277 romiplostim-treated subjects (5.1%; 95% CI:  2.8, 8.3) had a preferred term reported from the haematopoietic thrombocytopenia (SMQ) broad  search  after  cessation  of  romiplostim,  compared  with  24  of  634  romiplostim-treated  subjects (3.8%; 95% CI:  2.4, 5.6) with ITP &gt; 12 months.

- -For subjects with ITP ≤ 12 months in the integrated analysis set, based on laboratory values, there were 131 of 277 subjects (47.3%) who had a platelet count of &lt; 150 x 10 9 /L after cessation of romiplostim. Forty-three of these 131 subjects (32.8%) had a platelet count less than their baseline value; while thirty-two of these 43 subjects (24.4%, 32 of 131 subjects) had grade 3 or grade 4 platelet counts after cessation of romiplostim.
- -For subjects with ITP &gt; 12 months, there were 456 of 634 subjects (71.9%) who had a platelet count of  &lt;  150  x  109/L  after  cessation  of  romiplostim.  One  hundred  forty-five  of  these  456  subjects (31.8%) had a platelet count less than their baseline. Ninety of these 145 subjects who had a platelet count (19.7%, 90 of 456 subjects) had grade 3 or grade 4 platelet counts after cessation of romiplostim.

## Discontinuation due to adverse events

The subject incidence and duration-adjusted event rate (per 100 subject-years) of adverse events leading to discontinuation were similar in subjects with ITP ≤ 12 months and ITP &gt; 12 months (8.7% versus 8.4%; 7.3 versus 6.0). The duration-adjusted event rate (per 100 subject-years) was lower in the romiplostim group compared with the placebo/SOC group in subjects with ITP ≤ 12 months, while it is higher in subjects with ITP &gt; 12 months (Table 49 summary clinical safety).

- -For subjects with ITP ≤ 12 months, the subject incidence was similar for the romiplostim group and the  placebo/SOC  group  (8.7%  [24/277  subjects]  versus  5.9%  [2/34  subjects]),  6  of  the  24 romiplostim treated subjects discontinued investigational product due to treatment related adverse events.  The duration-adjusted incidence event rate was lower for the romiplostim group compared with the placebo/SOC group (7.3 events per 100 subject-years [28 events] versus 13.7 events per 100 subject-years [5 events]).  Nine of the 28 events in the romiplostim treated subjects that led to discontinuation of investigational product were reported by the investigator to be treatment related .
- -For subjects with ITP &gt; 12, the subject incidence was higher for the romiplostim group compared with the placebo/SOC group (8.4% [53/634 subjects] versus 2.2% [2/92 subjects]); 27 of the 53 romiplostim treated subjects discontinued investigational product due to treatment-related adverse events.  The duration-adjusted incidence event rate was also higher for the romiplostim group compared  with  the  placebo/SOC  group  (6.0 events  per  100  subject-years  [66  events]  versus 2.8 events  per  100  subject-years  [2  events]);  39  of  the  66  events  in  the  romiplostim-treated subjects that led to discontinuation of investigational product were serious.

## Treatment-related Adverse Events Leading to Discontinuation of Investigational Product

Among subjects treated with romiplostim, the subject incidence and event rate (per 100 subject-years) of treatment-related  adverse  events  leading  to  discontinuation  of  investigational  product  were  similar  in subjects with ITP ≤ 12 months compared with ITP &gt; 12 months (2.2% versus 4.3%; 2.4 versus 2.5).

<div style=\"page-break-after: always\"></div>

## Discontinuation from study

The  subject  incidence  and  the  event  rate  (per  100  subject-years)  of  adverse  events  leading  to discontinuation of subject from study were similar in ITP ≤ 12 months and ITP &gt; 12 months groups (7.9% versus 6.9%; 5.8 subject-years versus 4.1 subject years) (Table 54 summary clinical safety). The PTs with highest subject incidence (≥ 0.5%) and/or highest event rate (≥ 0.5 adverse events per 100 subject -years) which led to discontinuation from study were reported by subjects from the romiplostim group only in subjects with ITP ≤ 12 months and ITP &gt; 12 months .

## Treatment-related Adverse Events Leading to Discontinuation from Study

Subjects  from  only  the  romiplostim  group  reported  treatment-related  adverse  events  which  led  to discontinuation from study in both ITP ≤ 12 months and ITP &gt; 12 months groups. Among s ubjects treated with  romiplostim,  the  subject  incidence  and  event  rate  (per  100  subject-years)  were  similar  between subjects with ITP ≤ 12 months and subjects with ITP &gt; 12 months (2.2% versus 4.1%; 1.6 versus 2.4).

## Adverse Drug Reactions

Adverse drug reac tions (ADRs) for romiplostim in subjects with ≤ 12 months ITP duration are presented in Table 48.  The MAH applied a numerical algorithm to the ≤ 12 months ITP duration analysis set and the &gt; 12 months duration analysis set (at least 5% subject incidence in the romiplostim group and at least 5% higher subject incidence in the romiplostim group compared to placebo/SOC). Preferred terms present in both of these analysis sets were then compared to the existing ADRs from the pivotal adult ITP studies which supported the initial approval of romiplostim and selected if they were an existing ADR in this dataset (preferred terms of Arthralgia, Myalgia, Headache, and Dizziness). If the numerical criteria were only met in the ≤ 12 months ITP duration analysis set, the n those preferred terms were also selected as ADRs (preferred terms of Post marketing experience Bronchitis, Sinusitis, and Vomiting; although in the SmPC, vomiting is also  noted  as  an  ADR  for  adult  ITP).    In  addition,  due  to  biological  plausibility,  the  preferred  term  of thrombocytosis was selected as an ADR, even although it did not meet the numerical algorithm thresholds (with a subject incidence in the ≤ 12 months ITP duration analysis set of 1.8% in the romiplostim group versus 0.0% in the placebo/SOC group (Table 48).

Table 48. Adverse Drug Reactions

| MedDRA. System Organ Class                     | AdverseReactions (Preferred term [PT])   | Placebo/SOC N= 34   | Romiplostim N=277   |
|------------------------------------------------|------------------------------------------|---------------------|---------------------|
| Infectionsand                                  | Bronchitis Sinusitis                     | 0.0%                | 8.39                |
| Infestations                                   |                                          | 0.0%6               | 5.4%                |
| Gastrointestinal Disorders                     | Vomiting                                 | 960'0               | 7.296               |
| Musculoskeletaland Connective Tissue Disorders | Arthralgia                               | 11.8%               | 19.996              |
|                                                | Myalgia                                  | 2.996               | 7.996               |
| Nervous System                                 | Headache                                 | 20.6%               | 28.2%               |
| Disorders                                      | Dizziness                                | 2.9%                | 11.696              |
| Blood andlymphatic system disorders            | Thrombocytosis                           | 0.0%                | 1.8%                |

Soc=StandardofCare

Codedusingthe MedDRA version 21.0.

<div style=\"page-break-after: always\"></div>

## 2.5.1. Discussion on clinical safety

To support the safety of romiplostim in patients with ITP ≤ 12 months, the MAH also relied on data derived from  the  integrated  analysis  where  safety  was  evaluated  in  311  subjects  (277  romiplostim,  34 placebo/standard of care [SOC]) with ITP ≤ 12 months across 7 parent clinical studies and 2 extension studies previously assessed (Figure 8). The integrated analysis set included all adult subjects aged ≥ 18 years who received at least 1 dose of investigational product in the integrated dataset. Subject disposition was the same as previously stated  in  efficacy  assessment  (refer  to  Table  24).  There  were  no  notable differences between the two subgroups in terms of baseline and demographic characteristics, except from female percentage which was a slight superior for subjects with ITP with &gt; 12 months (64,2% vs 53,4%). When  compared  the  exposure  to  romiplostim  between  subgroups,  it  was  lower  for  patients  with  ITP for ≤ 12 months than for patients with ITP &gt; 12 months (median total duration of the treatment of 51.86 weeks versus 70.93 weeks, median average weekly dose of 3.03 μ g/kg/week versus 3.59 μ g/kg/week). The MAH argues that the difference in treatment duration result from different distribution of subjects among studies which had different treatment duration.

With respect to safety assessment, the MAH has carried out a comparison between subjects with ITP ≤ 12 months and ITP &gt; 12 months regarding different safety variables. When compared subject incidence and duration-adjusted incidence event rates (per 100 subject-years) between treatment groups, anything &lt; 3% subject incidence or &lt; 3 adverse events per 100 subject-years was considered to be similar. In addition, subgroup analyses were conducted for subjects who had ITP duration of &lt; 3 months, ≥ 3 to ≤ 12 months, and &gt; 12 months.

## Results

Data from different safety variables in the integrated analysis showed no meaningful differences in the safety profile of romiplostim in subjects with ITP ≤ 12 months when compared to subjects with ITP &gt; 12.

Analysis  of  treatment-emergent  adverse  events,  showed  a  slight  reduced  subject  incidence  and duration-adjusted  incidence  event  rate  (per  100 subject-years)  for  romiplostim  group  in  subjects  with ITP ≤ 12  moths  (92.8%,  854.2)  when  compared  with  subjects  with  ITP  &gt; 12  months  (94.2%,  945.7). Adverse  events  with  highest  subject  incidence  ( &gt; 15%)  and/or  duration-adjusted  incidence  event ( &gt; 15 events per 100 subject-years) and with higher subject incidence and/or event rate in the romiplostim group vs. placebo/SOC group were similar across all ITP subgroups ( &lt; 3 months, ≥ 3 to ≤ 12 months and &gt; 12 months).    In  subjects  with  ITP ≤ 12 months  these  were  headache,  arthralgia,  diarrhoea,  upper respiratory tract infection, cough, contusion, nausea, and thrombocytopenia.  Similarly, in subjects with ITP &gt; 12 months, adverse events of headache, nasopharyngitis, arthralgia, epistaxis, nausea, diarrhoea, pain in extremity, back pain, cough, upper respiratory tract infection, and thrombocytopenia all occurred at higher subject incidence in the romiplostim group compared with the placebo/SOC group.

Meanwhile, treatment- related adverse events showed a slight increased subject incidence (39.4%  vs. 32.4%) (50.9% vs. 37.0%) and a lower duration-adjusted incidence event rate (per 100 subject-years) (85.3 vs. 134.2); (102.0 vs 146.9) for the romiplostim group compared with the placebo/SOC group, for both subgroups (ITP ≤ 12 months and ITP &gt; 12 months), respectively. Both, headache and arthralgia had the highest subject incidence ( &gt; 3%) of treatment-related adverse events (by PT) in the romiplostim group compared with the placebo/SOC group in both ITP duration groups. Adverse events with higher incidence evet rate (headache, arthralgia, nausea, myalgia, fatigue) were similar between different subgroups (&lt; 3 months, ≥ 3 to ≤ 12 months and &gt; 12 months).

Among subjects treated with romiplostim, the subject incidence and duration-adjusted incidence event rate (per 100 subject-years) of grade ≥ 4 adverse events were lower in subjects with ITP ≤ 12 months compared with subjects with ITP &gt; 12 months (10.1% vs. 13.4%; 11.0 events per subject-years vs. 14.8 events per subject-years).  The  adverse  events  by  preferred  term  with  highest  event  rate  ( ≥ 0.5 events  per  100

<div style=\"page-break-after: always\"></div>

subject-years)  (thrombocytopenia,  immune  thrombocytopenic  purpura,  among  others)  were  similar between both subgroups, and were mostly reported by subjects from the romiplostim group. Meanwhile treatment-related adverse events of grade ≥ 4 were only reported by subjects with ITP &gt; 12 months.

Similarly, the same trend was observed for adverse events of grade ≥ 3. For grade ≥ 3 treatment -related adverse events, both subject incidence and duration-adjusted incidence event rate were lower in patients with ITP ≤ 12 months than in patients with ITP &gt; 12 months.

Serious adverse events reported among subjects treated with romiplostim, were also lower for subjects with ITP ≤ 12 months  when  compared  with  ITP &gt; 12 months  (30.3%  vs.  34.2%;  51.0 events  per  100 subject-years vs. 56.4 events per 100 subject-years). When related-serious adverse events were analyzed, the subject incidence was similar between ITP ≤ 12 months and ITP &gt; 12 months (5.4% vs. 7.3%), while event rate was lower in ITP ≤ 12 months compared with the ITP &gt; 12 months subgroup (4.2 events per 100 subject-years vs. 7.4 events per 100 subject-years) among subjects treated with romiplostim. Of these, fatal events were only reported in subjects with ITP &gt; 12 months subgroup.

Data about overall deaths showed similarity among subjects treated with romiplostim, in subjects with ITP ≤ 12 months and ITP &gt; 12 months (4.7% vs. 4.1%; 3.4 events per 100 subject-years vs. 2.4 events per 100 subject-years). Nevertheless, no related-treatment deaths were reported in subjects with ITP ≤ 12 months.

If focus in adverse events of especial interest of romiplostim (thrombotic events, increased bone marrow reticulin, or progression of existing myelodysplastic syndrome, among others), no notable differences were observed between the two subgroups, since all of them showed similar or lower subject incidence and duration-adjusted rate in patients with ITP ≤ 12 months (refer to Table 40). In both subgroups, the adverse events of special interest with the high subject incidence were pulmonary disorders, haemorrhages and hypersensitivity and/or angioedema and/or anaphylactic reactions and/or anaphylactic-anaphylactoid shock conditions, showing the three of them, similar or lower values of subject incidence and duration-adjusted incidence  rate  in  patients  with  ITP ≤ 12 months.  Specifically,  with  respect  to  haemorrhages,  subject incidence  and  corresponding  duration  adjusted  rate  were  lower  in  subjects  with  ITP ≤  12 months consistently in, the overall population, in subjects with consistently low platelet counts and in subjects with variable platelet counts.

It is known that thrombocytopenia is likely to reoccur upon discontinuation of treatment with romiplostim. Data from the integrated analysis showed that, in subjects with ITP ≤ 12 months, 5.1% of subjects had a preferred term reported from the haematopoietic thrombocytopenia (SMQ) broad search after cessation of romiplostim while in subjects with ITP &gt; 12 months, it was 3.8%.

The administration of romiplostim to adult subjects with ITP ≤ 12 months resulted in 2.9% (8/272) of the subjects  developing  binding  antibodies  to  romiplostim  and  0.7%  (2/272)  of  the  subjects  developed neutralising antibodies to romiplostim. No neutralising antibodies to TPO were detected in the subject dosed with romiplostim, including the 2 subjects that were positive for neutralizing antibodies to romiplostim.

The subject incidence and duration-adjusted event rate of adverse events leading to discontinuation of both investigational product and study, were similar in subjects with ITP ≤ 12 months and ITP &gt; 12 months, and no notable differences were observed with respect to serum chemistry and hematological parameters.

In addition, the MAH has explored different subgroups only for the romiplostim group with ITP ≤ 12 months. Incidence of subjects reporting adverse events in the romiplostim group was lower for subjects aged &lt; 65 years compared with subjects aged ≥ 65 years (91.2% versus 96.4%), for white subjects compared with non-white (92.0% versus 100%) and for subjects who received &lt; 3 prior ITP treatments compared with subjects who received ≥ 3 prior ITP treatments (91.7% versus 95.1%). Subject incidence of adverse events was similar regardless baseline hemoglobin and was higher for subjects with bleeding at baseline compared with subjects with no bleeding at baseline (96.2% versus 89.6%). Among subjects with ITP ≤ 12 months,

<div style=\"page-break-after: always\"></div>

there were more females compared with males in the romiplostim group (53.4% versus 46.6%).The incidence of subjects reporting adverse events in the romiplostim group was higher for females compared with males (95.3% versus 89.9%); while the duration-adjusted incidence event rate (per 100 subject-years) was lower for females compared with males (830.9 versus 880.7 events per subject-years).

When subgroups regarding time for diagnosis were explored (&lt; 3 months, (N=140), ≥ 3 to ≤ 12 months (N=137), no significant differences were observed between them in terms of safety (see Table 46).

No formal drug-drug interaction studies of romiplostim have been performed.

In summary, data from different safety variables explored in the integrated analysis showed no meaningful differences in the safety profile of romiplostim in subjects with ITP ≤ 12 months when compared to subjects with ITP &gt; 12. It is worth mentioned that a notable number of variables showed lower values for subjects with ITP ≤ 12 months with respect to subjects with ITP &gt; 12; nevertheless, these differences were small and since it is an integrated analysis, no robust conclusion can be drawn.

## 2.5.2. Conclusions on clinical safety

To support the safety of romiplostim in patients with ITP ≤ 12 months, the MAH has provided an integrated analysis where safety was evaluated in 311 subjects (277 romiplostim, 34 placebo/standard of care [SOC]) with ITP ≤ 12 months across 9 clinical trials previously assessed (Figure 8), and has carried out a comparison between subj ects with ITP ≤ 12 months and ITP &gt; 12 months regarding different safety variables. Data derived from the integrated analysis showed similarity in romiplostim safety profile between subjects with ITP ≤ 12 months and subjects with ITP &gt; 12 months. Although a notable number of variables showed lower values in subject incidence and/or adjustedevent rate for subjects with ITP ≤ 12 months with respect to subjects with ITP &gt; 12 months; these differences were small and since it is an integrated analysis, no robust conclusion can be drawn about this aspect.

When subgroups regarding time for diagnosis were explored (&lt; 3 months, (N=140), ≥ 3 to ≤ 12 months (N=137), no significant differences were observed between them in terms of safety.

Although it does not seem that safety profile of romiplostim presents new or increased safety risks in patients with ITP ≤ 12 months with respect to subjects with chronic ITP, in Rapporteur´s opinion, as stated previously  in  efficacy  assessment,  providing  information  of  only  277  patients  in  a  context  of  10-year post-marketing experience was considered limited during the initial assessment of the dossier. In response to the CHMP RSI, the MAH has provided safety data of romiplostim use off-label during clinical practice in newlydiagnosed/persistent  ITP  patients  ≤  12  months  refractory  to  other  treatments .  Although  robust evidence that can be drawn from routine clinical settings is limited, and that, consequently, interpretation of data should be done with caution, no new safety signals were observed in newly and persistent ITP in line in line with what was previously observed in clinical trials.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

<div style=\"page-break-after: always\"></div>

The PRAC considered that the risk management plan version 20.1 is acceptable.

The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 20.1 with the following content:

## Safety concerns

| Important identified risks   | Reoccurrence of thrombocytopenia after cessation of romiplostim Increased bone marrow reticulin Thrombocytosis Risk of bleeding in ITP patients who have consistently low platelet counts Risk of bleeding during the period of low platelet counts in patients with variable platelet counts Progression of existing MDS a,b Thrombotic/thromboembolic complications   |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks    | Neutralizing antibodies that cross-react with eTPO Bone marrow fibrosis                                                                                                                                                                                                                                                                                                 |
| Missing information          | Concurrent leukocytosis and anemia Renal impairment Use in pregnant or breastfeeding women Use in patients with renal, hepatic, cardiac, or pulmonary impairment Use in patients with bone marrow stem cell disorder and/or any active malignancy Use in patients concurrently receiving rituximab or alkylating agents                                                 |

## Pharmacovigilance plan

| Study Status                                                                                                                                                                  | Summary of Objectives                                                                                                                                                                                      | Safety Concerns Addressed                                                                                                                           | Milestones                                                    | Due Dates                                                                                                 |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| Category 3 - Required additional pharmacovigilance activities                                                                                                                 | Category 3 - Required additional pharmacovigilance activities                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                       | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities                                             |
| Study 20070797 Prospective observational registry postmarketing surveillance study Population based prospective annual assessment of safety of romiplostim treatment in adult | Estimate the incidence rate of increased bone marrow (BM) reticulin and/or BM fibrosis with associated clinical signs 1, confirmed by BM biopsy findings in adults with chronic ITP receiving romiplostim. | • Reoccurrence of thrombocytope nia after cessation of romiplostim • increased bone marrow reticulin • thrombocytosis • progression of existing MDS | Annual update Final report                                    | Progress reports on enrolment and intermediate analysis results will be provided yearly. Anticipated 2021 |

<div style=\"page-break-after: always\"></div>

| patients with chronic idiopathic (immune) thrombocytopenic purpura (ITP) based on national health registry systems in Denmark, Sweden, and Norway Ongoing   | • thrombotic/ thromboemboli c complications • bone marrow fibrosis • concurrent leukocytosis and anemia • renal impairment   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|

## Risk minimisation measures

| Safety Concern                                                  | Risk Minimization Measures                                                                                                                                                                                                                                                                                                                         |
|-----------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks                                      |                                                                                                                                                                                                                                                                                                                                                    |
| Reoccurrence of thrombocytopenia after cessation of romiplostim | Routine risk minimization measures: • SmPC Section 4.2, where recommendation for clinical evaluation is given • SmPC Section 4.4, where treatment recommendation and monitoring is provided • SmPC Section 4.8 • PL Section 2 • PL Section 3 • PL Section 4 • Legal status: Restricted medical prescription Additional risk minimization measures: |
| Increased bone marrow reticulin                                 | • None Routine risk minimization measures: • SmPC Section 4.4, where recommendation for examination of blood smear, CBC and bone marrow biopsy is provided • SmPC Section 4.8 • SmPC Section 5.3 • PL Section 2 • PL Section 4 • Legal status: Restricted medical prescription Additional risk minimization measures: • None                       |
| Thrombocytosis                                                  | Routine risk minimization measures: • SmPC Section 4.2 • SmPC Section 4.4, where recommendation to monitor                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| Risk of bleeding in ITP patients who have consistently low platelet counts                          | platelet counts is given • SmPC Section 4.5 • SmPC Section 4.8 • SmPC Section 4.9 • PL Section 3 • PL Section 4 • Legal status: Restricted medical prescription Additional risk minimization measures: • None Routine risk minimization measures: • SmPC Section 4.2 • SmPC Section 4.4, where recommendation to monitor platelet counts is given • SmPC Section 4.8 • SmPC Section 5.1 • PL Section 3 • PL Section 4 • Legal status: Restricted medical prescription Additional risk minimization measures:   |
|-----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Risk of bleeding during the period of low platelet counts in patients with variable platelet counts | Routine risk minimization measures: • SmPC Section 4.2 • SmPC Section 4.4, where recommendation to monitor platelet counts is given • SmPC Section 4.8 • SmPC Section 5.1 • PL Section 3                                                                                                                                                                                                                                                                                                                       |
| Progression of existing MDS                                                                         | Additional risk minimization measures: • None Routine risk minimization measures: • SmPC Section 4.4 • SmPC Section 4.8 • PL Section 2 • Legal status: Restricted medical prescription Additional risk minimization measures: • None                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Thrombotic/ thromboembolic complications               | Routine risk minimization measures: • SmPC Section 4.2 • SmPC Section 4.4, where recommendation to monitor platelet counts is given • SmPC Section 4.8 • SmPC Section 4.9 • PL Section 3 • PL Section 4 • Legal status: Restricted medical prescription Additional risk minimization measures: • None                                                                                                                                                               |
|--------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Romiplostim medication errors (dosing/ administration) | Routine risk minimization measures: • SmPC Section 4.2, where detailed dosing instructions are provided • SmPC Section 4.4, where recommendation to monitor platelet counts is given • SmPC Section 4.8 • SmPC Section 4.9, where recommendation to monitor platelet counts is given • SmPC Section 6.5 • SmPC Section 6.6 • PL Section 3 • PL Section 6 • Legal status: Restricted medical prescription Additional risk minimization measures: • Dosing calculator |
| Hypersensitvity reactions                              | • SmPC Section 4.3 • SmPC Section 4.8 • PL Section 2 • PL Section 4 • Legal status: Restricted medical prescription Additional risk minimization measures:                                                                                                                                                                                                                                                                                                          |
| Important Potential Risks                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Neutralizing antibodies that cross-react with eTPO     | Routine risk minimization measures: • SmPC Section 4.2 • SmPC Section 4.4 • SmPC Section 4.8, where recommendation for antibody testing is given                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                                                                       | • SmPC Section 5.3 • Legal status: Restricted medical prescription Additional risk minimization measures: • None                                                                                                                                                                                               |
|-----------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Bone marrow fibrosis                                                  | Routine risk minimization measures: • SmPC Section 4.4, where recommendation for examination of blood smear, CBC and bone marrow biopsy is provided • SmPC Section 4.8 • SmPC Section 5.3 • PL Section 2 • PL Section 4 • Legal status: Restricted medical prescription Additional risk minimization measures: |
| Concurrent leukocytosis and anemia                                    | • None Routine risk minimization measures: • SmPC Section 4.4, where recommendation for examination of blood smear, and CBC are given • SmPC Section 4.8 • SmPC Section 5.3 • PL Section 4 • Legal status: Restricted medical prescription Additional risk minimization measures:                              |
| Renal impairment                                                      | • None Routine risk minimization measures: • None • Legal status: Restricted medical prescription Additional risk minimization measures: • None                                                                                                                                                                |
| Missing Information                                                   |                                                                                                                                                                                                                                                                                                                |
| Use in Pregnant or Breastfeeding Women                                | Routine risk minimization measures: • SmPC Section 4.6 • SmPC Section 5.3 • PL Section 2 • Legal status: Restricted medical prescription Additional risk minimization measures: • None                                                                                                                         |
| Use in patients with renal, hepatic, cardiac, or pulmonary impairment | Routine risk minimization measures: • SmPC Section 4.2                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| Use in patients with bone marrow stem cell disorder and/or any active malignancy   | • SmPC Section 5.2 • Legal status: Restricted medical prescription Additional risk minimization measures: • None Routine risk minimization measures: • None • Legal status: Restricted medical prescription Additional risk minimization measures:   |
|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Use in patients concurrently receiving rituximab or alkylating agents              | Routine risk minimization measures: • SmPC Section 4.5 • Legal status: Restricted medical prescription Additional risk minimization measures: • None                                                                                                 |

adverse event; CBC = complete blood count; eTPO = endogenous thrombopoietin; HAT = home administration training; ITP = immune (idiopathic) thrombocytopenic purpura; MDS = myelodysplastic syndrome; PI = Prescribing Information; PL = Package Leaflet; SmPC = Summary of Product Characteristics.

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.4., 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

Changes were also made to the PI to bring it in line with the current Agency/QRD template, SmPC guideline and other relevant guideline(s) [e.g. Excipients guideline, storage conditions, Braille, etc…], which were reviewed by QRD and accepted by the CHMP.

## 2.7.1. User consultation

No justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH. However, the changes to the package leaflet are minimal and do not require user consultation with target patient groups.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Primary  immune  thrombocytopenia  (ITP)  is  an  acquired  immune  mediated  disorder  characterised  by isolated thrombocytopenia, defined as a peripheral blood platelet count less than 100 x 10 9 /L, and the absence of any underlying cause. It is now clear that, primary ITP, is an acquired immune disorder where the thrombocytopenia  results  from  pathologic  antiplatelet  antibodies,  impaired  megakaryocytopoiesis,  and T-cell-mediated destruction of platelets, with each pathologic mechanism playing varying roles in each patient [Lambert &amp; Gernsheimer. Blood. 2017; 129:2829-2835].

<div style=\"page-break-after: always\"></div>

Until recently, the abbreviation ITP stood for idiopathic thrombocytopenic purpura, but due to the current knowledge of the immune mediated mechanism of the disease, and the absence or minimal signs of bleeding in most cases, have led to a revision of the terminology [Rodeghiero et al, 2009].

In 2010, the most established guidelines, the \"International Consensus Report\" (ICR) 2010  [Provan et al. 2010]  and  the  \"American  Society  of  Hematology\"  (ASH)  2011  [Neunert  et  al,  2011],  recommended replacing 'acute' with 'newly diagnosed' for all cases at diagnosis, which includes the period of first 3 months since diagnosis, 'persistent' to define the period between 3 and 12 months after diagnosis, and 'chronic' to describe patients with ITP lasting beyond 12 months. This new classification replaces the old one that only considered \"acute\" (first 6 months) and \"chronic\" (&gt;6 months since diagnosis). Therefore, ITP is classified by duration into newly diagnosed, persistent (3-12 months) and chronic ( ≥ 12 months).

Therefore, the MAH extended the currently authorised indication as follows:

'Adults: Nplate is indicated for the treatment of immune (idiopathic) thrombocytopenia purpura (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see section 4.2 and 5.1)

Paediatrics: Nplate is indicated for the treatment of chronic immune (idiopathic) thrombocytopenia purpura (ITP)  in  paediatric  patients  one  year  of  age  and  older  who  are  refractory  to  other  treatments  (e.g. corticosteroids, immunoglobulins) (see section 4.2 and 5.1).'

## 3.1.2. Available therapies and unmet medical need

There are several guidelines including different treatment approaches in ITP, with the updated ASH 2019 guideline [Neunert et al, 2019] and the updated ICR [Provan et al, 2019] being the more relevant ones. Inferences regarding the efficacy of treatments are mainly based on platelet counts as the more reliable surrogate outcome measure. The major goal for treatment of ITP is to provide a platelet count that prevents major bleeding rather than correcting the platelet count to normal levels.

In newly diagnosed ITP (first 3 months), treatment is aimed at rapidly obtaining a safe platelet count (&gt; 30 x 10 9  /L) to prevent or stop haemorrhages and to ensure an acceptable quality of life, avoiding as much as possible treatment-related adverse effects. In both updated guidelines, corticosteroids, unless contraindicated, remain the standard initial treatment of newly diagnosed patients, although they should be used for a limited time ( ≤ 6 weeks). Prednisone 1 mg/kg/ for 2-3 weeks, or dexamethasone 40 mg/d for 4 days, repeated up to 3 times, followed by a tapering period, is a general standard approach. Use of IV Ig, or IV anti-D where available, may be another appropriate first-line treatment in patients with bleeding, at high risk  for  bleeding,  who  require  a  surgical  procedure,  or  who  are  unresponsive  or  contraindicated  to prednisone.

Most adult patient relapse upon cessation of steroid treatment. Patients still remaining thrombocytopenic after 3 months from diagnosis or initial treatment (corticosteroids, IVIg, anti-D) are classified in persistent (between 3 to 12 months) or chronic (after at least 12 months).

While the old guidelines did not specifically address patients with persistent ITP (between 3 to 12 months) due to lack of robust efficacy/safety data, the updated guidelines propose different treatment approaches for this refractory population. Usual second-line treatment options are TPO-RA, rituximab and splenectomy, nevertheless, there is no solid evidence that defines the best strategy. Each of these second-line treatments may be effective therapy and therefore the choice of treatment should be individualized based on duration of ITP, frequency of bleeding episodes requiring hospitalization or rescue medication, comorbidities, age of the patient, medication adherence, medical and social support networks, patient values and preferences, cost, and availability.

<div style=\"page-break-after: always\"></div>

Available second-line treatment options for adult ITP patients can be broadly categorised into those that are given  only  once  (or  for  only  1  course)  and  are  intended  to  induce  long-term  remission  (splenectomy, rituximab), and those that need continued or chronic administration.

TPO-RAs (eltrombopag, romiplostim) have provided excellent responses (&gt;60%) in splenectomised and non-splenectomised patients. Response to continued TPO-RAs persists for up to 6 to 8 years and often allows other ITP therapy to be reduced or discontinued. Cessation of treatment will lead to the return of thrombocytopenia in most cases, but some patients (10%-30%) may achieve a durable response after TPO-RAs are tapered and withdrawn.

Rituximab shows a response of 60% of patients. Long-term durable responses occur in 20% to 25% of adult patients. Prior to treatment, hepatitis B status should be determined, and vaccination against encapsulated gram-positive bacteria should be given.

Splenectomy  provides  long-term  efficacy  in  approximately  60%  of  cases.  Nonetheless,  splenectomy  is invasive,  irreversible,  associated  with  postoperative  complications,  and  its  effectiveness  is  currently unpredictable,  leading  many  physicians  and  patients  toward  postponement  and  use  of  alternative approaches. Both guidelines suggest that, if splenectomy is deemed necessary, surgery should be deferred for at least 12 to 24 months from diagnosis (chronic ITP) due to potential for spontaneous remission in the first year.

Fostamatinib represents an option in chronic ITP for adult refractory to the previous treatments. It offers an alternative mechanism for reducing platelet destruction; it may provide response rates of 43% but stable responses of only 18%.

Other medical therapies for patients failing previous therapies, with less robust evidence, are immunosuppressive agents, such as mycophenolate mofetil, cyclosporine A or azathioprine. Danazol and dapsone are 'corticosteroid-sparing' agents that may be particularly useful in some patients (e.g. those in whom splenectomy is contraindicated or if other agents are unavailable. Vinca alkaloids are not a chronic therapy option because of neurological toxicity.

## 3.1.3. Main clinical studies

No new clinical studies have been provided in this application. To assess efficacy and safety of romiplostim in patients with ITP ≤ 12 months, the MAH provides an integrated analysis with data from patients with ITP ≤ 12 months included in 9 studies previously assessed (7 parent and 2 extension) in conjunction with a pharmacodynamic model.

## 3.2. Favourable effects

In  pivotal  studies  which  support  the  initial  authorisation  of  romiplostim,  Study  20030105  and  study 20030212, 5 of 63 (7.9%) and 21 of 62 (33.9%) subjects enrolled, had a duration of ITP ≤ 12 months at study entry, respectively. In a post-hoc analysis of durable platelet response of pivotal study 20030105, 40.0% (2/5) of subjects with ITP ≤ 12 months treated with romiplostim attained a durable platelet response, as compared with 0 of 0 subjects (0%) treated with placebo. In the same way, in a post-hoc analysis of durable platelet response of pivotal study 20030212, 66.7% (10/15) of subjects with ITP ≤ 12 months treated with romiplostim attained a durable platelet response, as compared with 16.7% (1/6) in placebo group.

In the single-arm study 20080435, which exclusively included 75 subjects who was diagnosed with primary ITP  within  6  months  of  study  entry  (the  median  time  (range)  from  ITP  diagnosis  to  the  first  dose  of romiplostim was 2.2 months [0.1 to 6.6 months]), 93.3% of subjects had a platelet response. A post-hoc

<div style=\"page-break-after: always\"></div>

analysis of durable platelet response was carried out (after imputation of missing platelet counts due to self-administration or other reasons), where 73.3% (95% CI: 61.9, 82.9) of the subjects attained a durable platelet response. After a sensitivity analysis was conducted (imputation of weekly platelet response was done only for subjects who had self-administered romiplostim); 64.0% of the subjects (95% CI: 52.1, 74.8) attained a durable platelet response.

In addition, efficacy variables were explored through an integrated analysis which included 311 subjects with ITP ≤ 12 months and 726 subjects with ITP&gt; 12 months at the start of the study. Of the 311 subjects with ITP ≤ 12 months, 277 received romiplostim and 34 received placebo/SOC. O ne hundred forty subjects had ITP &lt; 3 months from diagnosis and, 137 subjects, ITP ≥ 3 to ≤ 12 months from diagnosis.

Overall, in the integrated analysis, results from platelet response in subject with ITP ≤ 12 months showed platelet counts increasing to ≥ 50 x 10 9 /L across all variables analysed, with no significant differences when compared to subjects with ITP &gt; 12 months.

For the platelet response endpoints, weekly/monthly platelet response were imputed for time points without a collected platelet count measurement (see Statistical Methods section above).

Platelet response was higher in the romiplostim group than in placebo/SOC group when analysed: incidence of platelet response [86.3% (CI: 81.7, 90.1) vs 61.8% (CI: 43.6, 77.8)], durable platelet response (without imputation)  [26.7%  (CI:21.6%,  32.3%)  vs  2.9%  (CI:0.1%,  15.3%)],  durable  platelet  response  (with imputation) [52.7% (CI: 46.6%, 58.7%) vs 23.5% (CI: 10.7%, 41.2%) and subject incidence of sustained platelet response [74.4% (CI: 68.8, 79.4) vs 35.3% (CI: 19.7, 53.5)].

Romiplostim  reduced  rescue  medication  in  the  adult  ITP ≤ 12 months  population,  with  less  rescue medication use in the romiplostim subject groups (46.2%; 102/221 subjects) than the placebo subject groups (71.4%; 5/7) being the corticosteroids and /or immunoglobulins the most commonly used rescue medications across all ITP subgroups in both treatment groups.

2.0% (5/252) subjects in  romiplostim  group  vs  26.5%  (9/34  subjects  in  the  placebo/SOC  group)  had undergone a splenectomy or discontinued investigational product during the treatment period, in ITP ≤ 12 months subjects who had no prior splenectomy.

With respect to bleeding events, among subjects with ITP ≤ 12 months in the integrated analysis set, the incidence of subjects reporting events from the haemorrhages SMQ was similar for the romiplostim group compared with the placebo/SOC group (50.5% [140/277 subjects] versus 52.9% [18/34 subjects]) while the  corresponding  duration-adjusted  incidence  rate  (per  100 subject-years)  was  lower  for  romiplostim group compared with the placebo/SOC group (129.5 [495 events] versus 191.7 [70 events]). The same trend was observed for patients with ITP &gt; 12 months.

When subgroups regarding time for diagnosis were explored ( &lt; 3 months, (N=140), ≥ 3 to ≤ 12 months (N=137), and &gt; 12 months) no significant differences were observed between them in terms of efficacy, and the results showed the same trend as for the overall population (favoring romiplostim overt placebo/SOC group). Specifically, 82.1% ( &lt; 3 months) and 90,5% (≥ 3 to ≤ 12 months) of subjects attained a plat elet response, while 50.0% ( &lt; 3 months) and 55,5% (≥ 3 to ≤ 12 months) subjects attained a durable platelet response (after imputation) in the integrated analysis.

## 3.3. Uncertainties and limitations about favourable effects

Controlled studies have not yet been performed specifically in subjects with ITP ≤ 12 months. The number of subjects with ITP ≤ 12 months included in pivotal trials, which supported the initial approval of romiplostim and which provide the greatest robustness, were limited, 5 of 63 (7.9%) in study 20030105, and 21 of 62

<div style=\"page-break-after: always\"></div>

(33.9%) in study 20030212. This number was even more limited when analysed more restricted subgroups regarding time from diagnosis ( &lt; 3 months: 9 patients; ≥ 3 to ≤ 12 months: 17 patients) .

Scientific Advice from AEMPS was sought on 23 May 2017, for the romiplostim clinical program in adult patients who have ITP for ≤ 12 months. The proposal for Study 20130273, an RCT designed to evaluate the efficacy and safety of romiplostim compared to placebo for the treatment of adult subjects with ITP ≤ 12 months was discussed and welcomed. AEMPS agreed in general that the phase 3 study along with the existing data may prove sufficient to support the extension of the indication, provided that the results were internally robust and clinically and statistically meaningful. Recommendations regarding the proposed study design were provided. It is disappointing that the company decided finally not to conduct that controlled study. Instead, the company seek in 2018 an EMA protocol assistance on a non-interventional cohort study in  \"real  world\"  off-label  use  (outside  the  approved  indication  in  chronic  ITP)  designed  to  evaluate  the comparative effectiveness of romiplostim in adult patients with ITP ≤ 12 months. The MAH proposed to conduct this study in place of the RCT Study 20130273 that had been previously discussed with AEMPS. EMA advised that a decision would not be made on the extension of indication to patients without restriction in terms of disease duration in a refractory setting based only on observational data but a combination of available clinical trial data, justification of extrapolation of findings to adult patients earlier in their disease course, the PK/PD modelling and the observational study.

Neither the controlled study 20130273 proposed in the AEMPS scientific advice in 2017 nor the planned non-interventional study that was the matter of EMA advice in 2018 were initially submitted within the dossier. The non-interventional study was submitted by the MAH after being requested to provide data from real world evidence. Interpretation of this study is very limited due to small size and potential for residual confounding. Nonetheless, the results were in line from those observed in the clinical trials.

The data submitted in the current application is based on an integrated analysis of subgroups from controlled studies performed which include both subjects with ITP ≤ 12 months and subjects with ITP &gt; 12 months. Of the 311 subjects with ITP ≤ 12 months included in the integrated analysis, a total of 111 subjects (77 romiplostim, 34 placebo/SOC) had been enrolled in the controlled studies and a total of 200 subjects had been  enrolled  in  single-arm  studies.  Long-term  studies  are  uncontrolled  and  as  such  assessments  of causality of treatment effect when there is no comparator group are difficult to prove.

## 3.4. Unfavourable effects

The safety profile of romiplostim in the population of subjects with ITP ≤ 12 months seems similar to that observed in the ITP &gt; 12 months population with no significant differences between them. The subject incidences of the most frequent treatment-related adverse events in patients with ITP ≤ 12 months  (39.4% romiplostim treated patients; 32.4% placebo), headache (10.1% versus 5.9%; 11.0 versus 8.2), arthralgia (6.9% versus 0%; 6.5 versus 0) myalgia (2.9% versus 0%; 5.2 versus 0), nausea (2.9% versus 0%; 5.2 versus 0) were similar to those reported in patients with ITP &gt; 12 months. Only bronchitis and sinusitis were detected as new ARDs (with at least 5% higher subject incidence in the romiplostim group compared to placebo/SOC) in patients with ITP ≤ 12 months when compared to subjects with ITP &gt; 12 months and it has been proposed to include them in SmPC section 4.8.

Subjects who fail to increase their platelet counts in response to romiplostim are at risk of bleeding due to the inherent nature of ITP. In the integrated analysis, in subjects with ITP ≤ 12 months, the incidence of subjects with consistently low platelet counts reporting any hemorrhages (SMQ) events was 75.0% (95% CI:  47.6, 92.7) in subjects who received romiplostim and 100.0% (95% CI:  15.8, 100.0) in placebo/SOC group. On the contrary, among subjects with ITP &gt; 12 months, the incidence of subjects reporting events was higher for the romiplostim group compared with the placebo/SOC group (78.2% [43/55 subjects] versus 63.6% [7/11 subjects]).

<div style=\"page-break-after: always\"></div>

Thrombocytopenia is likely to reoccur upon discontinuation of treatment with romiplostim. In subjects with ITP ≤ 12 months, 5.1% (95% CI:  2.8, 8.3) of subjects had a preferred term reported from the haematopoietic thrombocytopenia (SMQ) broad search after cessation of romiplostim; while among subjects with ITP &gt; 12 months it was 3.8%.

Platelet counts above the normal range present a risk for thrombotic/thromboembolic complications. For subjects treated with romiplostim, the subject incidence and duration-adjusted incidence rate of thrombotic/thromboembolic events were similar between subjects with ITP ≤ 12 months versus subjects with ITP &gt; 12 months (5.4% versus 7.3%; 4.4 versus 6.1.).

Romiplostim may change the natural rate of progression of MDS to acute myeloid leukemia (AML). In the adult ITP ≤ 12 months safety set, 1.4% romiplostim treated subjects (95% CI:  0.4, 3.7) and 0% placebo/SOC treated subjects (95% CI:  0.0, 10.3) had a haematological malignant adverse event; while in the adult ITP &gt; 12 months, 0.3% romiplostim treated subjects and 3.3% placebo/SOC treated subjects had a haematological malignant adverse event.

Increased bone marrow reticulin is believed to be a result of TPO receptor stimulation, leading to an increased number of megakaryocytes in the bone marrow, which may subsequently release cytokines. In subjects with ITP ≤ 12 months duration, the incidence of subjects who had a preferred term from the myelofibrosis AMQ search was 0.4% (1 subject) for romiplostim and 0% for placebo/SOC. This patient who received romiplostim and reported an adverse event of 'Myelofibrosis' was considered to have experienced reticulin fibrosis, but detailed grading of the bone marrow finding was not provided.

No subjects reported romiplostim medication errors adverse events.

The unfavourable effects of the product are already included in sections 4.4, 4.8 and 5.1 of the approved SmPC.

## 3.5. Uncertainties and limitations about unfavourable effects

The number of patients with ITP ≤ 12 months included in pivotal studies (which provides the greater robustness) is very limited (26/125), especially with regard to subgroups (time since ITP diagnosis &lt; 3 months; ≥ 3 to ≤ 12 months) and although the integrated analysis increases the number of patients to 277, this number of patients seems very small in the context of a 10 year post-marketing experience available with the product. In response to the CHMP RSI, the MAH has provided further safety data available in newlydiagnosed and persistent ITP patients ≤ 12 months from company -sponsored studies, from off-label use in prescription databases and from literature. Although it must be taken into account that robust evidence that can be drawn from routine clinical settings is limited, and that, consequently, interpretation of data should be done with caution, no new safety signals were observed, in line with what was previously observed in the integrated analysis.

## 3.6. Effects Table

Table 47. Effects Table for romiplostim in adult ITP refractory to other treatments

| Effect   | Short description   | Unit   | Romiplost im   | Control   | Uncertainties / Strength of evidence References   |
|----------|---------------------|--------|----------------|-----------|---------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| Effect                                                       | Short description                                                                                                                                 | Unit               | Romiplost im                                                                               | Control                                                                       | Uncertainties / Strength of evidence                                  | References                        |
|--------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|--------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------|
| Favourable Effects                                           | Favourable Effects                                                                                                                                | Favourable Effects | Favourable Effects                                                                         | Favourable Effects                                                            | Favourable Effects                                                    | Favourable Effects                |
| Platelet response (integrated analysis)                      | at least 1 monthly platelet count of ≥ 50 x 10 9 /L without any use of rescue medication within 8 weeks prior to date of the platelet measurement | %                  | ITP < 12 months 86.3% (239/277) ITP > 12 months 87.2%                                      | ITP < 12 months 61.8% (21/34) ITP > 12 months 32.6%                           |                                                                       | Integrated analysis 1,5           |
| Platelet response (Study 20080435 2)                         | platelet response of ≥ 50 x 10 9 /L during the 12-month                                                                                           | %                  | ITP < 12 Months 93.3% (70/75)                                                              |                                                                               | Uncontrolled/ median time from ITP diagnosis: 2.2 months (0.1 to 6.6) | Study 20080435 2                  |
| Durable platelet response (integrated analysis)              | Incidence of subjects with ≥ 6 weekly platelet counts of ≥ 50 x 10 9 /L during weeks 18 through 25 of treatment a)No imputation b)Imputation      | %                  | a) ITP < 12 months 26.7% (74/277) b) ITP < 12 months 52,7% (146/277) ITP > 12 months 49.2% | ITP < 12 months 2.9% (1/34) ITP < 12 months 23,5% (8/34) ITP > 12 months 9.8% |                                                                       | Integrated analysis               |
| Durable platelet response (Post-hoc pivotal trial analysis)  |                                                                                                                                                   | %                  | Study 20030105 40.0% (2/5) Study 20030212 66.7% (10/15)                                    | 0% (0/0) 16.7% (1/6)                                                          | Limited number of patients with ITP < 12 months: (5/63) (21/62)       | Study 20030105 3 Study 20030212 3 |
| Durable platelet response (post-hoc analysis Study 20080435) | weekly platelet count ( ≥ 50 x 10 9 /L) for at least 6 of the last 8 weeks of treatment for the week 18 to 25 measurements                        | %                  | ITP < 12 months 73.3% (55/75)                                                              |                                                                               | Uncontrolled/ median time from ITP diagnosis: 2.2 months (0.1 to 6.6) | Study 20080435 2                  |

<div style=\"page-break-after: always\"></div>

| Effect                      | Short description                                                                             | Unit                 | Romiplost im                                          | Control                                             | Uncertainties / Strength of evidence   | References                                     |
|-----------------------------|-----------------------------------------------------------------------------------------------|----------------------|-------------------------------------------------------|-----------------------------------------------------|----------------------------------------|------------------------------------------------|
|                             | (after imputation)                                                                            |                      |                                                       |                                                     |                                        |                                                |
| Sustained platelet response | platelet response for at least 9 weeks within a 12-week period                                | %                    | ITP < 12 months 74.4% (206/277) ITP > 12 months 72.7% | ITP < 12 months 35.3% (12/34) ITP > 12 months 19.6% |                                        | Integrated analysis                            |
| Rescue medication use       | subject incidence of rescue medication use at any time during treatment                       | %                    | ITP < 12 months 46.2% (102/221) ITP > 12 months 54.5% | ITP < 12 months 71.4% (5/7) ITP > 12 months 45.7%   |                                        | Integrated analysis excluding study 20060131 4 |
| On-study splenectomy        | undergone a splenectomy or discontinued investigational product due to need for a splenectomy | %                    | ITP < 12 months 2.0% (5/252)                          | ITP < 12 months 26.5% (9/34)                        |                                        | Integrated analysis                            |
| Unfavourable Effects        | Unfavourable Effects                                                                          | Unfavourable Effects | Unfavourable Effects                                  | Unfavourable Effects                                | Unfavourable Effects                   | Unfavourable Effects                           |
| SAES                        | Serious adverse events                                                                        | Subject incidence %  | ITP < 12 months 30.3% ITP > 12 months 34.2%           | ITP < 12 months 41.2% ITP > 12 months 27.2%         |                                        | Integrated analysis                            |
| Treatment related AE        |                                                                                               | Subject incidence %  | ITP < 12 months 39.4% ITP > 12 months 50.9            | ITP < 12 months 32.4% ITP > 12 months 37.0%         |                                        | Integrated analysis                            |

<div style=\"page-break-after: always\"></div>

| Effect                                                           | Short description                                                                               | Unit                | Romiplost im                                                                                            | Control                                                                                             | Uncertainties / Strength of evidence   | References          |
|------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|---------------------|---------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|----------------------------------------|---------------------|
| Risk of bleeding in ITP                                          | Haemorrhages (SMQ) overall Haemorrhages (SMQ) in subjects with consistently low platelet counts | Subject incidence % | ITP < 12 months 50.5% ITP > 12 months 59.0% ITP < 12 months 75.0% (12/16) ITP > 12 months 78.2% (43/55) | ITP < 12 months 52.9% ITP > 12 months 56.5% ITP < 12 months 100% (2/2) ITP > 12 Months 63.6% (7/11) |                                        | Integrated analysis |
| Reoccurrence of thrombocytope nia after cessation of romiplostim | Incidence of subjects reporting any haematopoietic thrombocytopenia (SMQ) adverse events        | %                   | ITP < 12 months 5.1% ITP > 12 months 3.8%                                                               |                                                                                                     |                                        | Integrated analysis |
| Thrombotic/ thromboemboli c complications                        | Incidence of subjects reporting any thrombotic/thromb oembolic (SMQ) adverse events             | %                   | ITP < 12 months 5.4% ITP > 12 months 7.3%                                                               | ITP < 12 months 5.9% ITP > 12 months 2.2%                                                           |                                        | Integrated analysis |
| Increased bone marrow reticulin Bone marrow fibrosis             | Incidence of subjects reporting myelofibrosis (AMQ) adverse events                              | %                   | ITP < 12 months 0.4% ITP > 12 months 0.9%;                                                              | ITP < 12 months 0% ITP > 12 months 0%                                                               |                                        | Integrated analysis |
| Progression of existing MDS                                      | Incidence of subjects reporting hematological malignant tumours (SMQ) adverse events            | %                   | ITP < 12 months 1.4% ITP > 12 months 0.3%;                                                              | ITP < 12 months 0% ITP > 12 months 3.3%                                                             |                                        | Integrated analysis |
| Inmunogenicity                                                   | Binding antibody for romiplostim                                                                | N (%)               | ITP < 12 months 15(5.5)                                                                                 | 8 patients novo                                                                                     |                                        | Integrated analysis |

<div style=\"page-break-after: always\"></div>

| Effect   | Short description                      | Unit   | Romiplost im                                                      | Control                        | Uncertainties / Strength of evidence   | References   |
|----------|----------------------------------------|--------|-------------------------------------------------------------------|--------------------------------|----------------------------------------|--------------|
|          | TPO antibody                           | N (%)  | months 51 (8.3) ITP < 12 months 15 (5.6) ITP > 12 months 34 (5.6) | 9 patients novo                |                                        |              |
|          | Neutralising antibodies to romiplostim | N (%)  | ITP < 12 months 2 (0.7) ITP > 12 months 1 (0.2)                   | 2 patients novo and persistent |                                        |              |

Abbreviations: SMQ; Standardized MedDRA Query. AMQ; Amgen MedDRA query. Notes:

- (1) Integrated analysis : comprises 7 parent clinical studies (studies 20030105, 20030212, 20040209, 20060131, 20060216, 20080009, 20080435) and 2 extension studies (20030213, 20060113).
- (2) Study 20080435: phase 2, interventional, single-arm, in subjects ITP diagnosed within 6 months of study entry

(3) Study 20030105 and Study 20030212: pivotal phase 3, randomized, double blind, placebo controlled

(4) Study 20060131 had a different approach of collecting rescue medication use.

- (5) Integrated analysis: For the platelet response endpoints, weekly/monthly platelet response were imputed for time points without a collected platelet count measurement (see Statistical Methods section)

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

ITP is an uncommon condition that may be life threatening and where limited therapeutic alternatives are available. Romiplostim is regarded as a suitable therapeutic option able to increase platelet counts above a level which reduces the risk of bleeding events.

Overall, the data presented are indicative of an increase in platelet counts in subjects with ITP ≤ 12 months treated with romiplostim when compared to placebo. The observed efficacy was generally consistent among different subgroups ( &lt; 3 months, ≥ 3 to ≤ 12 months, and &gt; 12 months) . The data obtained are in line with the efficacy in subjects with ITP &gt; 12 months, platelet counts are increased significantly in a majority of patients.  Nevertheless, since the data are limited, supporting data from clinical practice and literature were provided, which show that romiplostim is frequently used -off label during clinical practice in both newly and persistent ITP and, although interpretation of data should be done with caution, results show the achievement of clinically relevant platelet responses in a considerable proportion of patients with no new safety signals in patients with both newly and persistent IPT, in line with what has been observed in clinical trials.

<div style=\"page-break-after: always\"></div>

Nplate is considered well tolerated and the risks are well known and manageable. The main safety concerns already known for Nplate, such as, medication errors, increased reticulin formation and bone marrow fibrosis, reoccurrence of thrombocythemia after cessation of romiplostim, thromboembolic events, progression of existing myelodysplastic syndrome, immunogenicity or haemorrhages did not showed an increased risk in patients with ITP ≤ 12 months.

## 3.7.2. Balance of benefits and risks

This variation application pertains to a change in the wording of the indication to replace \" adult with chronic ITP who are refractory to other treatments \" to \"ITP in adult patients who are refractory to other treatments', extending, therefore, romiplostim's indication to adult patients with ITP regardless time from diagnosis (newly/persistent and chronic ITP according to current guidelines).

To support this extension of indication, the company is based on the revised definition of 'chronic' within the medical community according to the IWG 2009 guidelines (ITP &gt; 12 months from diagnosis). The MAH believes that some patients who would have been previously considered to have chronic ITP, would now be considered to have persistent ITP (3 to 12 months from diagnosis). Since the previous submitted studies enrolled patients with newly and persistent ITP, the MAH pursues to extent romiplostim's indication to adult patients with ITP who are refractory to other treatments regardless time from diagnosis.

No specific new clinical studies have been submitted to ascertain whether the favourable effect of romiplostim (increase in platelet count and subsequent decreased risk of bleeding) may differ depending of ITP time from diagnosis (i.e. ≤ 12 months since ITP diagnosis vs. &gt;12 months since ITP diagnosis). The company has submitted an integrated analysis with data from 9 previously submitted trials (277 patients treated with romiplostim), as well as post-hoc analysis of the pivotal randomized clinical trials in subjects with ITP ≤ 12 months regarding durable platelet response. In addition, a single arm study (also included in the integrated analysis), exclusively provides data of 75 patients who were diagnosed with primary ITP withing 6 months of study entry. All this is complemented by a pharmacodynamic model and simulation where it was demonstrated the appropriateness of the currently romiplostim labelled dosing algorithm to treat patients with ITP ≤ 12 months.

Platelet responses explored were attained and durable and can be considered clinically relevant for subjects with ITP ≤ 12 months. Consistent favourable effects were also observed for the use of rescue medication, which was generally low for romiplostim group when compared to placebo group.

The main safety concerns already known for romiplostim and addressed in the SmPC, such as, medication errors, increased reticulin formation and bone marrow fibrosis, reoccurrence of thrombocythemia after cessation of romiplostim, thromboembolic events, progression of existing myelodysplastic syndrome, immunogenicity or haemorrhages did not showed an increased risk in patients with ITP ≤ 12 months.

Nevertheless, it is acknowledged that the number of subjects with ≤ 12 months, and particularly ≤ 3 months (newly diagnosed ITP) is limited, specifically the one that derives from controlled trials. Although it does not seem that romiplostim lacks efficacy in patients with ITP ≤ 12 months, as a high use-off label of romiplostim in patients with ≤ 12 months is expected, the MAH was requested to provide the totality of the data available. In the response to CHMP RSI, the company provided extensive real-world evidence (RWE) search from various sources. The evidence submitted show that romiplostim is frequently used -off label during clinical practice in both newly and persistent ITP, as it was expected and according to current guidelines (Neunert et al, 2019; Provan et al, 2019). Although it must be taken into account that robust evidence that can be drawn from routine clinical settings is very limited, and that, consequently, interpretation of data should be done with caution, results show the achievement of clinically relevant platelet responses in a considerable proportion of patients with no new safety signals in patients with both newly and persistent IPT,

<div style=\"page-break-after: always\"></div>

in line with what has been observed in the integrated analysis and phase II Study 20080435 which provide the greatest evidence.

The totality of the evidence from routine clinical settings has been submitted and reviewed (non-interventional studies [including published literature and published and unpublished Amgen studies]) and it was observed that the results from real world evidence does not differ with results from clinical trials. Hence, it can be concluded that romiplostim does not lack effectiveness or safety in patients with newly and persistent ITP. Although it is acknowledged that the number of subjects with ITP ≤ 12 months in the pivotal controlled trials is small (26/125), it is considered that results from them, in conjunction with results from the integrated analysis (n=277 treated with romiplostim), and from phase 2 Study 20080435 (n=75 treated with romiplostim), complemented with real world evidence, provide enough evidence to consider that the balance benefit-risk of romiplostim in newly and persistent ITP is positive. Further specific RCTs in subjects with newly and persistent ITP will be welcomed, but the data provided is sufficient to grant the requested amendment in the indication. In the context of limited treatment options, benefits of the treatment are deemed to overweigh the risks for patients with ITP ≤ 12 months.

## 3.7.3. Additional considerations on the benefit-risk balance

None.

## 3.8. Conclusions

The overall B/R of Nplate is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to add the use of romiplostim in adult patients who have had ITP for ≤ 12 months and who have had an insufficient response to corticosteroids or immunoglobulins. Sections 4.1, 4.4., 4.8, 5.1 and 5.2 of the SmPC have been updated. In addition, the MAH has taken the opportunity to implement minor editorial changes in sections 4.2, 4.4, 4.8 and 5.1 of the SmPC. The Package Leaflet is updated in accordance. Version 20.1 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template (version 10.1).

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

<div style=\"page-break-after: always\"></div>

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## · Risk management plan (RMP)

The Marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

In addition, an updated RMP should be submitted:

At the request of the European Medicines Agency;

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## · Additional risk minimisation measures

The MAH shall agree the details of the following educational tools with the National Competent Authorities and must implement such programme nationally.

## Dose calculator

- Physicians involved in the prescribing of romiplostim are provided with a dosing calculator to simplify the calculation of the correct dose and as a guide to the correct reconstitution, dilution (if required) and administration procedures.

## Home Administration Training (HAT) pack

- Physicians who express an interest in initiating self-administration for specific patients are provided with a HAT pack for those patients. The HAT pack includes materials for HCPs on how to select and train patients for self-administration of romiplostim; and for patients, in order to help them with the process of preparation and self-administration of the correct dose of romiplostim.
- As self-administration of Nplate is not allowed for paediatric patients, the HAT pack is intended for use with adult patients and not with paediatric patients.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Nplate-H-C-000942-II-0077'